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Abstract 
The prevalence of chronic diseases has increased in children and adolescents and 
physical inactivity, sedentary lifestyle and obesity have been identified as risk factors 
for earlier onset of chronic disease. Times spent in 24-hour movement behaviours have 
become important public health concerns because of their potential to impact on an 
individual’s health.  
 
The concept of 24-hour movement behaviours - comprising physical activity (PA), 
sedentary behaviour and sleep - is relatively new and quantifying the various 
movement behaviours with confidence is still a challenge. The adequacy of levels of 
24-hour movement behaviors in children with chronic disease is unknown as is 
whether there are systematic differences between children with chronic disease and 
their healthy peers. 
 
Aims: To examine the habitual amount of time spent in moderate to vigorous physical 
activity (MVPA) and sedentary time (ST) in children and adolescents with chronic 
disease and in children and adolescents with obesity; to compare measured MVPA 
against MVPA recommendations in children with chronic disease and their healthy 
peers and to investigate 24 hour-movement behaviours (PA, standing, sedentary and 
sleep behaviours – sleep; quantity and sleep quality) for 5-7 days in children with 
chronic childhood diseases and test whether there were differences between children 
with chronic disease and their healthy peers. 
 
In systematic literature reviews (Chapters III and IV): the literature searching was 
focused on four key elements: children and/or adolescents, MVPA, ST and/or SB, 
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measured objectively by accelerometer, and common chronic disease (obesity, chronic 
cardiovascular disease, chronic respiratory disease, diabetes mellitus and 
malignancies). For each review, an extensive search was carried out in the five most 
relevant electronic databases: Medline, Cochrane library, EMBASE, SPORTDiscus 
and CINAHL from 2000. Study selection: Studies with accelerometer-measured 
MVPA and/or SB (at least 3 days and 6 hours/day) in children and adolescents (0-19 
years) with cardiovascular disease, respiratory disease, diabetes, malignancy and 
obesity, studied while well and clinically stable. Study quality was assessed formally. 
Meta-analyses were planned for all outcomes. In the systematic review of MVPA and 
ST in children and adolescents with chronic disease, 25 studies were eligible, in four 
chronic disease categories: cardiovascular disease (7 studies), respiratory disease (7 
studies), diabetes (8 studies), and malignancy (3 studies). Patient MVPA was generally 
below the recommended 60 min/day and ST was generally high regardless of the 
disease condition. Comparison with healthy controls suggested no marked differences. 
MVPA in children with chronic disease was not very much lower than in healthy 
control or comparison groups with the exception of children being treated for 
malignancy.  
 
In the systematic review of MVPA and ST in children and adolescents with obesity, 
26 studies were eligible (n=14,739 participants; n=3523 with obesity); 6/26 studies 
involved children aged 0 to 10 years and 18/26 involved adolescents aged 10.1 to19 
years. In the participants with obesity, time spent in MVPA was consistently below 
the recommended 60 min/day, and ST was generally high regardless of the 
participant’s age and sex. Comparison with controls suggested that the time spent in 
MVPA was significantly lower in children and adolescents with obesity, though 
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differences were relatively small. There were no marked differences in ST between 
obese study participants and their non-obese peers. 
 
The primary data collection studies (Chapters V and VI) were based on an 
observational case-control study of 24-hour movement behaviours in children with 
common chronic diseases likely to disrupt these behaviours, and included 160 
participants; 80 children with chronic disease; 20 with type 1 diabetes mellitus 
(T1DM), 20 with juvenile idiopathic arthritis (JIA), 20 with congenital heart disease 
(CHD), 20 with cystic fibrosis (CF). Patients were recruited from outpatient clinics at 
the Royal Hospital for Children, Glasgow. 80 healthy children were individually pair-
matched for age, sex, and timing of measures. Habitual time spent in PA, standing, 
sedentary and sleep behaviours – sleep quantity – particularly sleep timing (sleep 
onset/offset), and sleep duration - and sleep quality) and step counts were all measured 
with the activPAL accelerometer/inclinometer over 7 days. Comparisons against 
recommendations were made and differences between the groups with chronic disease 
and controls examined. Mean time spent in PA and step counts per day were 
consistently lower in the children with chronic disease compared to healthy controls, 
reaching statistical significance only for the T1DM and CHD groups. Only 20/80 
children with chronic disease and 29/80 controls met the daily step count 
recommendations. ST was consistently higher in children with chronic disease, though 
this reached significance only for the group with CF. Time spent asleep was slightly 
greater in the children with chronic disease, significant only for the group with JIA. 
Sleep disruption was consistently greater in those with chronic disease, reaching 
significance for groups with T1DM, CHD and CF. 
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When data from the groups of children with chronic disease and controls were 
combined, permitting a comparison of 80 vs 80 children respectively in the primary 
data collection studies, differences between children with chronic disease and healthy 
controls were more obvious when the children with chronic disease were compared as 
a single group with their healthy controls. The most important finding was that there 
were significant differences between children with chronic disease and healthy 
controls for ST, standing, PA and sleep. Those with chronic disease had greater time 
spent sedentary with significantly lower number of sedentary breaks, less standing 
time with slightly longer sleep time than their healthy controls. Time spent in PA was 
significantly lower (in both PA time and steps counts) in children with chronic disease 
compared to healthy controls.  
 
The most obvious concerns in the present study arise from differences between patient 
and control groups with patient group showing greater ST, with consistently lower 
number of sitting bouts and lower PA levels than their healthy controls. However, 
differences between patient and control groups for the 24-h movement behaviours 
were generally quite small in the children studied and their biological significance of 
the differences is unclear. Finally, optimising levels of 24-hour movement behaviours 
should confer a number of benefits for child health, development, and wellbeing. There 
is a need for further research with a clinical focus on these behaviours in those with 
chronic disease. 
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CHAPTER I  
GENERAL INTRODUCTION 
 
Chapter I 27 
1.1. Background 
Over the past few decades, the importance of physical activity (PA- defined as any 
bodily movements) for maintain the health of the population has been increasingly 
recognised (1). The start of this recognition can be traced back to Morris et al in 1953, 
when they observed that both bus drivers and office workers who had prolonged periods 
of sitting were at a higher risk of coronary artery disease than more physically active 
workers like bus conductors and postmen (2). 
 
Nowadays, the growth in electronic media along with dramatic environmental and 
social changes particularly in relation to modes of transportation has created sedentary 
lifestyles. This behavioural shift represents a move from traditional to more 
industrialised lifestyles and is characterised by having less opportunity for being 
physically active and much greater involvement at work or during leisure in activities 
that are more sedentary (3). Church et al reported a steady shift toward more sedentary 
occupations over the last 50 years in the United States (US), a trend probably seen in 
the rest of the western world. Adults spend more time sitting or reclining during waking 
hours (at work or home, watching television, or while driving a car (4)) and less time 
in physical activity. Further international evidence using the International Physical 
Activity Questionnaire (IPAQ) showed that adults typically spent ≥ 9 hours of their 
waking hours in sedentary behaviours (SB) and the prevalence of PA occupations has 
decreased from 48% in 1960 to 20% in 2008 (4) 
 
Sedentary behaviour (SB) has been defined in the Sedentary Behaviour Research 
Network (SBRN) consensus as any waking behaviour characterised by energy 
expenditure ≤1.5 metabolic equivalents (METs) while sitting, reclining or lying (5))(6). 
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More recent studies using objective measurements (accelerometers) to measure the 
time spent in SB in adult population revealed that adults today typically spend about 
55–70% of their waking hours sedentary (7, 8).  
 
Studies of SB in children and young people showed that the majority of their 
discretionary time is also sedentary, associated with time spent consuming audio-visual 
media, such as watching television, using computer, and playing computer games (7). 
For instance, United States and Canadian children and adolescents are spending an 
average of 6-8 and 8.6 hours per day respectively being sedentary (7, 9, 10).  
As a result of these studies and increasing evidence that SB is related to health outcomes 
separate from the decline in PA, SB in children has been receiving greater attention 
from researchers recently. Many complementary lines of evidence suggest sedentary 
lifestyles have a negative impact on health status (11, 12) with high levels of SB having 
been shown to increase the risk of obesity, to elevate metabolic risk profile in children 
and adolescent (13-15) and to be associated with obesity-related health problems, 
including type II diabetes, cardiovascular disease, certain cancers later in adulthood (8, 
16-19). 
 
Collectively, most studies on the influence of PA or SB on health outcomes in children 
have examined the influence of one behaviour in isolation from other behaviours (e.g. 
only PA and not the other 24 hour movement behaviours—SB, light physical activity 
(LPA) and sleep) and that may have restricted our understanding of how these 
behaviours might interact together and affect heath. Moreover, while there is no doubt 
that moderate-to-vigorous intensity physical activity (MVPA) provides many important 
health benefits in children (20), it is important to recognise that MVPA only accounts 
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for a small proportion (typically <5%) of the 24h day, even among active children and 
young people, while other movement behaviours fill almost 95 % of the 24h day. 
Typically, sleep (usually ~40%), SB (around ~40%) and LPA (around ~15%) make up 
the remaining 95% of the day (21), as summarised in Figure 1.1. Indeed, Chaput 
highlighted that focusing on one behaviour such as MVPA while ignoring other 
components of the ‘integrated movement’ spectrum limits our understanding of how 
these various ‘activities’ interact together to impact children’s health (21). 
 
 
Figure 1.1: Estimated distribution of movement behaviours in children, adapted from Chaput et al (21) 
 
 
This introductory chapter brings together information about integrated movement 
behaviours in healthy children before examining what is known about movement 
behaviours in children with common chronic disease. It begins by briefly reviewing the 
components of integrated movement behaviours in children, and then refers to how 
these behaviours have been measured, and current guidelines for them in children. It 
goes on to discuss some common chronic childhood diseases and what is known about 
movement behaviours in this context. By necessity much of the evidence describes each 
behaviour in isolation from other movement behaviours as that is what has been studied 
to date, rather than providing an integrated view of 24h movement behaviours in 
chronic disease. 
24 hours 
MVPA: Moderate-Vigorous Physical Activity 
LPA:    Light Physical Activity 
ST:       Sedentary Time 
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1.2. Integrated Movement Behaviours in Healthy Children 
The concept of integrated movement behaviours over the 24-hour period (referred to as 
“24-hour movement behaviours” throughout this thesis) is a new concept attracting 
growing interest. The idea is to study all of the 24-hour movement behaviours in 
combination, extending from sleep through to MVPA  because having one “unhealthy” 
movement behaviour might moderate the health benefits of another (22). For example, 
the health benefits of MVPA might be reduced if children have poor sleep habits and/or 
engage in excessive time spent in SB and conversely, increased PA might promote 
better sleep and could well ameliorate the detrimental effects of insufficient sleep 
and/or extended periods of sedentary in some individuals.  
 
There is some preliminary evidence available to support this. A Danish longitudinal 
study in of 785 aged 8-11 year investigated both independent and combined 
associations between all movement behaviours and risk of cardio-metabolic syndrome. 
They found that, low PA and short sleep duration were associated with increased risk 
of cardio-metabolic syndrome. Conversely, greater time spent in SB and more sleep 
disturbances were associated with increased risk cardio-metabolic syndrome. The study 
has shown that greater time spent sedentary with low PA and with short sleep duration 
was associated with higher risk of cardio-metabolic syndrome in children. It suggests 
that multiple movement behaviours may need to be targeted to improve cardio-
metabolic risk markers in childhood (23).  
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1.2.1. Physical Activity 
 Definition 
PA is defined as any “bodily movements” produced by skeletal muscles including 
activities undertaken while working, playing, carrying out household chores, travelling, 
and engaging in recreational pursuits (1) that requires energy expenditure more than 
1.5 metabolic equivalent units (METs) (24) One MET is the energy cost of resting 
quietly, often defined in terms of oxygen uptake as 3.5 mL·kg-1·min-1 in adults (25). 
Resting energy expenditure is much higher in children than in adults but the same 
concept applies with one MET in childhood being equivalent to the energy expended 
at rest (1)) However, the term "physical activity" should not be confused with 
"exercise" (26), which is a subcategory of PA defined as planned, structured, repetitive 
bodily movement, and aims to improve or maintain one or more components of physical 
fitness, such as swimming, and yoga (1, 27).  
 
PA is characterised and described in terms of frequency, duration, intensity and type. 
PA frequency is defined as the number of times an activity is performed in a particular 
period of time (28). PA duration refers to total amount of time spent in an activity, 
which could be either continuous or cumulative over a specified unit of time (29). PA 
intensity is defined as the energy expenditure during specific activity and is usually 
measured by METs. PA is commonly categorised into four levels according to the 
intensity: LPA is any activity that requires energy expenditure above 1.5 but less than 
3.0 METs; in MVPA energy expenditure ranges between 3.0 to 6.0 METs; while 
vigorous intensity physical activity (VPA) energy expenditure is more than 6.0 METs 
(30, 31). Finally, the type or mode of PA refers to the activity type e.g. running, jogging 
or walking (32). 
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 Physical Activity in Healthy Children  
Physical activity, particularly MVPA is associated with a wide range of health benefits 
in adults. MVPA plays an important role in maintaining their health as well as 
protecting against several diseases such cardiovascular disease, diabetes, hypertension 
and obesity and also of reduced risks of all-cause mortality, some cancers and 
depression (33-37).  
 
In children too, several reviews have summarised the substantial evidence of the 
relationship between physical activity and health and have concluded that meeting a 
minimum of 60-minute per day in MVPA.  
 
The largest and most consistent body of evidence has been accumulated for a few 
outcomes: children should spend at least 60 minutes in MVPA per day in order to 
promote healthy growth and development (20, 38-41), to obtain cognitive and 
educational effects (41, 42), and multiple associated benefits for physical, mental, and 
psychosocial health (43-45) leading to improved health and reduced morbidity and 
mortality in the general child population (42). Further, MVPA has a positive impact on 
aerobic capacity, insulin sensitivity, lipid profiles, and it also reduces stress, anxiety, 
and depression (36, 43, 44, 46, 47). Indeed, the benefits of adequate childhood PA could 
be summarised in three ways: an improvement in childhood health status and quality 
of life; an increased likelihood of maintaining adequate activity into adulthood and an 
improvement of future adult health status by delaying the onset of chronic disease in 
later life (48, 49), as summarised in Figure 1.2.  
 
Chapter I 33 
In some children levels of MVPA are low while levels of LPA are extremely high as 
resulted they spent many hours per day walking, but the pace of walking was slow (50). 
One of the most valuable sources of evidence on physical activity and health during 
childhood and adolescence is the large prospective Avon Longitudinal Study of Parents 
and Children (ALSPAC) study conducted in England. In adolescent ALSPAC 
participants, it was found that body fatness was influenced by MVPA (rather than LPA 
or VPA), LPA was the main influence on blood pressure, while VPA was the main 
influence on bone health (51). 
 
 
Figure 1.2: The relationships between physical activity and health in children and adults, adapted 
from Blair et al (49) 
 
On the other hand, low PA in childhood compromises child health and development 
(43) and is associated with adverse effect on adult health. Because levels of PA have 
been shown to track from the childhood to adulthood (52), low childhood PA 
predisposes to low adolescent PA, and in turn predisposes to low adult PA (52-54). 
Moreover, a report in the Lancet 2012 (37) had reported that low PA level in childhood 
creates two adverse effects constituting a ‘double hit’ on PA and health in adulthood, 
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as shown in Figure 1.3. The first ‘hit’ is that low PA acts directly and has biological 
effects (e.g. on the cardiovascular system) from childhood that are cumulative over the 
time. The second ‘hit’ is an indirect behavioural effect stems from the fact that low 
childhood PA tracking to low PA in adulthood (52), and this then causes many and 
serious health effects such as increased risk for several diseases and poorer overall 
quality of life (37, 55). 
 
 
Figure 1.3: The effect of low physical activity (PA) in childhood on adult health, adapted from Lee 
et al (37) 
 
 Physical Activity in Children with Obesity 
The prevalence and severity of obesity is increasing in children and adolescents (obesity 
defined as body mass index (BMI) above the 95th percentile for age and sex) (56-58). 
The short- and long-term association with poor health outcomes raises the level of 
importance for understanding childhood obesity as a major public health concern (59). 
Moreover, in children and adolescents with obesity obesity is more likely to persist into 
adulthood and has been shown to be associated with increased overall mortality rate 
and specifically with increased risk of cardiovascular disease and diabetes in adulthood 
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(60). Obese children also are more likely to experience significant short-term health 
problems such as hyperlipidemia, hypertension, glucose intolerance and orthopedic 
complications than their children and adolescents with healthy weight (59, 61). In 
addition, the adverse social consequences of obesity in children and adolescent may 
have long-lasting negative impact on self-esteem, body image and economic mobility 
(62).  
Previous studies have linked levels of PA and obesity in children and adolescent and 
suggested that lack of PA is an important contributing factor in the development and 
or maintenance of childhood obesity (63, 64). However, such a relationship between 
and low PA could potentially be bidirectional with low PA increasing the risk of 
developing obesity in children and adolescents. In keeping with this possibility, obese 
children and adolescents have been shown to be less active than their normal-weight 
peers with a level of PA in those children lower than the recommended level (65, 66).  
 
 
Figure 1.4: Aggravating effect of childhood obesity on the life-time risk for other disease conditions, including 
a greater risk for adult obesity, which itself continues to worsen disease development, adapted from Barton 
et al (69). 
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Thus, its attendant health risks justify widespread efforts toward prevention of 
obesity in children and adolescent. PA therefore has been emphasised as an 
appropriate intervention in childhood obesity that by increasing energy expenditure 
and resting metabolic rate help could protect from the development of obesity. 
Indeed, several public health bodies’ interventions designed to increase levels of PA 
in children at schools, families and communities suggest these might be promising 
strategies for the prevention of childhood obesity (65, 67, 68). 
 
 Physical Activity in Children with Chronic Disease 
In children with chronic disease increasing PA, specifically MVPA, has a significant 
positive impact on their disease by improving their quality of life, reducing or 
preventing co-morbidities and premature mortality (70, 71). Recently, for example, 
epidemiological studies have provided evidence that MVPA has a significant effect on 
lowering high blood pressure, preventing obesity, reducing body fat and controlling 
weight, improving cardio-metabolic profile, and increasing bone mineral density, as 
well as reducing rates of depression and improving self-esteem in children with chronic 
disease (34, 72, 73). Thus PA is considered a principal intervention for primary and 
secondary disease prevention (74). Indeed, it is important for patients with chronic 
diseases, especially for paediatric patients, because it influences their growth, 
promoting bone strength and improves body composition (75). Further, some studies 
have shown that in adult patients regular PA during treatments helps them to tolerate 
better treatment-induced side effects and improves their quality of life.  
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 Physical Activity Guidelines in Children  
The appropriate amounts of PA for general population, including children and youth 
have been developed by several government and non-government organisations. The 
first PA guidelines for children and youth were introduced by Canada in 2002 (76, 77). 
The basic recommendation within these guidelines was that children and youth should 
increase their time spent on PA by 30 minutes per day, independent of their current PA 
level and progress over approximately 5 months to more than 90 minutes per day Based 
on large amounts of strong and consistent evidence which have been summarised and 
synthesised in several systematic and narrative reviews (notably (20, 38, 78-82) it has 
been suggested in numerous more recent evidence-based guidelines that participating 
in a minimum 60 minutes per day of MVPA will have meaningful health benefits for 
children and youth. As an illustration of the available evidence, the systematic review 
of Strong et al (20) reviewed 850 articles. They found that evidence-based data are 
strong for beneficial effects of physical activity on musculoskeletal health, several 
components of cardiovascular health, adiposity in overweight youth, and blood 
pressure in mildly hypertensive adolescents. Evidence was adequate to make informed 
judgments about the beneficial effects of physical activity on lipid and lipoprotein 
levels and adiposity in normal weight children and adolescents, blood pressure in 
normotensive youth, other cardiovascular variables, self-concept, anxiety, and 
depression symptoms, and academic performance. Although the definition of the 
metabolic syndrome for youth is not yet firmly established, the association between the 
MS and adiposity, lipid and lipoprotein levels, and blood pressure suggests that 
regulation of overweight through physical activity may have a beneficial effect on 
components of the syndrome. The authors noted that most of intervention studies used 
supervised programs of moderate to vigorous physical activity of 30 to 45 minutes 
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duration 3 to 5 days per week. The reviewing panel believed that a greater amount of 
physical activity would be necessary to achieve similar beneficial effects on health and 
behavioural outcomes in ordinary daily circumstances where activity is typically 
intermittent and unsupervised. They concluded by recommending that school-age 
youth should participate daily in 60 minutes or more of moderate to vigorous physical 
activity that is developmentally appropriate, enjoyable, and involves a variety of 
activities. Several world public health organisations now recommend that, children and 
adolescents should accumulate a minimum of 60 minutes of MVPA daily. A dose 
greater than 60 minutes provides greater health benefits (9, 20). 
 
While national and international guidelines recommend at least 60 minutes/day of 
MVPA for school-age children and adolescents, it is widely accepted ((81, 82)) that for 
those individuals with levels of MVPA below the recommendation there should be 
benefits of increasing MVPA levels, even if they do not meet the 60 minutes/day 
recommended. In addition, the recent evidence based guideline acknowledge that the 
60 minutes per day is somewhat arbitrary, and based on the need to have a simple 
recommendation for public health messaging, and for public health surveillance (e.g. 
national and international surveys of MVPA in children and adolescents) (83). Recent 
evidence based guidelines also acknowledge that there are benefits to increasing MVPA 
beyond the 60 minutes/day (81-83), and that the recommendation should not be seen as 
a simple target or threshold. Therefore, children and youth who are very inactive and 
could not achieve the MVPA recommendation should be encouraged to accumulate a 
minimal target of 60 minutes of MVPA per day in shorter bouts (e.g., 10- 15 min) 
throughout the day (80, 84). 
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In respect of the number of steps needed per day to achieve the daily recommended 
levels of physical activity to promote and maintain the health, Tudor-Locke provided 
accumulated evidence from reviewing objectively monitored step-defined PA 
literature; the minimal recommendation of total volume of PA is associated with 
10,000-14,000 free-living steps/day in children aged 4-6 years; for children aged 6-11 
years 12000-16000 steps/day in boys and 10000 to 13000 steps/day in girls with this 
difference in the steps recommendation could be related to sex-and-age specific data of 
Beets et al (85). For children aged 12-19 years 8000-9000 steps/day is recommended 
and associated with good health (86). These recommendations have also been applied 
to children with chronic disease (30, 87). 
 
1.2.2. Sedentary Behaviour 
 Definition 
Sedentary behaviour (SB) – often called “Sitting“ is defined currently as any PA that 
has an energy requirement of less than 1.5 METs in sitting/lying position as noted above 
(88). Total sedentary time (ST) can be further sub-classified into a variety of specific 
categories of SB such as reading, playing quietly, or engaging in screen-based 
entertainment include watching television, using a computer, or playing video games 
(5, 89). Thus, SB is a complex construct which includes both being sedentary and a 
range of behaviours that take place while being sedentary, some of which may be more 
harmful than others (e.g. screen time); as explained in details later (36, 90). 
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 Sedentary Behaviour in Healthy Children  
The previous literature clearly indicates that SB might have an impact on health status. 
The first report provided by Bernadino Ramazzini that showed there is a relationship 
between SB and deleterious health consequences (91, 92). Indeed, the original Morris 
studies of London bus drivers vs bus conductors have even been re-interpreted by some 
as providing evidence of the harmful effects of sitting rather than just evidence of the 
benefits of PA (2). Many epidemiologic studies have now linked high levels of SB in 
childhood with many of unfavourable health consequences (36, 55), which lead to an 
increased risk of morbidity and premature mortality in adult life (88). A sedentary 
lifestyle has been consistently and positively associated with an increased risk of 
various chronic diseases in adult life including cardiovascular diseases, diabetes, cancer 
and psychological problems (36).  
 
So far, multiple lines of evidence have suggested a link between screen-time sedentary 
and gain weight in children (65). Indeed, it has been clearly demonstrated that there is 
a time dependent dose response relationship; every additional hour of time spent on 
viewing television, using computer and playing video games was significant associated 
with being overweight and having higher central adiposity among in children and 
adolescents (6, 67, 90, 93-96). Screen time guidelines are now common around the 
world (5, 9, 89, 96). 
Further, while children and adolescents typically do not have cardiovascular diseases 
there is a positive association between SB and risk factors for development of 
cardiovascular diseases in children and adolescents. Byun et al has shown that time 
spent on screen-based SB was significantly positively associated with cardiovascular 
diseases risk factors independent of levels of PA (97). A cross sectional study in 
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Portugal on the associations between cardiovascular risk markers and three types of 
screen-time SB (viewing television, using computer and playing video games) in school 
children, with screen time data collected by a questionnaire reported that, time spent on 
television viewing was strongly associated with increased risk of cardiovascular 
markers especially for those children watching television > 2 h/day, independent of 
levels of PA (98). In addition, some studies have reported that SB, such as excessive 
time spent in television viewing, video games and computer use, is associated with 
raised blood pressure in both childhood and adolescence (99, 100). 
 
 Sedentary Behaviour in Children with Obesity 
In addition to insufficient PA and diet, sedentary life have been suggested as one of the 
causes in the development and or maintenance of obesity in children and adolescent 
(67). As noted above, the relation between both might be bidirectional: more time spent 
on SB might increase risk of development of obesity while obesity could be the cause 
of more time spent sedentary in children and adolescent (101). Indeed, a cross-sectional 
study that included 712 child aged from 9-16 years old in Mexico using questionnaires 
to evaluate the time spent watching television, reported that children spent an average 
of 4 hours/ day watching television and this time was related to increase obesity 
prevalence with each additional hour of watching associated with 12% greater risk of 
obesity (102). This observation was confirmed by large cohort study were included 
5434 children used an accelerometer for seven days to examine the association between 
ST and obesity among 12-year-old children (68).  
 
This is of importance and concern, since more time spent in SB has been shown to 
increase the risk of obesity-related health problems, including adverse metabolic 
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profiles as a consequence of the increased adiposity in children (67), and type II 
diabetes, CVD, certain cancers, and various metabolic risk factors in adult (103). 
 
 Sedentary Behaviour in Children with Chronic Disease 
Children where health impairments are present (e.g. chronic cardiovascular or 
respiratory disease), grow up with a daily burden of disease, such as disease symptoms, 
or treatment effects that might encourage the adoption of a sedentary lifestyle (104). 
There are a growing number of studies exploring ST in children with chronic disease 
which have demonstrated that children with chronic disease spend most of their waking 
time sedentary, a behaviour that seems to be associated with increased risk of co-
morbidities and reduced quality of life (105, 106). 
 
 Sedentary Behaviour Guidelines in Children 
Currently there are no guidelines for total time spent in SB with those available only 
for SB based on screen time. Several bodies have recommended minimizing the screen 
time for 1-2 hours/day in children and adolescents and have recommended that those 
aged 0-2 years should not spend any time watching TV or electronic media to maintain 
healthy growth and wellbeing, as well as reducing the risk of development of chronic 
diseases (9, 96). 
1.2.3. Sleep  
 Definition 
Perhaps the most novel aspect of the integrated movement behaviours concept is the 
inclusion of sleep, usually regarded as a period of very reduced or no movement, as 
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part of the spectrum of movement behaviours. Sleep is a natural occurring state 
resulting from a complex amalgam of physiological and behavioural processes (107). 
It is a reversible, periodic and recurring state of perceptual disconnection from and 
unawareness of the environment (108). Sleep can be defined as a behavioural state 
controlled by the hypothalamus and brainstem where the response to outside 
stimulation is reduced, consciousness and muscular activity is temporarily suspended 
or diminished. Individuals vary greatly in their need for sleep, and the amount of sleep 
needed depends on many factors including age with duration of sleep shorter as age 
increases (109). Not surprisingly, infants require the greatest amount of sleep − about 
16 hours per day − as hormones that promote growth are released during sleep. Children 
and adolescents need about 9 -11 hours on average per day (110). For most adults, 7 - 
8 hours per day are required although some people such as pregnant women may need 
as many as 10 hours of sleep each day during the first 3 months of pregnancy (109, 
111). 
 Sleep in Healthy Children  
Sleep is critically important to children’s health and wellbeing (112). Sleep (quantity 
as well as quality) are essential for physical growth, mental development and 
maintenance of emotional and mental wellbeing in children and adolescents (113). 
Thus, healthy sleep (meaning adequate sleep duration, at appropriate times, and of good 
quality - with no or limited disturbance/interruption by awake episodes) is particularly 
important during childhood, as inadequate sleep is associated with atypical physical 
and cognitive development (112, 114).  
 
In recent years, the notion that children are sleeping less has become popular and there 
is evidence of a secular decline in sleep duration in children, the cause of which is not 
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fully understood (115). However, the literature has suggested a number of reasons 
including increased use of technology leading to later bed times “onset of sleep” with 
unchanged wake time “sleep offset” as they have to go to school in morning. As a 
consequence it is widely suggested that many children are getting less sleep than they 
should be (115-118). 
 
Inadequate sleep during the childhood is associated with increased risk of a number of 
medical conditions that may contribute to the premature mortality rate in later adult life 
(119, 120). Unfavourable consequences include: obesity, diabetes, depression, suicidal 
ideation, and poor academic performance that may occur with either short or long sleep 
duration independent of other movement behaviours (115, 121-124). 
 Sleep in Children with Chronic Disease 
Healthy sleep is an integral part of physical and mental health in children as noted above 
(112, 125) and influences risk of premature mortality in later adult life (119). Children 
with chronic disease are especially believed to be at increased risk for sleep problems 
in terms of sleep duration, quality and night time awakenings, and a number of 
epidemiological studies have found an increased rate of sleep problems in children with 
chronic diseases (126-129). In one Norway study, that included 496 children with 
different chronic diseases and used both parent and child reports to assess sleep 
problems, Hysing et al. found that the children and their parents reported more 
problems falling asleep and had more night-time awakenings compared to healthy 
children (130). 
Chapter I 45 
1.2.4. Integrated Movement Behaviours Guidelines 
The 24-hour movement behaviours guidelines for children and young people have been 
developed from both Canadian and Australian 24-Hour movement guidelines in healthy 
preschool, children and adolescent (131-133). This new a paradigm that consider all 
movement behaviours occurring over 24 h period in combinations for optimal health 
(132). Twenty-four-hour movement behaviours guidelines are summarised in Table 
1.1.  
Table 1.1: Integrated movement behaviours guidelines for children and adolescents 
 
Behaviours <5 years 5 – 17 or 18 years  
Sleep Good-quality sleep including naps 
per night as14-17 h for age 0-
3months, 12-16 h for age 4-
11months, 11-14 h for age 1-2 
years, 10-13 h for age 3-4 years. 
Uninterrupted 9-11 h of sleep per 
night for age 5-13 years, 8-10 h 
of sleep per night for age 14-17 
years, with consistent bed and 
wake-up times  
Physical activity For those< 1year: being physically 
active several times per day in 
variety ways. 
 
For those 1-4 years, accumulation of 
≥ 180 minutes per day of a variety 
PA. 
 
For those 3-4 years, ≥ 60 minutes 
per day of an energetic play 
An accumulation of ≥ 60 minutes 
per day of MVPA involving 
aerobic activity 
Vigorous PA and muscle and 
bone strengthening activities 
should be ≥ 3days per week 
Light physical activity  Several hours of a variety of 
un/structured LPA 
Sedentary behaviour Not being restrained for more than 1 
h at a time. 
 
No < 1 h per day of screen time For 
those 3-4 years; while no screen SB 
for 0-2 years  
No < 2 h per day of recreational 
screen time. 
Limited sitting for extended 
periods 
General 
recommendation 
Replacing time restrained or screen 
time with additional energetic play, 
trading indoor time for outdoor time 
and preserving sufficient sleep 
Preserving sufficient sleep, 
trading indoor time for outdoor 
time, and replacing SB and LPA 
with additional MVPA. 
h - hour; LPA - light physical activity; MVPA - moderate to vigorous physical activity; SB - 
sedentary behaviour. Adapted from Canadian and Australian 24-hour movement behaviours 
guidelines for children and youth (131-133). 
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1.2.5. Measurements of Integrated Movement Behaviours  
The 24-hour movement behaviours concept is new and guidelines based on it even 
newer. Few studies have addressed basic issues such as measurement of the 24-hour 
movement behaviours in healthy children. In the available studies the PA, SB and sleep 
were measured either subjectively, or objectively, or using a combination of 
subjectively and objectively. The previous literature reported pros and cons of the 
several methods that available to assess PA, SB and sleep in free-living conditions, 
summarised in Table 1.2. The accurate combined measurement of these behaviours is 
a key factor in improving our understanding how these behaviours interact together and 
impact on our health, for example. Low PA levels have been linked to poor sleep quality 
(134) while sleep deprivation is linked to decline in daily PA and to increases in obesity 
in children. Thus, accurate and reliable measurement of the 24-hour movement 
behaviours may be an important step in guiding activity recommendations throughout 
a day, but there is difficulty inherent in measuring PA, SB and sleep simultaneously. 
Although, the 24-hour movement behaviours is a new concept and the researches still 
going on and currently the most of the studies have used self-report data to investigate 
the levels of activity, SB and sleep which are not reliable in children (135) and do not 
allow for distinguishing between SB/sleep, LPA, and MVPA.  
Accelerometry is now one of the most widely, accurately and valid tools for measuring 
PA levels, SB and sleep objectively. There are a variety of accelerometer types and 
models and with different measurement protocols. 
 
Traditionally, accelerometers have been worn on the hip or low back as this location 
has been considered to provide the best estimates of PA intensity and energy 
expenditure (136). Accelerometers worn on the wrist or ankle have been shown to 
Chapter I 47 
promote good device compliance over longer wear times and have been used to assess 
sleep among children (137-139). Accelerometer worn on the thigh provided high 
accuracy for classification of PA intensity (LPA and MVPA) and sitting/lying 
behaviours and breaks in SB with other advantages such as improved comfort and better 
compliance over longer periods of measurement(140). However, until now, there is no 
single device could be captures all behaviours data across the entire 24- hour and the 
accurate assessment may require a subject to wear two accelerometers or more that 
would likely be an expensive and result in lower compliance, particularly when a 
minimum of four consecutive days of accelerometer data are recommended to obtain 
valid and reliable measurements.  
 
For several reasons, the ActivPALTM device was chosen as the assessment method in 
the present studies. These includes that while most accelerometers are usually worn 
around the waist, hip or lower back with an elastic belt and adjustable buckle, while 
The ActivPALTM is a thigh-worn accelerometer, which, when compared with wrist and 
waist-worn monitors is more convenient to keep in place for longer periods. This is an 
important benefit in young children including those with chronic diseases when 
prolonged periods of wear are planned. Further, it has proved to be the best at measuring 
and identifying times spent in postures such as sitting/lying, standing and walking 
(141). Also, it is a very useful characteristic for determining time spent in SB, walking 
and total number of steps. The strong evidence shows that the ActivPALTM offers 
acceptable validity, utility and reliability tool in measuring posture and activity during 
the daily activities of children, further details provided in Chapter II, section 2.2.6 pages 
84-86. 
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Table 1.2: Measurements of integrated movement behaviours 
 
Behaviours Methods Type Advantage Disadvantage 
Physical activity and 
sedentary 
behaviours 
Subjective methods Self-report; interviews, proxy-report 
(informed by another person usually parent 
for children under 10 years old); diaries 
and questionnaires  
Non-invasive; inexpensive; not require 
a well- trained researcher to apply; 
suitable for large studies 
Recall bias; low reliability and validity; 
potential reactivity. 
 Criterion methods  Direct and indirect calorimeter (27, 142) Accurate method for measuring EE 
and assess PA 
Relatively expensive; not suitable for 
children 
  Doubly labelled water  Gold standard method for evaluating 
TEE in free living conditions; safe, 
easily applied and is not affected by 
patterns PA (27, 143). 
Relatively expensive; not suitable for 
children and large studies; difficult to 
obtaining the isotope; cannot provided 
information about patterns PA (27, 143). 
  Direct observation  Non-invasive; reliable and valid; 
eliminated self-report bias; gold 
standard for SB and posture changes. 
Potential reactivity; high cost of time and 
energy; not suitable for large studies lack 
objective measures of energy expenditure 
(144) 
 Objective methods Heart rate monitor Non-invasive; measures of full day 
over multiple days; relatively 
inexpensive (145). 
Heart rate changes maybe unrelated to PA; 
not suitable for water activity; requires a 
known relationship between heart rate and 
PA workload; provided only total activity 
per time period; affected by environmental 
and emotional factors (145). 
  Pedometers (146) Non-invasive; relatively inexpensive; 
visibility of measurements to user 
varies between models; provided total 
activity and number of steps over 
period of time. 
Measurements accuracy various with cost; 
not suitable for water activity; technical 
limitation to detection and measurement of 
certain types of activity depending on 
model used and it placements on body 
  Accelerometer including Actigraph, actical Non-invasive; activity intensity and 
duration; measures of full day over 
Technical limitation to detection and 
measurement of certain types of activity 
Chapter I 49 
and activPALTM multiple days; shock and water 
resistant, with some models being 
suitable for water activity; suitable for 
adult and children; measurements are 
not visible to user; recording of 
activity cannot be altered by user 
(146). 
depending on model used and it 
placements on body 
Sleeping behaviour 
assessment  
Subjective methods Sleep habits questionnaires and structured 
sleep diaries (147, 148) 
Non-invasive; inexpensive; ease to 
use, not require a well- trained 
researcher to apply; suitable for large 
studies 
Low degree of accuracy to recall 
information and the variability inherent 
subjective reporting  
 Criterion methods  Polysomnography (149) Gold standard procedure to monitoring 
the sleep stages 
Relatively expensive; complicated 
procedure that needs well-trained 
personnel  
 Objective methods Accelerometer (138, 139) Gold standard measure of in 
community research to measure sleep 
time and pattern; gathering PA, SB 
and sleep data simultaneously with/out 
an accompanying sleep diary; suitable 
for large studies  
Technical limitation depending on model 
used and its placements on body 
EE- energy expenditure; SB- sedentary behaviours; PA- physical activity; TEE- total energy expenditure.
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1.2.6. Factors Influencing Integrated Movement Behaviours 
 Age  
Age is the one of the main factors believed to determine levels of integrated movement 
behaviours in children and adolescents. There is a decline in PA level with age, 
confirmed by cross-sectional studies and longitudinal studies (150-155). For example, 
a cross-sectional study in Canada that included (n=401) children aged from (8-13 years 
of age) and measured daily MVPA and VPA by actiGraph accelerometer over seven 
consecutive days found that levels of PA decreased with increasing chronological age 
(151). A recent longitudinal cohort study in United Kingdom (UK) (Gateshead 
Millennium Study) with 8 years of follow-up included 545 children and measured 
habitual MVPA objectively by ActiGraph GT1M accelerometer first at 7 years of age, 
and then at 9, 12 years of age. This study reported there was a decline in levels of PA 
across the eight years, with evidence that the total volume of PA had started declining 
by age 7 years (156). 
 
Several studies have confirmed that time spent in sitting and screen based activity was 
higher in adolescents compared to young children (157). Increasing age was associated 
with more prolonged sitting bouts with fewer breaks in sitting. Strong recent evidence 
comes from a longitudinal analysis of the Gateshead Millennium Study cohort in the 
UK in 2016 with eight years follow up as noted above - in this study ST increased with 
chronological age from 7 to 15 years of age and this increase in ST displaced time 
spent in PA; median ST increased from 51% of waking hours at 7 years to 74% at 15 
years of age, with sedentary fragmentation decreasing from 7 years to 15 years as 
median number of breaks in sitting time /hour decreased from 8.6 to 4.1 (158). 
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Duration of sleep is also age-dependent as noted above: preschool-age children had 
longer sleep durations than school-age children (earlier bed time and later wake-up 
time), while children at school age and older had less sleep duration as they had later 
sleep onset time with unchanged wake-up time. Waking time appears more stable 
perhaps because of the need to wake-up early to go to school (118). 
 
 Sex 
Sex is a second important determinant of levels of integrated movement behaviours in 
children and adolescents. Boys are more active compared to girls of the same age, 
confirmed by both cross-sectional studies and longitudinal studies (151-156). For 
instance, evidence comes from the Lifestyle of our Kids (LOOK) longitudinal study, 
which included 276 boys and 279 girls from 29 schools aged 8-12 years of age. PA 
was measured using pedometers (Walk 4 Life, Plainfield, IL, USA) over seven 
consecutive days and the results revealed that, level of PA was lower in girls compared 
to boys and girls were 19% less active than boys (159). 
 
Similarly, on average girls accumulate higher ST than boys (67, 101, 157, 160). 
Interestingly, an observational cross-sectional survey within the framework of the 
ENERGY-project (EuropeaN Energy balance Research to prevent excessive weight 
Gain among Youth) that included 686 children aged 10-12 year of age, 53% girls, 
across 5 European countries using accelerometers to determine the amount of ST again 
found that ST was higher in girls and girls spent significantly more time sedentary 
(500 minutes/day) than boys (474 minutes/day) (161). 
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There is only limited evidence that sleep duration and timing are influenced by gender, 
at present. In the French Mother–Child Cohort (EDEN Study) cross-sectional study 
factors associated with short sleep duration 1028 child (boys (n=546) and girls 
(n=482)) aged 3 years of age, were investigated by using parent report. This study 
found that, boys had significantly shorter sleep duration compared to girls as boys had 
later bedtimes and earlier wake‐up times than girls. However, the mean total sleep 
duration, if the time naps were included, did not differ significantly by gender (162). 
Sleep duration guidelines are not gender-specific at present (131-133). 
 
 Season  
Lastly, some studies confirm that there is seasonal effect on at least some of the 24 
hour movement behaviours in at least some parts of the world. Seasons are defined as 
the natural periods in which the year is divided, which vary by weather conditions, 
daylight hours and temperature (163). A systematic review included 37 primary 
studies with a total of 291,883 children and adolescents (140,482 male and 152,085 
female) from eight different countries to explore the effect of season, and consequently 
weather, on levels of PA, and they revealed that, level of PA varies with season (163). 
Further, boys had different PA patterns as they tended to be more sedentary and less 
active during the winter, while girls had more consistent levels of PA and ST across 
the seasons. A pilot study in 24 participants aged 10-13 years characterised seasonal 
variation in MVPA and ST. They found that, participants were more active in the 
summer and activity levels were higher after school than in school and ST was higher 
in winter than in the summer time (164). 
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At present, there is limited evidence that sleep duration and timing are influenced by 
seasons in children and youth. A recent cross-sectional analysis of 669 participants 
aged at age’s 12–14years, used wrist accelerometers to assess the sleep timing, 
duration and quality with season and daily weather conditions. They found that season 
was associated with large changes in sleep timing but not with sleep duration. Sleep 
onset time was 41 minutes later in summer and 28 minutes earlier in spring and autumn 
compared to winter and that indicating seasonal variation in the timing of the sleep 
period (165). 
 
In summary, these three factors – age, sex and season - are amongst the most important 
confounding influences in studies 24-hour movement behaviours in children. Thus, 
investigators need to consider these three factors (age, gender, time of year) when 
designing studies to consider variation in or differences in 24-hour movement 
behaviours between groups.  
 
1.3. Integrated Movement Behaviours in Children with 
Chronic Disease 
Although, there are many studies of levels of PA, ST and sleep in healthy children and 
adolescents, there are surprisingly few such studies in those with chronic disease. In 
fact, numerous previous studies and national PA surveillance programmes have 
actually excluded children and adolescents with chronic disease. Also, the 24-hour 
movement behaviours concept is so new that it has not yet been applied to studying 
children with chronic disease.  
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Chronic illness in children and adolescents can be defined as any physical, emotional, 
or mental health problem that lasts at least three months, and affects a child’s physical 
appearance and/ or growth and daily normal activities and results in frequent 
hospitalisations with regular therapy and sometimes unpleasant procedures, with home 
and medical care (166). Chronic illness frequently results in impairment of a child’s 
psychosocial development and impairment of their educational progress through 
possible loss of schooling (166). Indeed, the most important features that characterise 
chronic medical conditions are their prolonged duration, their lack of spontaneous 
resolution, and the fact that are rarely cured completely. Chronic illness in children is 
also disrupting to their families and that might lead to negative impact on daily 
functioning and quality of life for multiple family members (167).  
 
The prevalence of chronic diseases in children and adolescent is often hard to ascertain 
due to the varying conceptual definitions and differing approaches to measurement. 
But epidemiologic studies suggest that the prevalence of chronic disease in children 
and adolescents has actually been increasing and is likely to continue to rise (166, 
168), accompanied with rising obesity rates (169). Increasing childhood obesity could 
be driving the increase in a number of other chronic conditions (166). Further, based 
on evidence from the United States. National Survey of Children’s Health, in children 
and adolescents aged from 0-17 years 13.6% were living with one chronic disease, 
around 8.7% had two or more chronic conditions excluding obesity. In 65.6% of them 
their health conditions affected their daily activities at least some of the time. In the 
UK about one in seven (15%) children aged 11-15 report having been diagnosed with 
a chronic disease (170). 
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Common chronic childhood diseases 
Chronic condition is an "umbrella" term. The most common childhood chronic illness 
are asthma, cystic fibrosis (CF), diabetes either type 1 or type 2 (T1DM and T2DM), 
obesity, arthritis, malnutrition, congenital heart disease (CHD), developmental 
disabilities, including attention-deficit/ hyper-activity disorder and the autism 
spectrum disorders, cerebral palsy and mental illnesses (171).  
 
The present thesis focuses on four common chronic childhood diseases: T1DM, 
juvenile idiopathic arthritis (JIA), CHD and CF. These conditions were chosen due to 
their prevalence and their potential to impact on 24-hour movement behaviours (PA, 
SB and sleep), as described below.  
 
1.3.1. Type 1 Diabetes Mellitus 
T1DM is a serious lifelong condition and is defined as an autoimmune disease 
characterised by inability of the beta cells in the pancreas to produce endogenous 
insulin needed to regulate blood glucose. The lack of insulin leads to high levels of 
blood glucose (hyperglycaemia) and the need for insulin therapy to control the level 
of blood glucose (172).  
 
 Incidence and Prevalence  
The incidence of T1DM in children under the age of 15 years is increasing in many 
countries, and it is now usually counted as the third most common chronic disease in 
the paediatric population after asthma and cerebral palsy (173). In the UK, prevalence 
of T1DM in children aged < 19 years of age is 1 in 430-530 children, and the disease 
incidence about 24 in 100,000 in children aged <14 years of age each year (174). 
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 Diagnostic Criteria and Glycemic Control  
T1DM is characterised by a fasting plasma glucose concentration of ≥7.0 mmol/l (126 
mg/dl) in repeated measurements, or a 2-h plasma glucose concentration of ≥11.1 
mmol/l (200mg/dl). Additionally, a random plasma glucose value of ≥11.1 mmol/l 
(≥200mg/dl) in conjunction with symptoms of diabetes (thirst, polyuria, weight loss) 
also leads to a diagnosis of diabetes (172). In children with T1DM long-term 
glycaemic control is clinically determined by level of the HbA1c. According to the 
UK National Institute for Health and Care Excellence (NICE guideline) the optimal 
blood glucose control that children should be aiming to achieve will result in an HbA1c 
≤ 48 mmol/mol (HbA1c referred to glycated haemoglobin (A1c)), with higher HbA1c 
levels indicating poorer diabetes control (175).  
 
 Treatment of Type 1 Diabetes Mellitus in Children  
Treatment optimisation requires a lifelong commitment to achieving optimal blood 
glucose control. Insulin is delivered subcutaneously, either by injected boluses 
(multiple daily injection therapy) or a continuous subcutaneous infusion administered 
by an insulin pump attached to the skin by cannula (insulin pump therapy) (175). 
 
 Type 1 Diabetes Mellitus Complications  
Children with T1DM are at high risk of diabetic complications. The complications are 
divided into micro-vascular complications (nephropathy, retinopathy, and neuropathy) 
and macro-vascular complications such as coronary artery disease, peripheral arterial 
disease, and stroke. (176) Recent studies show that signs of atherosclerotic disease, 
diabetic retinopathy, and diabetic nephropathy are already detectable in young 
children with T1DM (177-179). T1DM complications are related to blood glucose 
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levels, and are more pronounced in children with poor glycemic control HbA1c > 48 
mmol/mol. In the UK 2013-2014 evidence from England and Wales reported that, less 
than 19% of children with T1DM had achieved the NICE guideline target for blood 
glucose control when it was set at 58 mmol/mol (175). Development of diabetes 
complications could be prevented only by good metabolic control of the disease 
through maintaining target blood glucose levels (175). Achieving control is based on 
treatment with insulin, compliance with the dietary restrictions and rules and proper 
level of PA (discussed below) combined with good education (172, 175). 
 
 Possible Disease Effects on Integrated Movement Behaviours 
in Children with Type 1 Diabetes Mellitus 
Physical activity is routinely recommended in paediatric T1DM management (180, 
181). PA recommendations for those with T1DM are to achieve a minimum of 60 
minutes of MVPA per day (175, 180), the same as for healthy children. Achieving this 
could have significant positive effects on short- and long-term health outcomes (182), 
such as improving insulin sensitivity and glycaemic control, limiting excessive weight 
gain, increasing sense of wellbeing, improving known risk factors for atherosclerosis 
and helping in the prevention of later cardiovascular disease (181, 183).  
 
Current research indicates that most children with T1DM lead sedentary lifestyles, and 
high amounts of SB have been linked with poor glycemic control (184). Sedentary 
lifestyles in those with T1DM have also been associated with a rapid reduction in 
insulin sensitivity and raised blood glucose level particularly postprandial glucose, 
leading to increased risk of obesity, hypertension and cardiovascular disease (106), 
and the consequent development of cardiovascular disease already has been observed 
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in diabetic children with abnormal lipid concentrations level (185). Cardiovascular 
diseases are the main cause of increased morbidity and mortality rates in adults with 
T1DM (186, 187). Indeed, recent evidence suggests that children with T1DM had 
remarkably high levels of SB and focusing just on MVPA may not be enough to reduce 
risk of diabetic complications. Hence focusing on simultaneously decreasing levels of 
SB is warranted to decrease cardiovascular risks (188, 189). 
 
Sleep has physiological and behavioural impacts on health outcomes in children with 
T1DM (190). It is therefore increasingly identified as an important variable to consider 
as part of management in children with T1DM (190). Recent evidence shows that 
children with T1DM had short sleep duration with more disturbances that were due to 
disease management issues such as night-time blood glucose monitoring (127), as 
most of those with diabetes might wake up several times during the night to check or 
adjust level of blood glucose to avoid the nocturnal hypoglycaemic attack (190). 
Inadequate sleep whether in terms of sleep quality and or sleep duration had negative 
impact on children with T1DM (191, 192), either directly through poor control of 
blood glucose and reduced insulin sensitivity, or indirectly through reduced self-
esteem and decreased academic performance. Short sleep duration in children with 
T1DM has been linked with increased risk of cardiovascular disease through lack of 
the normal decline in blood pressure during sleep (193, 194). 
 
It is believed that many diabetic children do not follow the PA recommendation, as 
they or their parents may fear hypoglycaemia from PA in spontaneous or organised 
exercise, thus leading to spent greater amounts of their daily time in SB. Fear of 
hypoglycaemia may also impact their sleep quality and duration (106, 190, 195, 196). 
Hypoglycaemia could be due to administration of an excessive dose of insulin before 
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exercise, increased of glucose uptake, or may due to increased insulin sensitivity (197, 
198). Despite risk of hypoglycaemia, children with T1DM should be encouraged to 
participate in PA and reduce the time spent in SB, by taking into account duration and 
intensity level of PA and adjusting the insulin dose, level of blood glucose and need 
for carbohydrate replacement (175).  
 
1.3.2. Juvenile Idiopathic Arthritis  
Juvenile idiopathic arthritis (JIA) previously also called juvenile chronic arthritis and 
juvenile rheumatoid arthritis has been regarded as an autoimmune disease and is the 
most common arthritic disease of childhood. The underlying cause and processes are 
poorly understood (199). JIA is not a single disease; rather it is a heterogeneous group 
of diseases and based on the current concepts, system-onset JIA is an auto-
inflammatory than autoimmune disease (200). According to the International League 
of Associations for Rheumatology (ILAR) (200), JIA is defined as joint pain, swelling, 
tenderness and morning stiffness  associated with a limitation in the range of joint 
movement that begins before the sixteenth birthday and persists for at least six weeks 
or more, after other reasons for arthritis are excluded (201). In addition to arthritis, 
children with JIA frequently have extra-articular manifestation such as uveitis (Uveitis 
is the inflammation of the uvea (comprising the iris, choroid and retina) and it is most 
frequent extra-articular manifestation. 
 
 Incidence and Prevalence  
The incidence and prevalence of JIA are exactly unknown worldwide (202), and 
several epidemiological studies have reported a wide variance in different regions of 
the world. In the United States prevalence of JIA in children aged less than sixteen is 
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about 6 in 10,000 children (202), and the annual incidence is about 1 per 10,000 
children (203, 204). In Europe annual incidence is about 16–150 per 100.000 children. 
In the UK an estimated 12, 000 children have JIA (205, 206). 
 
 Diagnostic Criteria and Classification  
There are no specific diagnostic tests for JIA. Thus, children aged less than 16 years 
old with chronic arthritis lasting for more than six weeks in the absence of any known 
cause, may be diagnosed as having JIA. Further, JIA can be classified into eight 
different categories based on the ILAR (201), as follow: systemic onset JIA, 
oligoarthritis persistent, oligoarthritis extended, polyarthritis (RF-negative), 
polyarthritis (RF-positive), psoriatic arthritis, enthesitis-related arthritis and an 
undifferentiated arthritis, diagnostic, definition and excluded criteria are provided in 
Table 1.3. 
 
Table 1.3: International League of Associations for Rheumatology classification of JIA 
 
Category Definition Exclusions 
Systemic arthritis Arthritis in one or more joints with 
fever for two weeks (at least 3 days 
with a daily pattern) plus one or more 
systemic manifestations: 
1. Erythematous rash. 
2. Generalized lymphadenopathy. 
3. Hepatomegaly and/or 
splenomegaly. 
4. 4. Pericarditis and/or pleuritis 
and/or peritonitis. 
A. Psoriasis or history of 
psoriasis in a first-degree 
relative  
B. Arthritis in a HLA-B27 
positive male beginning at 6 
years of age or older  
C. History of ankylosing 
spondylitis, enthesitis-
related arthritis, sacroilitis 
with inflammatory bowel 
disease, Reiter’s syndrome  
D. IgM RF on two or more 
occasions, 3 months apart  
Oligoarthritis Persistent Arthritis affecting 1–4 joints 
throughout the disease course 
A–D above, plus 
E. The presence of systemic 
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JIA 
Oligoarthritis Extended Arthritis affecting 1–4 joints during 
the first 6 months, than affecting more 
than four joints 
A, B, C, D and E 
Polyarthritis (RF-
negative) 
Arthritis affecting 5 or more joints 
during the first 6 months following the 
onset of the disease RF negative 
A, B, C, D and E 
Polyarthritis (RF-
positive) 
Arthritis affecting five or more joints 
during the first six months of the 
disease rheumatoid factor positive two 
or more times at least three months 
apart 
A, B, C, D and E 
Psoriatic arthritis Arthritis and psoriasis, or arthritis and 
at least 2 of the following: 
1. Dactylitis* 
2.   Nail pitting** and onycholysis 
3. Psoriasis in a first-degree relative 
B, C, D and E 
Enthesitis-related 
arthritis 
Arthritis and Enthesitis+, or arthritis 
or enthesitis with at least 2 of the 
following:  
1. The presence of or a history of 
sacroiliac joint tenderness and/or 
inflammatory lumbosacral pain++ 
2. The presence of HLA-B27 
antigen 
3. Onset of arthritis in a male over 6 
years of age 
4. Acute anterior uveitis 
5. History of spondylitis, enthesitis-
related arthritis, sacroiliitis with 
inflammatory bowel disease, 
Reiter’s syndrome  
A, D and E 
Undifferentiated arthritis Arthritis that fulfils criteria in no 
category or in 2 or more of the above 
categories. 
 
RF- rheumatoid factor, the table Adapted from (Petty et al (201). 
*Dactylitis is swelling of one or more digits, usually in an asymmetrical distribution, which 
extends beyond the joint margin.  
**A minimum of 2 pits on any one or more nails at any time.  
+Enthesitis is defined as tenderness at the insertion of a tendon, ligament, joint capsule, or 
fascia to bone.  
++Inflammatory lumbosacral pain refers to lumbosacral pain at rest with morning stiffness that 
improves on movement.  
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 Evaluation of Disease Activity  
In children with JIA, persistent active disease could be the primary cause of joint 
damage and physical disability; thus evaluation of disease activity is a critical 
component of the clinical assessment of those children (207). In clinical assessment 
the JIA disease activity is evaluated by using a number of variables such as: the number 
of swollen joints, number of tender joints, number of painful joints, number of joints 
with restricted movement, inflammatory markers (erythrocyte sedimentation rate 
(ESR) and/or C-reactive protein (CRP) values), physicians global assessment of 
disease activity (range from 0= best to 10=worst), and the parents/patients global 
assessment of disease activity (range from 0= best to 10=worst) (208). Recently, a 
composite tool to assess the disease activity in JIA has been developed, named the 
Juvenile Arthritis Disease Activity Score (JADAS). JADAS has been developed and 
validated in children (207) and consists of 4 components: number of joints with active 
disease assessed in 10, 27 or 71 joints; an inflammatory marker ESR and/or CRP; 
physician global assessment of disease activity; parent/patient global assessment of 
well-being (207). Using the JADAS tool gives the capacity to assess the disease 
activity at a single visit as well as to compare the results between patients or groups, 
and to assess changes over time (209). 
 
 Inactive Disease and Remission  
Recently, the American College of Rheumatology published provisional criteria for 
inactive disease and remission in children with JIA, in order to standardise the 
definition of inactive disease and remission states in those children (210). ACR criteria 
had summarised in Table 1.4. 
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Table 1.4: American College of Rheumatology provisional criteria for inactive disease and remission of 
juvenile idiopathic arthritis 
 
Category  Criteria 
Inactive disease* 
 No joints with active arthritis. 
 No fever, rash, serositis, splenomegaly, or generalized 
lymphadenopathy attributable to JIA.  
 No active uveitis as defined by the SUN Working Group** 
 ESR or CRP level within normal limits or, if elevated, not 
attributable to JIA 
 Physician’s global assessment of disease activity score = best  
Clinical remission on 
treatment  
The criteria for inactive disease must be met for a minimum of 6 
continuous months while the patient is on medication in order for the 
patient to be considered to be in a state of clinical remission on 
treatment 
Clinical remission off 
treatment 
The criteria for inactive disease must be met for a minimum of 12 
continuous months while off all anti-arthritis and anti-uveitis 
medications in order for the patient to be considered to be in a state of 
clinical remission off treatment 
ESR - erythrocyte sedimentation rate; CRP - C-reactive protein. This table Adapted from 
Wallace et al (210, 211) 
*All criteria must be met. 
**The Standardization of Uveitis Nomenclature (SUN) Working Group defines inactive anterior 
uveitis as “grade zero cells,” indicating <1 cell in field sizes of 1 mm by a 1-mm slit beam. 
 
 Treatment Options in Children with Juvenile Idiopathic 
Arthritis  
There is no cure for JIA at the moment. However, there are a variety of treatments 
available that promote remission and make the disease inactive (212, 213). Around 
10% to 20% of children with JIA are at risk of developing anterior uveitis, a condition 
that potentially can lead to blindness later, so early treatment with aggressive use of 
therapies in treatment children with JIA is recommended (212, 214).  
 
 Possible Disease Effects on Integrated Movement Behaviours 
in Children with Juvenile Idiopathic Arthritis  
JIA may have considerable impact on growth and development, physical and 
psychosocial functioning with a wide range of potential consequences. It has been 
suggested that PA should be included in any JIA treatment protocol, for a number of 
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reasons. Activity may improve disease signs and symptoms; PA could lead to reduced 
pain and medication use (215, 216); PA might have a role in reducing inflammation 
(217). Indeed, some studies have shown an improvement of disease signs and 
symptoms or cardiorespiratory fitness (CRF) after exercise training and this has led to 
the inclusion of physical conditioning of various kinds in many JIA treatment 
protocols. In addition to the physical benefits of PA in children with JIA, PA may also 
positively impact on the psychological health of children with physical impairments 
by allowing them to feel that they can participate in the same activities as their peers 
(218, 219).  
 
Therefore, those with JIA should be encouraged to achieve at least 60 minutes per day 
of MVPA (219-221). Despite such guidance, children with JIA had less active and 
more sedentary lifestyles (222), associated with inadequate sleep (short sleep duration 
and more disrupted sleep) compared to their healthy children in a few studies (200, 
223, 224). Although results varied, most of the studies suggested that potential factors 
lead to low level of PA, high amount of SB, with short sleep duration and more 
disturbance in children with JIA, which might modulate the disease-related factors 
(such as disease duration, number of painful and swollen joints), severity and 
frequency of pain, medications, and poor physical fitness (223, 225-227). Those 
children with JIA were at high risk of decrease of bone density (Osteopenia) due to 
high disease severity and side effect of glucocorticoids treatment that lead to decreased 
bone strength and increase risk of fracture (228). 
 
1.3.3. Congenital Heart Disease  
Congenital heart disease (CHD) is one of the major global health problems and is one 
of the most common causes of morbidity and mortality in childhood (229, 230). CHD 
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is also named congenital heart anomaly, as the problem is present at birth and affects 
the heart structure and function. There are many types of CHD ranging from simple to 
complex and critical, depending on the affected part in the heart (231). 
 
 Incidence and Prevalence  
CHD represents about 28% of major congenital malformations (229). CHD at birth 
had affected approximately 1- 4 in 1,000 worldwide, but this figure has been rising 
steadily to 12 - 14 in 1,000 live births worldwide. In UK, up to 8 in every 1,000 new-
borns, and more than 35,000 child in the United States are born with CHD (232, 233). 
Indeed, according to very recent evidence from British Heart Foundation report from 
the UK, at least 1 in 180 births had diagnosed with CHD - that is an average of 12 
babies had diagnosed each day with CHD with more diagnoses later in life; eventually, 
as many as 1-2 per cent of the population may be affected.  
 
 Pathophysiological Classification of Congenital Heart Disease  
There are several classifications for CHD (234). However, the pathophysiological 
classification is more practical, because it is based on the clinical consequences of 
structural defects impairing the physiology of blood circulation and gives clearer 
meaning for clinical and laboratory findings in those patients (234-237). In this 
classification, patients with CHD have been grouped into:  
 CHD with increased pulmonary blood flow arising from septal defects 
without pulmonary obstruction and left-to-right shunts. These include venous 
pole, atrial septum defect, atrio-ventriculay septum (connection), ventricular 
septum defect, and patent ductus arteriosus.  
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 CHD with decreased pulmonary blood flow arising from septal defects with 
pulmonary obstruction and left-to-right shunt. These include pulmonary valve 
stenosis with atrial septum defect, tetralogy of fallot, tricuspid atresia, Ebstein 
anomaly of the tricuspid valve and single (double inlet) ventricle with 
pulmonary stenosis. 
 CHD with obstruction to blood progression and no septal defects and no 
shunt either right-to-left shunt or left-to-right shunt. These include pulmonary 
stenosis, aortic stenosis and coarctation of the aorta. 
 CHD incompatible with postnatal blood circulation; these are the most 
severe forms of CHD and include ductus-dependent CHD (pulmonary atresia, 
aortic and mitral atresia, and interrupted or atretic aortic arch), parallel 
systemic and pulmonary circulations (transposition of the great arteries) and 
anomalous connection/obstruction of the pulmonary veins 
 CHD silent until adult age. There are some CHD conditions that are 
asymptomatic before adult age or are discovered incidentally. These include 
bicuspid aortic valve, some congenital anomalies of coronary arteries, Wolff–
Parkinson–White syndrome, and congenitally corrected transposition of the 
great arteries.  
 
 Categories of Congenital Heart Disease Severity  
CHD is a significant cause of morbidity and mortality in children. It is therefore useful 
to grade CHD according to the severity of cardiac lesion. Based on a consensus 
guideline (238), CHD is classified into three categories depending on severity of 
cardiac lesions and impact of surgery: severe CHD, moderate CHD and mild CHD, as 
summarised in Table 1.5. 
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Table 1.5: Consensus guideline of classification of congenital heart disease severity* 
 
Category Definition Congenital heart disease 
Severe 
CHD group 
These patients at high-
risk, should be seen 
regularly at CHD 
centres. 
Cyanotic congenital heart (all forms); double-outlet ventricle; 
Eisenmenger syndrome; mitral atresia; single ventricle; 
pulmonary atresia; pulmonary vascular obstructive disease; 
transposition of the great arteries; tricuspid atresia; truncus 
arteriosus; other abnormalities of atrioventricular or 
ventriculoarterial connection (i.e., criss-cross heart, isomerism, 
heterotaxy syndromes, ventricular inversion) 
Moderate 
CHD group 
These patients at 
Moderate –risk, should 
be seen periodically at 
regional congenital 
heart disease centres. 
Aorto–left ventricular fistulas; APVD; AVD; coarctation of 
the aorta; Ebstein's anomaly; infundibular right ventricular 
outflow obstruction of significance; ostium primum ASD; 
PDA (not closed); pulmonary valve regurgitation (moderate to 
severe); pulmonary valve stenosis (moderate to severe); sinus 
of valsalva fistula/aneurysm; sinus venosus ASD; TOF; VSD; 
absent valve or valves; AR; COA; mitral disease; right 
ventricular outflow tract obstruction. 
Mild CHD 
group 
These patients at 
lowest-risk, usually be 
cared for in the general 
medical community. 
Native disease; isolated congenital aortic valve disease; 
isolated congenital mitral valve disease (eg, except parachute 
valve, cleft leaflet); small ASD; isolated small VSD; mild 
pulmonary stenosis; small PDA; repaired conditions; 
previously ligated or occluded ductus arteriosus; repaired 
secundum or sinus venosus ASD without residua and repaired 
VSD without residua 
APVD - anomalous pulmonary venous drainage; ASD- atrial septal defect; AR - aortic regurgitation; 
AVD- atrioventricular septal defects; CHD- congenital heart disease COA - coarctation of the aorta; 
PDA- patent ductus arteriosus; TOF- tetralogy of fallot; VSD- ventricular septal defect. 
*Congenital heart disease severity was categorised in accordance with consensus guidelines and this 
table adapted from Warnes et al (238). 
 
 
 Possible Disease Effects of Integrated Movement Behaviours 
in Children with Congenital Heart Disease  
The life expectancy in children with CHD has improved dramatically in the last decade 
because of advances in preoperative care, surgical procedures and postoperative 
management. However, even after the cardiac repair those with CHD remain at high-
risk of cardiovascular complications (176). Children with CHD may have other risk 
factors such as – possibly-inactive lifestyles, poor diet, stress, sleep disturbances and 
sedentary lifestyle that may contribute to progression of increase the risk of 
cardiovascular disease (239). Indeed, consistent evidence demonstrates the beneficial 
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impact of PA on the cardiovascular system in both healthy children as well as children 
living with CHD (240). Thus active lifestyles are believed to be important to achieve 
optimal long-term outcomes in CHD; to reduce or prevent co-morbidities; and to 
improve the physical (cardiovascular health) and psychosocial (self-esteem, anxiety, 
and depression) health in children with CHD (87). Children with CHD have been 
identified as spending more time in SB or inactivity than their healthy peers (241). 
Sedentary lifestyles in children with CHD have been recognised to increase risk of co-
morbidities such as obesity, diabetes and atherosclerosis and coronary artery disease 
(242) with increased risk of premature mortality in later adult life. It also has been 
associated with poor motor skill development and decreased activity self-efficacy 
(243, 244). Sleep too has an important role to maintain the normal physical and mental 
growth in those with CHD similar as in healthy children, and inadequate sleep linked 
to co-morbidity as mentions earlier (121-123). However there is a suggestion those 
with CHD had shorter low quality sleep as they have difficulty in initiating and 
maintaining sleep with early waking, as well as frequent sleep disturbance due to or 
from the symptoms that associated with their cardiac problems such as abnormal heart 
rhythms and sleep apnoea (a series of breathing pauses during sleep that stress the 
cardiovascular system (245, 246)). 
 
It is generally thought that children with CHD may be hesitant to participate in PA for 
a number of reasons that include reduced cardiac output, impaired myocardial 
contractility, and disrupted blood flow due to endothelial dysfunction as well as use of 
antithrombotic medication and history of arrhythmia (247); non-cardiac physical 
reasons including neurologic and or orthopaedic problems, which may prevent 
participation in PA; or psychosocial reasons including reduced self-efficacy, health-
related quality of life, and increased parental overprotection (248, 249). In addition, 
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lack of understanding of their situation by their teachers at school was identified as 
limiting PA in children with CHD (244), and other environmental factors, such as 
seasonality that also has been observed affect PA level in children with CHD (247). 
Despite these problems, most children with CHD are recommended to participate in 
PA and accumulated at least 60 minutes of daily MVPA (248). It is believed that low 
PA among the CHD population is more harmful than adequate PA (87, 240). 
 
1.3.4. Cystic Fibrosis  
Cystic fibrosis (CF) is a hereditary autosomal recessive disorder affecting the exocrine 
glands (mucous and pancreatic glands) in the body. It is a progressive condition and 
the most common deadly genetic disease affecting Caucasians (250, 251), although it 
also occurs in other races. Cystic fibrosis is a disease that involves several organs in 
body by affecting the transport of sodium across cell membranes. This causes the 
production of abnormally thick mucus (252), leading to the blockage of the pancreatic 
ducts, intestines, and bronchi. In the chest this often results in frequent respiratory 
infection (251, 253). 
 
 Incidence and Prevalence  
CF is the most common life-threating inherited conditions. It affects the white 
population more than the black population. CF incidence varies depending on the 
method of diagnosis (screening the new-born, from death certificates, or reports of 
new case diagnosis) and origin of sample population raging from 1 in 2000 to 1 in 
3000 live births in white population (254). According to the CF Foundation Patient 
Registry in United State the incidence of CF was approximately 1 in 3,200 white and 
1 in 15,000 black live birth (255). It is estimated that > 30,000 people are living with 
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cystic fibrosis (> 70,000 worldwide); around 1,000 new cases of CF are diagnosed 
each year with > 75% of these people with CF are diagnosed by second birthday. In 
the UK CF occurs in around one in 2,500 live births and around 10,000 people in the 
UK have CF (256).  
 
 Diagnostic Criteria  
The diagnosis of CF is mainly made on the basis of clinical signs and symptoms and 
a sweat test (252) and can now often be confirmed with genetic analysis. Rosenstein 
et al, reported that diagnosis of CF requires one criterion from each of the following 
two groups (257, 258):  
Group one:  
 Two occasions of sweat chloride concentration of >60 mmol/L.  
 Two genetic mutations causing CF.  
 Disturbed chloride transport measured as an epithelial potential difference. 
 
Group two:  
 Family history of CF.  
 Positive new-born screening.  
 Clinical symptoms; recurrent chest infection, weight loss, diarrheal, 
constipation, steatorrhoea, coughing, short of breathing and pulmonary 
exacerbations and a bowel obstruction in newborn (meconium ileus). 
 
In UK, children with CF are usually diagnosed shortly after birth during the 
newborn screen blood test with the diagnosis then confirmed by sweat and genetic 
tests (256).  
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 Evaluation of Disease Activity 
Cystic fibrosis is a complex disease and the severity of disease differs between 
patients. Contributing factors to disease variation include: age of diagnosis, an 
individual's health, nutritional status and the course of the disease and treatment have 
an important role in disease outcomes (259, 260). Thus, severity of disease provides a 
guide for the physician to adapt therapies. The Shwachman-Kulczycki score was the 
first score to assess the severity of CF (261). CF severity tools scores are mainly 
focused on 4 groups of variables: physiology, infection, inflammation, and radiology 
(262). Forced expiratory volume in 1 second (FEV1) is the typical measure of lung 
function and a key predictor of life expectancy in people with CF (263). 
 
 Treatments Options for Cystic Fibrosis 
There is currently no cure for children with CF, and they may need to take a range of 
different medicine to help control the symptoms and prevent or reduce complications 
(259). Specific treatment plans for each child with CF should be determined by close 
work between family and medical professionals based on several factors such as: child 
age, health, medical history, extent of the disease and child's tolerance for specific 
medications, procedures, or therapies (260).  Treatment options may include: Chest 
physical therapies to help loosen and clear lung secretions (264). Medical treatment 
such as antibiotics - the main treatment of the lung infections; mucus thinning 
medicines like dornase alfa that make the mucus easier to cough up (265, 266); 
bronchodilators and anti-inflammatories treatment help to widen the airways, 
decrease the inflammation, reduce the mucus section in lung and make breathing 
easier; management of digestive problems that include: appropriate diet, digestive 
enzymes, minerals and vitamins supplements (260). Also, Exercise can help loosen 
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mucus, stimulate coughing, and improve overall physical condition. Finally, those 
with CF may need psychosocial support to help them deal with issues such as 
surviving with CF, independence, fertility, and sexual issues.  
 
 Cystic Fibrosis Complications  
Serious complications include: lung complications like chronic obstructive bronchitis, 
recurrent chest infection with pseudomonas aeruginosa (267), pneumonia and 
destruction of the lung tissue, bronchiectasis, fibrosis and emphysema (255) leading 
to respiratory insufficiency and cor-pulmonale. At this stage lung transplantation is the 
only possible treatment option (268). Children with CF are also at risk of the following 
common complications: malnutrition and vitamin deficiencies (269), liver disease, 
meconium ileus (affects 1 in 7 newborn live birth), deficits in bone mineral density, 
reduced female fertility and male fertility (270). 
 
 Possible Disease Effects of Integrated Movement Behaviours 
in Children with Cystic Fibrosis  
Several studies show that exercise and daily habitual PA can improve health-related 
quality of life (271-274), pulmonary function and aerobic fitness, and help in improve 
bone mineral density in patients with CF (256), as well as reducing the rate of 
hospitalisation and (275, 276). PA may help in improving airway clearance by 
increasing trans-epithelial fluid transport and raising ventilation (277). Moreover, an 
active lifestyle in children with CF might reduce even prevent decline in lung function 
(272, 278, 279). Therefore, several bodies have recommended a minimum of 60 
minutes of MVPA every day for children with CF (30, 87, 256, 280), These 
recommendations for the general population are usually also considered to be 
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applicable to children and adolescents with chronic disease (39, 281). Further, 
increased time spent in SB has been associated with increased risk of co-morbidities, 
reduced quality of life and increased mortality rate in adult life (282). Collectively, 
sleep in children with CF had been inadequate in term of duration and quality. Some 
studies had noted that children with CF had short sleep with more sleep disturbance 
compared to healthy (129, 283, 284); reasons of short sleep could related to delay of 
sleep time with early of wake-up time (284) or might related to frequent awakenings 
episodes and more wake after sleep onset (129) or combination of the two. Overall, 
the lifestyles of children with CF might be less active and more sedentary with 
inadequate sleep (poor quantity and quality), and the reason for these compared to 
healthy children and recommendations, possibly related to disease symptoms or 
characteristics such as coughing or pain, or due to treatment regimen which is usually 
complex with multiple medications and airway clearance and physiotherapies that 
require several hours every day.  
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1.4. Aims: 
The aims of the present study were to: 
1. Complete a systematic review and meta-analysis (Chapters III) examining 
whether children and adolescents with chronic disease meet the current MVPA 
recommendations (79, 80, 281). Secondary aims were to examine the amount 
of accelerometer-measured ST in children and adolescents with chronic 
diseases, and to determine whether accelerometer measured MVPA and ST in 
children and adolescents with chronic disease were different from those in 
healthy control or comparison groups. (Paper I).  
 
2. To complete a systematic review (Chapters IV) to determine obese children’s 
and adolescents’ habitual amount of time spent in MVPA, and examine 
whether those living with obesity met the current MVPA recommendation for 
health of a minimum of 60 minutes per day (9, 30). Secondary aims were to 
examine time spent in accelerometer-measured SB by obese children and 
adolescents, and to determine whether MVPA and SB in obese children and 
adolescents were different from the non-obese peers (Paper II). 
 
3. To complete a study (Chapters VI) investigating the 24 hour-movement 
behaviours (Sitting/lying, PA, standing, and sleep) for 5-7 days in children with 
common chronic childhood diseases and test whether there were differences 
between children with chronic disease and their healthy peers, and whether 
both meet the current sleep duration recommendations (Manuscript submitted 
to PLOS One Paper III). 
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4. To complete a study (Chapters VII) investigating sleep quantity – particularly 
sleep timing (sleep onset/offset), and sleep duration - and sleep quality in 
children with chronic diseases and test whether these aspects of sleep in 
children with chronic disease differed from healthy controls and whether both 
met the current sleep duration recommendations (131, 132). 
 
  
 
 
 
 
 
 
 
CHAPTER II 
GENERAL MATERIALS AND METHODS 
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This chapter provides detail on the generic materials and methods used in the studies 
within this thesis. Specific methodological details of individual studies are described in 
the relevant study chapters.  
2.1. Materials and Methods of Literature Systematic Reviews 
The two systematic reviews of the literature included in this thesis (Chapters III and 
IV) were performed in accordance with the PRISMA guidelines (285) and the review 
protocols were registered on PROSPERO (registration numbers RD42015016783 and 
CRD42015026882). Study eligibility, search strategy and selection, data extraction and 
synthesis, and quality assessment tools used for each study are described in detail in 
relevant chapters (Chapters III and IV). Full details of the literature searches in 
electronic databases are summarised in Appendix I.  
 
In brief, the literature searching was focused on four key elements: children and/or 
adolescents, MVPA, ST and/or SB, measured objectively by accelerometer, and 
common chronic disease (obesity, chronic cardiovascular disease, chronic respiratory 
disease, diabetes mellitus and malignancies). For each review, an extensive search was 
conducted using the five most relevant electronic databases from the year 2000: 
MEDLINE OVID; Cochrane library; EMBASE; SPORTSDiscus and CINAHL. The 
year 2000 was chosen to increase generalisability because levels of MVPA, ST and/or 
SB might be different now than in the recent past, and because accelerometry became 
more widely used in research from the early 2000s. The literature search was adapted 
as required for the other four databases. The electronic search was complemented by 
reference tracking (forward and backward citation searching) of the included studies.   
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2.2. Materials and Methods of Primary Data Collection Studies 
Primary data collection was required for two of the studies:  
1. Study in Chapter VI was an investigation of 24-hour movement behaviours (PA, 
standing, sedentary and sleep behaviours) over period of 5-7 days in children 
with common chronic childhood diseases and aimed to test whether there were 
differences between children with chronic disease and their healthy peers. 
2. Study in Chapter VII investigated sleep quantity – particularly sleep timing 
(sleep onset/offset), and sleep duration - and sleep quality in children with 
chronic diseases and aimed to test whether these aspects of sleep in children 
with chronic diseases differed from healthy controls and whether both met the 
current sleep duration recommendations (131, 132). 
  
2.2.1. Study Design  
We carried out an observational case-control study to make pair-wise comparisons of 
the behaviours; we know that the power of the study is considerably increased if the 
subjects are matched for the main determinants of PA and SB in UK children (age, sex, 
and time/season of measurement (156, 158). 
 
2.2.2. Participants  
2.2.2.1. Children with Chronic Diseases 
We investigated children with four common chronic diseases (children with T1DM, 
children with JIA, children with CHD and children with CF). The children were 
recruited from Out Patient Clinics at Royal Hospital for Children, Glasgow, UK.  
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These conditions were chosen for a number of reasons: they are all examples of 
common, serious and chronic diseases that affect childhood. The frequency of their 
occurrence allowed us to recruit an appropriate number of children to study the inter- 
relations between PA, SB or sleep, as described in Chapter I (Section 1.3). 
 
2.2.2.2. Healthy Control Groups 
Healthy children were recruited from local primary schools in Glasgow, UK; from the 
Libyan weekend school for children of Libyan parents temporarily resident in Glasgow; 
from children of University of Glasgow staff members and friends. Libyan children 
were recruited from a Libyan school that runs only on Saturdays, for half days, to teach 
children an Arabic language and Libyan curriculum. The Libyan children attended their 
normal classes in local primary schools during weekdays; they therefore have almost 
similar daily activity like the other healthy children who recruited to enrolled in our 
study. Further, Libyan children were included as control groups in previous studies 
where their levels of SB and PA were similar to the other controls (286), as shown in 
Appendix III. It therefore was anticipated that most of these children would be suitable 
as controls for children with chronic disease in our studies.  
 
Further, the study had a paired design, with each patient matched with a healthy control 
child (matched for age, gender, and time/season of measurement - the main influences 
on PA and SB in UK children (287-290). 
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2.2.2.3. Participants Age  
We concentrated on preschool and primary school children (age range 3 -10 years old). 
The upper age was chosen because most children below 10 years are still expected to 
be pre-pubertal. Pre-pubertal children are more homogeneous between sexes in terms 
of their height and weight and in their patterns of activity, though with age-related 
changes within this range as noted in Chapter I (Section 1.2.6). 
 
2.2.3. Inclusion and Exclusion Criteria 
2.2.3.1. Inclusion Criteria of Children with Chronic Disease and 
Healthy Controls 
Children and parents/ carers were asked to participate in the study if they meet the 
following eligibility criteria: 
For children with Chronic Diseases: 
Children with T1DM: (1) Attending the Outpatient Diabetic Clinic at Royal Hospital 
for Children (Glasgow, U.K.); (2) meeting WHO diagnostic criteria for T1DM; (3) 
between 3 years and 10 years of age; (4) with duration of diabetes longer than 3 months; 
(5) with no known kidney or cardiovascular complication; (6) with no limitations to 
walking or PA because of other mobility issues. 
Children with JIA: (1) Attending the Outpatient Rheumatology Clinic at Royal 
Hospital for Children (Glasgow, U.K.); (2) meeting ILAR diagnostic criteria for JIA; 
(3) between 3 years and 10 years of age; (4) with duration of JIA longer than 3 months; 
(5) with no major limitations to walking or PA because of other mobility issues. 
Children with CHD: (1) Attending the Outpatient Cardiac Clinic at Royal Hospital 
for Children (Glasgow, U.K.); (2) previously diagnosed with CHD with a history of 
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surgical intervention for the cardiac lesion; (3) between 3 years and 10 years of age; (4) 
with no history of cardiac surgery within the last 3 months; (5) with no major limitations 
to walking or PA because of other mobility issues. 
Children with CF: (1) Attending the Outpatient Clinic at Royal Hospital for Children 
(Glasgow, U.K.); (2) previously diagnosed with CF; (3) between 3 years and 10 years 
of age; (4) with no limitations to walking or PA because of other mobility issues. 
For Children who Acted as Healthy Controls: (1) In good health; (2) with no chronic 
illness that would limit their PA; (3) between 3 years and 10 years of age; (4) not taking 
any medications that might influence cardiorespiratory function; (5) with no limitations 
to walking or PA because of other mobility issues. 
 
2.2.3.2. Exclusion Criteria of Children with Chronic Disease and 
Healthy Controls 
Participants/ their families were excluded from the study if they:  
Children with T1DM: (1) Had diabetes as a secondary condition; (2) were taking any 
medications other than insulin which might influence cardiorespiratory function; (3) 
were and younger than 3 years and older than 10 years of age; (4) had an orthopaedic 
condition limiting PA or who were using a wheelchair for mobility or with another 
condition that may have impacted their PA. 
Children with JIA: (1) Were taking any medications (except glucocorticoids/disease 
modifying anti-rheumatic drugs for JIA), which might influence cardiorespiratory 
function; (2) were younger than 3 years and older than 10 years of age; (3) had other 
conditions that might have led to limitations in PA and mobility. 
Children with CHD: (1) Had cardiac surgery within the last 3 months; (2) had any 
neurological dysfunction that might impair their ability to perform PA e.g. due to 
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chromosomal abnormalities such as Down’s syndrome; (3) were younger than 3 years 
and older than 10 years of age; (4) had an orthopaedic condition limiting PA or who 
are using a wheelchair for mobility or with another condition that may have impacted 
their PA.  
Children with CF: (1) Had an orthopaedic condition limiting PA or who are using a 
wheelchair for mobility or with another condition that may have impacted their PA; (2) 
were younger than 3 years and older than 10 years of age. 
 
For Children who Acted as Healthy Controls: (1) Children with any physical or 
mental dysfunction likely to affect their PA or ST; (2) were younger than 3 years and 
older than 10 years of age; (3) had an orthopaedic condition limiting PA or who were 
using a wheelchair for mobility or with condition that may affect their PA. 
2.2.4. Sample Size  
The study was designed as an observational case-control study. We aimed to recruit 
160 participants (80 pairs); 80 children with chronic disease and 80 healthy controls 
matched for age, sex and time/season of measurement. For the clinical groups we 
considered recruitment of 20 participants for each group should be feasible from the 
appropriate specialist clinics. 
Sample Size Calculation: Based on previous experience with the activPALTM, we 
expected that recruiting 160 children would provide reliable activPALTM data (≥ 4 days 
with at least 10 hours of waking wear time in 24h period) from at least 140-150 children. 
At the time our study started, there were no data to guide sample size calculations of 
24-hour movement behaviours in children with chronic disease. Our recent systematic 
review (291) found that  previous studies that examined differences in MVPA and ST 
between children with chronic disease and healthy controls using paired study designs 
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found significant differences with relatively small samples ranging between 7 pairs (7 
patient and 7 healthy children (292), and 38 pairs (38 children with chronic disease and 
38 healthy children) (75). Thus, we expected that a sample of around 73-75 paired 
comparisons might be sufficient to detect with a high degree of significance differences 
in 24-hour movement behaviours between children with chronic diseases and healthy 
controls.  
From previous studies, we know that the power of the study is considerably increased 
if the subjects are matched for the main determinants of PA and SB in UK children 
(age, sex, time/season of measurement (287, 288) with number of pairs of around 15-
20 often being sufficient to demonstrate significant differences in activity levels. In our 
study, we closely matched children with chronic illnesses and healthy controls on the 
basis of age, sex and time/season of measurement (287, 288). Age is particularly 
important because it is known that activity declines with age (156).  
 
The primary analysis examined the differences between children with each particular 
illness vs their healthy controls for each of the 24-hour movement behaviours. As a 
secondary exploratory analysis, we also compared the results in all children with 
chronic disease as a group with all healthy controls as a group using paired statistical 
tests. Such an approach could be justified on the basis that all the children in the chronic 
illness groups met the definition given earlier - any physical, emotional, or mental 
health problem that lasts at least three months, and affects a child’s physical appearance 
and/ or growth and daily normal activities and results in frequent hospitalisations with 
regular therapy and sometimes unpleasant procedures, with home and medical care. 
However, it is a difficult to know if the chronic disease group was sufficiently 
homogenous to allow a comparison as a group with the healthy children. 
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2.2.5. Study Plan and Procedure 
2.2.5.1. Study Plan and Procedure for Children with Chronic Disease 
Families of children were initially approached when attending outpatient clinics at the 
Royal Hospital for Children, Glasgow, UK. They were informed about the study and if 
they were interested in taking part were given a written information sheet explaining 
the study. If after reading this they were still interested in participating, a meeting was 
arranged at a mutually convenient time and place. At that meeting, any further questions 
were answered. If they were happy to proceed, informed written consent was obtained 
from the parent and written assent from the child, if appropriate, as summarised Figure 
2.1.  
 
 
Figure 2.1: Flow chart for identification of child with chronic diseases at Out patients Clinics at Royal 
Hospital for Children, Glasgow, UK. 
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2.2.5.2. Study Plan and Procedure for Healthy Control Children  
In schools, head teachers were asked to identify potentially suitable children of an 
appropriate age and sex. Selection was only on the basis of age and sex. Suitable 
children were given a letter, information sheet about the study and a participation form 
to take home to their parents. For parents who were willing to participate, they were 
asked to complete the form and return it in an enclosed stamped addressed envelope. 
They were contacted by phone and a meeting arranged to discuss the study in detail and 
obtain informed consent and the completion of a consent form by a parent/carer and an 
assent form for the child, as summarised in Figure 2.2. 
 
 
Figure 2.2: Flow chart for identification of healthy children controls at schools and nurseries, Glasgow, UK.  
 
Children were enrolled in the study only after their parent or guardian had given 
informed consent to participate in the study and the child had given assent, if 
appropriate.  
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2.2.6. Movement Behaviours Monitoring 
The 24-hour movement behaviours were measured objectively using an activPALTM 
micro accelerometer (PAL Technologies Ltd., Glasgow, UK). The activPALTM micro 
is a small (23.5mm x 43mm x 5mm), lightweight (10g) triaxial accelerometer with 
storage capacity to record more than 10 consecutive days successively (293), as shown 
in Figure 2.3. The accelerometer provided information about the thigh position and 
posture changes, and can thus distinguish very accurately time spent sedentary, 
standing or walking, and transitions between these postures (standing up and sitting 
down). It has been shown to be a valid and reliable tool for objective measurement of 
posture and motion during everyday activities in children (141, 294, 295) and adults 
(296, 297). This makes it a useful tool for studying a number of the 24-hour movement 
behaviours consecutively for seven days (295). The data output can be presented per 
second, 15-second, hour, day or week epochs. 
 
 
 
Figure 2.3: The activPALTM micro monitor (PAL Technologies Ltd., Glasgow, UK). 
 
The activPALTM micro is placed directly onto child’s skin on their mid-anteriorly on 
the thigh and covered with a transparent sticky film (Tegaderm™) to secure it. Children 
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were asked to wear the monitor continuously including sleep; 24 h a day, for seven 
consecutive days. As the monitor was not waterproof, parents were asked to remove it 
for any showering, bathing or swimming during the monitoring period and they were 
supplied with extra sticky film (Tegaderm) to reapply the device with orientation to 
correct direction indicated by the figure on the front of the monitor, if it was removed.  
 
2.2.7. Duration of Participation 
The monitor was worn on the mid-thigh. The researcher first attached the monitor to 
participants (at Out Patient’s Clinics at Royal Hospital for Children (Glasgow, U.K.), 
schools or at a convenient time and place). The aim was for the activPALTM micro 
monitor to be worn continuously for 7 days. During this time, the child would be free 
to continue their normal activity. However, as the monitor is not waterproof, it needs 
to be removed for showering, bathing or swimming during the monitoring period. All 
parents received verbal and written information and instructions about using the device 
before giving informed consent to the study.  
 
Parents also were provided with a Daily Activity Log sheet (as shown in Appendix II) 
and asked to keep a note of any time the device (date and timing) was removed and 
reattached. Participants were supplied with extra sticky film (Tegaderm) to reapply the 
device if it was removed. Children at this age were sleeping in their own rooms and 
timing for sleep onset/offset usually would not be known accurately to the parents. 
Accordingly, we did not ask them to record this in the Daily Activity Log sheet. For 
each child, periods noted in the daily diaries when the child was not wearing the device 
e.g. because of swimming, bathing/showering or delayed reattachment because of 
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forgetting were identified and excluded from the raw activPAL™ files before any 
analysis.  
At the end of 7 days, the researcher collected the activity monitors and recording sheets 
from the participants. The data were then transferred to a computer for analysis using 
the special software provided by the manufacturer.  
 
2.2.8. Criteria for Discontinuation  
Because the activPALTM micro monitor is small (23.5mm x 43mm x 5mm) and 
lightweight (10g) it does not interfere with normal activity or play. However, if a child 
was uncomfortable or not happy wearing the monitor, the parents were instructed to 
remove the monitor and so data collection was stopped for that participant. 
 
2.2.9. Confidentiality  
Each participant was assigned a numeric code number. Data such as name, medical 
condition and family contact details were kept in a separate database only accessible by 
the researcher. Study participant data was identified only by the assigned code number. 
2.3. Data Collection  
2.3.1. Participant Characteristics  
At the time participants were enrolled in our study, the anthropometric parameters 
detailed below as well as any relevant clinical variables for participants were obtained.  
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2.3.1.1. Anthropometric Parameters 
2.3.1.1.1. Age and Sex  
We recorded the age and sex for children with chronic disease and healthy controls. 
The age of our participants was recorded from data of birth up to the data of enrolment 
in the study. 
2.3.1.1.2. Weight and Height  
Weight was measured to the nearest 0.1 kg using a SecaTM scale. The children were 
weighted with light indoor clothing and we asked them to take off the outer clothing 
and shoes at the time of measurement. The participant’s height was measured to the 
nearest 0.1 cm by using stadiometer (Leicester Height MeasureTM). To ensure accurate 
height measurements were taken, we asked children to take off their shoes, standing up 
straight on platform with arms at their sides and heels and buttocks positioned in contact 
with the vertical backboard. Then, the headboard of the apparatus was carefully placed 
on the child and the height measurement was recorded from the instrument to the last 
complete millimetre.  
2.3.1.1.3. Body Mass Index 
Body mass index (BMI) was calculated from the children’s weight and height 
parameters using the formula weight in kilograms divided by the height in meters 
squared (i.e. weight (kg)/height2 (m)). BMI was classified into normal weight, 
overweight and obese according to international age- and sex-specific BMI cut-offs 
proposed by reference data (298-300).  
 
For each child, weight, height and BMI measurements were converted to Standard 
Deviation Scores (SDS) to allow comparison between age- and sex (301). To do this 
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we used the 1990 British growth reference database (302), and WHO Anthro software 
available at: http://www.who.int/childgrowth/software/en/). Participants were 
classified based on their BMI Z-score into overweight if BMI Z score was >+1SD and 
obese if BMI Z score >+2SD (302).  
 
2.3.1.2. Clinical Variables  
In children with chronic disease, we obtained clinical variables at the time of 
recruitment in our study to provide an indication of disease severity, and these variables 
depending to each disease were defined as follows: 
 
2.3.1.2.1. Children with T1DM 
In children with T1DM (diagnosis of diabetes was made based on WHO criteria 
described in the Chapter I)(166), we recorded the level of HbA1c to classify children 
into either those with: 
 Good glycaemic control if their HbA1c was ≤ 48 mmol/mol,  
 Poor glycaemic control if their HbA1c was ≥ 48 mmol/mol based on the 
2015 NICE recommendation (175) 
We also collected information the mode of insulin delivery. The mean disease duration, 
defined as the mean time from diagnosis to the time of enrolment in our study, was also 
collected. 
2.3.1.2.2. Children with JIA 
In children with JIA (diagnosis of JIA was made based on classification criteria 
described in the Chapter I), we recorded the following parameters to evaluate the 
current disease activity. These included number of joints actively inflamed; number 
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with limited joint movement; number of tender joint; Parents/Patient global 
assessments score; Physician global assessments score; subtype of JIA; type of 
treatment; and stage of disease. Disease duration was defined from date of diagnosis to 
the date of enrolment in our study. Recent measurements of anti-inflammatory 
biomarkers ESR and CRP were also recorded. 
2.3.1.2.3. Children with CHD 
The children with CHD were at least 3 months past their last operation. We recorded 
the cardiac diagnosis, number of surgeries for each child, current medical treatment. 
The disease ‘duration’ in children with CHD determined as the time from last surgery 
to the enrolment in our study time. 
2.3.1.2.4. Children with CF 
In children with CF (diagnosis of CF was made based on classification criteria, 
described in the Chapter I), we recorded percentage of forced expiratory volume in 1 
second (FEV1 % predicted), current medical treatment and the disease duration. In our 
study, the severity of the obstructive lung changes was evaluated by FEV1 % and BMI-
Z score.  
2.3.2. Objective Measurement of the 24-Hour Movement Behaviours  
As noted above, the activPALTM micro accelerometer was used to evaluate components 
of 24-hour movement behaviours (time spent in PA, standing, sedentary and sleep 
behaviours), as well as sleep quantity - in term of sleep timing (sleep onset/offset time) 
and sleep duration - and sleep quality in our studies. The activPALTM micro is a triaxial 
accelerometer with an inclinometer, which measures the acceleration of the thigh. This 
enables it to give information about the static (body posture sitting/lying and upright) 
and dynamic acceleration (body movement) that is used in algorithms to classify the 
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measured signal into sitting/lying, standing and walking. In addition to rich information 
about body posture and transitions between postures it may also be used in future to 
estimate energy expenditure (141, 303).  
 
The activPALTM micro has a 32 MB memory capacity, which with a default sampling 
frequency in the software of 20 Hz (80 Hz could be selected in research mood) allows 
up to 14 days of monitoring, The software also gives an option to changing the 
minimum sitting/upright transition period to define a new posture from 1  - 100  second 
and the manufacturer had recommended the 10  second, which meaning ≥10 s of 
sitting/lying or upright data is needed to register as a new event (303). It is therefore 
considered an ideal tool to use in our study for 7 days monitoring. The output data of 
activPALTM summarised the behaviours in terms of “events” (i.e., changes in posture), 
and categories the behaviours into three behaviours categories “sitting/lying”, quiet 
standing and “walking/stepping”. It also quantifies steps and accumulation in periods 
of time and shows start time, end time and time spent in each behaviour (303). Based 
on validation studies in different population (such as both children and adults, in both 
sex, in both healthy and diseased population) the device is considered a reliable and 
valid tool to distinguish postural changes (sitting/lying, standing, and stepping) and 
features of SB, including time spent sitting/lying and breaks- transitions between these 
postures (standing up and sitting down) and sleep (293, 304-309). 
 
Indeed, that based on the default values from the manufacturer, activPALTM 
Professional Research Edition software classifies the recorded data of each child into 
the three different categories: lying/sitting (1.25 MET); standing (1.4 MET); and 
‘walking’ (stepping at 120 steps per minute estimated to be 4 MET). This has 
Chapter II 93 
previously been shown to provide a valid measure of total physical activity- (141)). In 
addition, the software gives the number of transitions between the postures and the 
number of steps. ActivPAL data on movement/transitions has previously been used to 
successfully measure time spent asleep in children by identifying the timing of sleep 
onset and waking (286, 310, 311). It is correct that the activPAL cannot measure all of 
the 24-hour movement behaviours e.g. it cannot measure screen time and the time spent 
MVPA. Currently, no single device can do this and so we did not set out to measure all 
these components in the work for the thesis. We considered using additional devices, 
and/or adding parent-reports or diary measures of time spent in some of the behaviours 
(e.g. screen time, sleep), but these would have added to the burden of the study for 
families and a recent systematic review (312) found that there was little evidence that 
parent-report measures were accurate. 
 
In summary, we chose to measure of those behaviours for which there was some 
evidence of validity, i.e. time spent in total physical activity, time spent in sleep, which 
were objective and did not rely on parental report and for which the experimental 
burden on families was considered both reasonable and achievable. Since the main aims 
of the research in the present study was to investigate differences between patient and 
control groups having exactly the same methods with a similar accelerometry 
monitoring duration between the groups was the most important experimental 
consideration.  
 
Future studies with greater time/human resources and with newer technologies will be 
needed to do the kind of comprehensive 24-hour movement behaviour monitoring 
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which would be ideal. At present, the technology is not available to do such studies 
either practically or accurately. 
2.3.2.1. Charging and Programming of ActivPALTM Monitor 
The activPALTM is recharged using a docking station connected to a computer by USB 
cable. The ActivPAL device is placed into one of eleven ports of docking station for 
recharging. An orange light indicates the device is charging. Three hours is needed for 
full recharge and then the light disappears, as shown in Figure 2.4. 
 
 
Figure 2.4: The docking station for activPALTM A) A device in programming site. B) Devices being 
in charge sites. 
 
There are some steps prior to the ActivPALTM accelerometer programming. First of all, 
we downloaded the ActivPALTM professional software from PAL Technologies Ltd 
web site, and installed it on a computer Windows 7. Then we connected the 
ActivPALTM device to the computer by using a USB port in the docking station cable. 
Next, we placed the ActivPALTM in programming port of docking station, as shown in 
Figure 2.4. After that we selected “Communicate with activPALTM” from the menu file 
in activPALTM professional software (Version 7.2.32), then selected “reprogramming 
A 
B 
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and clear memory” option to clear the ActivPAL device memory and prepare it for 
measurements. A series of rapid green flashes indicates that the device is programmed 
and ready for use. In the professional software, we could choose the suitable starting 
data and time for monitoring based on convenient time of our participants. Once our 
participants were ready to start the monitoring then we entered the data and time. The 
green light flashes every six seconds throughout recording process indicate the 
ActivPAL device was recording (303).  
 
2.3.2.2. Placement of ActivPALTM and Monitoring Duration  
Once an activPALTM device was recharged and programmed, it was attached to the 
child at outpatient clinic, at school, or at suitable place for our participants. The 
researcher was attached the activPALTM device to the child in front of their parents and 
they were given verbal information on how they could remove the device and reattach 
it again at home, if needed.  
 
2.3.2.3. Monitor Collection and Data Download  
At the ending of seven days monitoring period, the families removed the device from 
the child and returned it back to the researcher. Once the device had been returned, the 
data were downloaded via USB cable to a PC from the monitor using ActivPALTM 
Professional software (Version 7.2.32). To do this we first connected ActivPALTM by 
chose the option of “Communicate with activPAL” from the File menu in ActivPALTM 
Professional software. Then download was initiated and the data saved to the PC by 
choosing the option of “download store data”. The raw activPAL™ data for each child 
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were saved into a file labelled with an anonymous code for further analysis and long-
term storage. 
 
2.3.2.4. Definition of Valid Day  
A day was defined from one wake time to the next day wake time (313). Valid day is 
defined by the minimum number of wearing during waking hours per day that is needed 
to provide a valid measurement of SB and low, moderate and high PA. In previous 
accelerometry studies, a valid day ranged from 6 to 10 hours per monitoring day (314, 
315). In our studies, we requested the participants to wear the activPALTM for 24h per 
day and to provide at least ten hours wear time during the waking in a 24h period to be 
included in the analysis (316). The monitoring time provided by our participants was 
always much greater than the minimum previously established for reliable data.  
 
2.3.2.5. Minimum Number of Valid Wear Days  
Research has shown that the minimum number of days required to obtained a valid 
representation of usual SB, activity and sleep using accelerometers ranges from four to 
nine days (317, 318). In this study, the participants were asked to wear the activPALTM 
for 24h per day for seven consecutive days. This duration of wear allows for a 
reasonable estimate of usual levels of the behaviours, and for any differences between 
weekday and weekend days to emerge, as previous studies suggested that children were 
less active and more sedentary at the weekend compared with week days (319, 320). 
Although, seven days monitoring period were requested, children included in the study 
had to provide a minimum of four valid days of activity data (including one wakened 
day and night) to be included in the analysis as in previous studies (289, 316, 321).  
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The minimum number of days and hours required for adequate measurement of the 
usual (habitual) levels of the different 24-hour movement behaviours by accelerometry 
is currently unknown and has not been the subject of research attention, probably 
because the ’24-hour movement behaviours’ concept is so new (322). However, 
minimum numbers of days to obtain reliable estimates of usual levels of child PA and 
SB has been studied for a number of accelerometers (321, 323-325). These studies find 
consistently that across a wide age range in childhood and adolescence around 3- 4 days 
of accelerometry monitoring is an acceptable minimum, with as little as 4- 6 hours 
being an acceptable number of hours per day. A detailed investigation of the minimum 
number of hours and days required with activPAL in the present study was beyond the 
scope of this thesis, but the actual activPAL monitoring times were consistently far 
longer than minimum durations usually cited in the literature. In addition, one of the 
main aims of the research in the present study was to investigate differences between 
patient and control groups, and so having a similar accelerometry monitoring duration 
between the groups was important. 
 
2.3.2.1. Definition of Valid Night and Minimum Number of Valid 
Night  
Based on previous research that used the accelerometer to quantify sleep in healthy 
children (326-328), we defined a valid night as having at least 160 minutes of sleep 
(316), with measurements required over at least 3 valid nights, including 1 weekend 
night (Friday night and or Saturday night), before including it in this study (316). 
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2.3.2.2. Non-Wear Time within a Day  
Non-wear time during a day refers to the number of consecutive zero counts that must 
be recognised before considering that the monitor is not being worn. Assuming there 
are no technical problems with the monitor, a period of consecutive zero counts (≥ 60 
minutes within a day in “sitting/lying” posture (329)) is commonly taken to indicate 
that the monitor has been removed and is not attached. This might arise during removal 
for a period of water based activities or might reflect removal of the activPALTM 
accelerometer because the participant is not complying with the monitoring protocol 
(330).  
 
In our study, non-wear time was first identified from the parent note in the Daily 
Activity Log sheet for any time the device was taken off and reattached again. Then by 
manual inspection of the event file any unchanging sitting/lying period lasting for ≥ 60 
minutes within a day (63, 329) that indicated the monitor was removed and placed in a 
horizontal position with no movement recording were noted and also considered as 
non-wear time (63, 329). Once the non-wear time was identified, the sum of the non-
wear time data (identified by the parents and confirmed on the monitor output plus other 
periods not documented by the parents and defined as above) was calculated for each 
child and then excluded from the analysis.  
 
2.3.2.3. Sleep Time and Wake Monitoring Time 
The investigators needed a valid and reliable procedure to identify the sleeping time. 
Until recently, it has been difficult to differentiate between sedentary and sleeping time 
in accelerometer data (330). In previous studies with the activPALTM and the present 
study (311, 331) the sleep time was identified by the researcher using manual inspection 
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of the event file created by HSC PAL analysis software v 2.14 to identify the sleeping 
time as described below. The wake monitoring times was calculated from the event file 
of HSC PAL analysis software v 2.14. For each participant, the wake monitoring time 
is calculated as total wake time after excluding sleeping time and non-wear time 
summed in hours per 24 h period, and then averaged as the total waking monitoring 
times over the number of monitoring days. 
 
2.3.3. Data Processing  
First of all, the activPALTM data were processed and analysed by using the activPALTM 
Professional Research Edition software (Version 7.2.32) which classifies the recorded 
data of each child into the three different postures: lying/sitting; standing; and walking, 
as well as giving the number of transitions between the postures and the number of 
steps. Although, the manufacturer had recommended the 10 second as a minimum of 
sitting/lying or upright transition period this might not be appropriate for all population. 
Indeed, Alghaeed et al found that the 2 second as minimum activPALTM sitting/upright 
period is optimal for young children that they change their posture very rapidly (331), 
Thus, the 2 second as minimum activPALTM sitting/upright period was used in our 
study, as shown in Figure 2.5. 
 
The activPALTM files generated by Professional Research Edition software (Version 
7.2.32), were imported into custom software known as HSC PAL analysis software 
(Version 2.14) developed by Dr. Dall and Professor Granat at Glasgow Caledonian 
University, Glasgow, UK. The HSC PAL analysis software generates an event file in 
seconds at which a change in postural (i.e., a transition) occurred. In this way the event 
file of HSC PAL software allows detailed analysis of the activPAL output. 
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Figure 2.5: Example of output of the activPALTM event file (summarised by hour). 
Sit/lie period represented by yellow colour, stanfing period represented by green colour, and walk/steps 
represented by red colour. Red arrow for the number of steps per hour; Blue arrow for number of breaks in 
(Up transition [sit to stand (u)]); Green arrow represented the first transitions from sitting/lying-to-stand (i.e. 
sleep offset time where ended the day and starting the new monitoring day). 
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From the activPALTM Professional software we obtained the number of steps per 24h 
period, and the number of sitting bouts (the number of breaks in sitting/lying periods) 
per 24h period. From the event file of the HSC PAL analysis software (version 2.14) 
we also obtained total time spent in 24h movement behaviours “sitting, standing, PA 
and sleep as well as the percentages of 24h movement behaviours, sleep onset/offset 
times, nocturnal sleep/wake episode and duration were calculated from the event file of 
the HSC PAL analysis software, as shown in Figure 2.6. 
 
 
 
Figure 2.6: Flow chart the products of software programmes used in the analysis of ActivPAL data. 
 
2.3.3.1. Characterising the 24-hour Movement Behaviours Study 
As noted above, data included in this analysis came from only those children with ≥ 4 
days with at least 10 hours of waking wear time in 24h period including one weekend 
day and night, in an effort to reflect habitual levels of the behaviours. During processing 
and treatment of the 24-hour data obtained from our participants we used HSC PAL 
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analysis software version 2.14 to first identify the nocturnal sleeping time (the time 
from sleep onset to the sleep offset, including all sleep/wakefulness period after sleep 
onset (332)).  
 
Sleeping time for each participant was determined by manual inspection of the event 
file and was identified as the last transition from standing to sitting/lying in the day to 
the first transition from sitting/lying to standing of the next day as described by 
Alghaeed et al (141, 331). Non-wear time was identified from the parent activity Log 
sheet, and in activPAL file. Once the non-wear time was identified, the sum of the 
missing data was calculated for each child and then excluded from the recording before 
any data analysis was made. Finally, the remaining time that was not sleep or non-wear 
time was labelled as waking wear time. For these studies the monitoring day was 
defined as the first transition from sitting/lying to standing as the start of monitoring 
time of the day and the first transition from sitting/lying to standing of the next day was 
the end time of this day. While, awake time was defined by the first up transition in the 
morning to the last up transition in the evening, indicating the beginning of sleeping 
time. The total monitoring time during waking hours per 24 h period was calculated by 
taking the average of total monitoring times, after excluding non-wear and sleeping 
times, the data were sorted by colour for each day (yellow colour for sitting/lying, green 
colour for standing and orange colour for ‘walking/stepping’) for further analysis. 
 
In this study, the 24h movement behaviours were characterised in the following ways:  
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2.3.3.1.1. Sedentary (Sitting) Time (ST) 
ST for each participant in this study was quantified in 3 ways: 1. the total sedentary 
time per 24h period, 2. the percentage of sedentary time per 24h period, and 3. the 
number of sitting bouts (reflecting the number of breaks in sitting= posture transitions). 
 
Total Sedentary Time (hours per 24h period): 
Total ST during waking time per 24h period was calculated from the event file of HSC 
PAL analysis software version 2.14. The total time recorded as ‘‘sit/lie’’ during awake 
hours - from sleep offset till sleep onset- in HSC PAL analysis software event file was 
then calculated after excluding non-wear, all ST of participant were summed in hours 
normalised to per 24 h period and then averaged as time spent in ST over the number 
of monitoring days. 
 
Percentage of Sedentary Time 
Percentage of ST was calculated to quantify how much ST was in the daily life of child. 
For each participant in our study, the percentage of ST in waking hours per 24h period 
calculated as total ST in hours normalised to 24 h period and expressed as a percentage 
by multiplied by 100 (percentage of ST per 24h period = [total ST (h)/ 24 h period (h)] 
✕ 100). 
Breaks in Sitting (Up transitions)  
The number of breaks in periods of sitting was calculated as the number of up 
transitions recorded (postural change from “sit/lie” posture to “stand”) during each 24h 
period by using the activity profile file output file (data summarised in a 24 hour file) 
from the activPALTM Professional Research Edition software (Version 7.2.32), as 
shown in Figure 2.7. We avoided double counting by including the number of 
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transitions from sit/lie to stand posture (up transitions) only, but not from stand to sit/lie 
posture (down transitions) transitions. For each participant, the number of breaks (up 
transitions) was summed for each 24h period and then averaged over the total number 
of monitoring days. Breaks in sitting were quantified as a numerical value (i.e. the 
number of breaks).  
 
2.3.3.1.2. Standing Time 
The standing time was quantified for each participant in this study as 1. total standing 
time per 24h period and 2. the percentage of standing time per 24h period. 
 
Total Standing Time (hours per 24h period) 
Total time spent standing during waking hours per 24h period was calculated from the 
event file output of the HSC PAL analysis software version 2.14. The total time 
recorded as ‘‘stand’’ during awake hours in HSC PAL analysis software event file 
output was then calculated after excluding non-wear. For each participant, all standing 
times were summed in hours than normalised per 24 h period and finally averaged as 
standing times over the number of monitoring days. 
 
Percentage of Standing Time  
The percentage of standing in waking hours per 24h period was calculated as total 
standing time in hours divided by 24 h period and then expressed as a percentage by 
multiplied by 100 (percentage of standing time per 24h period = [total standing time 
(h)/ 24 h period (h)] × 100). 
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2.3.3.1.3. Physical Activity 
The PA data were expressed in three ways: 1. the total time spent in PA (PA duration) 
in hours per 24h period, 2. the percentage of PA per 24h period and 3. the number of 
steps per 24h period.  
 
Total Physical Activity Time (hours per 24h period) 
Total time spent in PA during waking hours per 24h period was calculated from the 
event file output of the HSC PAL analysis software version 2.4. The total time recorded 
as ‘‘walk/stepping’’ during waking hours was then calculated after excluding non-wear 
and sleeping times. All ‘‘walk/stepping’’ times of participant were summed in hours, 
expressed per 24 h period and averaged as time spent in PA (‘‘walk/stepping’’ times) 
over the number of monitoring days. 
 
Percentage of Physical Activity  
Percentage of PA was calculated to quantify how much the PA contributed in 24-hour 
movement behaviours in daily lifestyle of child. The percentage of PA in waking hours 
per 24h period was calculated as total PA time in “hours” divided by 24 h period and 
then expressed as a percentage by multiplied by 100 (percentage of PA per 24h period 
= [total PA time (h)/ 24 h period (h)] ×100). 
 
Number of steps per day  
The total number of steps per 24 h period was obtained from the activPALTM
 
professional research edition software (Version 7.2.32). For each participant, the 
number of steps was calculated by measuring the total number of steps per 24 h period, 
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as shown in Figure 2.7. The figure was then averaged to give the average number of 
steps per monitoring day.  
 
 
Figure 2.7: Example of output of the activPALTM file (summarised by 24hour). 
 
2.3.3.1.4. Sleep Behaviour 
The nocturnal sleep behaviour in this study was expressed as 1. the nocturnal sleeping 
time (sleep duration) in hours per 24h period and 2. the percentage of sleeping time per 
24h period. 
 
Nocturnal Sleeping Time (hours per 24h period) 
As noted above, sleeping time was identified as the time from the last transition from 
standing to sitting/lying in the day to the first transition from sitting/lying to standing 
of the next day (331). In this study, nocturnal sleep-period time was defined as the 
duration accruing between sleep onset and offset time. Between these 2 time points, 
however, there were consecutive sequences of sleep and frequently minutes of 
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movement, suggesting repositioning, restlessness, wakefulness, or short breaks for 
visits to bathroom, to get drink etc. during the night. Thus our definition of “sleep-
period time” reflects the time of sleep onset to the end of sleep “sleep offset”, was 
including all sleep epochs and wakefulness after onset (332), as shown in Figures 2.8, 
2.9 and 2.10.  
 
Sleeping time for each participant was determined by manual inspection of the event 
file and was identified using the event file of HSC PAL analysis software version 2.14as 
the last transition from standing to sitting/lying in the day to the first transition from 
sitting/lying to standing of the next day as described by Alghaeed et al (286, 331). The 
nocturnal sleeping time for each participant was summed in hour per 24 h period and 
then averaged as time spent in sleep per monitoring nights. 
A)  
 
B) 
 
Figure 2.8: Example of event file produced by HSC PAL analysis software v 2.14 file for one of 
participants show sleep quantity and quality variables. 
                A) Sleep episode and sleep episode movements, and B) Sleep episodes and wake episode. 
 
1st sleep episode  
Sleep episode movements  
Sleep onset  
Sleep offset  
1st sleep episode  
1st sleep episode  
Wake episode 
2nd sleep episode  
Sleep onset  
Sleep offset  
Sleep time  
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Percentage of Sleeping Time  
Percentage of sleeping time was calculated to quantify how much the sleep was counted 
per 24-hours. The percentage of sleep per 24h period was calculated as a total sleeping 
time in hour divided by 24 h period and then expressed as a percentage by multiplied 
by 100 (percentage of asleep per 24h period = [total sleeping time (h)/ 24 h period (h)] 
×100). 
 
2.3.3.2. Comparisons Against Recommended Levels of the 24-hour 
Movement Behaviours 
Currently the only 24-hour movement guidelines for school-age children and 
adolescents are from the Canadian Society for Exercise Physiology and these were 
published in 2016 (CSEP 2016) (131, 132) and are available at: 
http://www.csep.ca/home. These recommendations were evidence-based, i.e. they were 
based on a process of systematic reviewing and quality appraisal of the literature and 
followed standard GRADE methodology (Grading of Recommendations Assessment, 
Development, and Evaluation (333-335)). In summary, these Canadian Society for 
Exercise Physiology guidelines for school-age children and adolescents are expressed 
as what makes up a healthy 24-hour period and are as follows: 
 
 Sleep = 10-13 h for age 3-4 years, 9-11 h of sleep per night for age 5-13 years, 
8-10 h of sleep per night for age 14-17.  
 SB = screen time=< 1 h per day of screen time for age 3-4 years and < 2 h per 
day for age 5-17of screen time. 
 PA = ≥ 60 minutes per day of MVPA. 
 LPA = several hours of a variety of un/structured LPA. 
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In the UK the guideline which applies to school-age children and adolescents (from 
Start Active Stay Active 2011(336)) refers only to MVPA, recommending that a 
minimum of 60 minutes per day every day is spent in MVPA; the only reference to SB 
is that time spent being sedentary should ‘be minimised’ (Start Active Stay Active 2011 
(336)). One problem with the 24-hour movement guidelines at present is that measuring 
compliance with the guideline is not simple. There are no single methods which will 
measure sleep, screen time, and PA for example. Options include measuring as many 
behaviours as possible with a single device, using multiple devices to measure multiple 
behaviours (which would increase the burden on the researchers and the families), using 
devices for some of the behaviours and parent or self-report questionnaires for the other 
behaviours (but this latter option would involve subjective methods of unknown 
accuracy) or possibly measuring some parameters at different time and then combining 
them to produce a composite picture.  
 
For the studies in this thesis it was felt that the activPAL would be a suitable method 
as it can measure time spent asleep, time spent in PA (both step counts and potentially 
also time spent in MVPA so long as methods are available to convert activPAL output 
to MVPA, which was true at least for pre-schoolers at the time the thesis work started- 
(337)), and time spent sedentary and breaks in sedentary time (though not screen time) 
(141, 294, 295). Obvious alternative accelerometers such as the Actigraph are probably 
less suitable for sleep measurement-or at least methods are not yet agreed for Actigraph 
sleep measurement - and are not designed to measure posture so only give proxy 
measures of sitting/lying and standing. 
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Given the difficulties with measuring the behaviours, and since the activPAL was 
chosen for the thesis studies, this left only a small number of comparisons with 
recommendations, which were possible at the present moment. First, sleep duration 
recommendations are available for school-age children and for pre-school children 
which are evidence based on CSEP 2016 and so activPAL measures of sleep were 
compared against these recommendations. These sleep recommendations were as 
follows: 10- 13 h per night in children aged 3-4 years, and 9- 11 h per night in children 
aged 5-13 years, with consistent bed and wake-up times (131, 132).  
 
Second, while the activPAL cannot measure MVPA in school-age children at the 
moment, it can provide an accurate measure of step count (294) and step counting is 
being used as a convenient proxy for total volume of the physical activity in school-age 
children in many studies (86, 338). Recommended step count equivalents which are 
age-specific and which are equivalent to total volume of the physical activity have been 
suggested (86, 339), though these are not currently ‘evidence based’ i.e. not based on 
systematic review and evidence appraisal, but have effectively come from expert 
opinion. Number of steps per day and time were therefore compared against the 
appropriate age-specific recommendations: for steps per day 10,000- 14,000 steps/day 
in children aged 4-6 years, 13,000- 15,000 steps per day in boys and 11,000- 12,000 
steps per day in girls aged 6-11 years old to achieve an average of 60 minutes per day 
of total physical activity volume (86). 
 
2.3.3.3. Characterising of Sleep Quantity and Quality Study 
Based on previous research that used the accelerometer to quantify the sleep in healthy 
children (326-328), we defined a valid night as having at least 160 minutes of sleep, 
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and participants had to have accumulated at least 3 valid nights, including 1 weekend 
night (Friday night and or Saturday night) (326, 328), to be included in this study. The 
nocturnal sleep-period time was defined as the duration accruing between sleep onset 
and offset time. In this study, sleep offset represent the time of transition in the morning 
to sustained upright activity, a point that was clearly evident in the data sets. Between 
these 2 time points, however, there were consecutive sequences of sleep and frequently 
minutes of movement, suggesting repositioning, restlessness, wakefulness, or short 
breaks for visits to bathroom, to get drink etc. during the night. Thus our definition of 
“sleep-period times” reflects the time of sleep onset to the end of sleep “sleep offset” 
including all sleep epochs and wakefulness after onset (332).  
 
Sleeping time for each participant was determined by manual inspection of the event 
file and was identified as the last transition from standing to sitting/lying in the day to 
the first transition from sitting/lying to sustained standing in the next day as described 
by Alghaeed et al (286, 331). Thus, the sleeping time represented the longest sit/lie 
interval between two valid days and the mean number and duration of breaks (Up 
transition) during the sleeping time represented the quality of sleep, as shown in Figures 
2.9 and 2.10 A-D to show our steps to determine all sleep quantity and quality variables. 
 
Definitions of Sleep Behaviour Variables  
As noted above, in our study the nocturnal sleep quantity and quality variables were 
identified by manual examination the event output file of HSC PAL analysis software 
version 2.14, these variables were defined as follows: 
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2.3.3.3.1. Nocturnal Sleep Quantity Variables 
The nocturnal sleep quantity for each participant in this study was characterised as 1. 
sleep onset, 2. sleep offset, and 3. sleeping time (Duration h per 24h period). 
 
Sleep Onset 
Sleep onset is the clock time− identified manually by the researcher from the event 
output file of HSC PAL analysis software version 2.14 as the last transition from 
standing to sitting/lying (331) as shown in Figures 2.8, 2.9 and 2.10. For each 
participant, after we identified the time of sleep onset each night this was averaged as 
sleep onset time over the number of monitoring nights.  
 
Sleep Offset 
Sleep offset is the clock time - identified manually by the researcher from the event 
output file of HSC PAL analysis software version 2.14 as first transition from 
sitting/lying to standing in the morning of the next day, as shown in Figures 2.8, 2.9 
and 2.10. For each participant, after we identified the time of sleep offset per night this 
was averaged as sleep offset time over the number of monitoring nights. 
 
Sleeping Time (hours per 24h Period) 
As noted above (in sleep behaviour section 2.3.3.1.4), sleeping time “sleep duration” 
defined as the sleep period time (i.e. the duration (h) from sleep onset to sleep offset). 
Sleeping time could be register as single or multiple sleep periods interrupted by 
posture changes, standing and stepping as explained in Figures 2.8, 2.9 and 2.10. 
Chapter II 113 
2.3.3.3.2. Nocturnal Sleep Quality Variables 
The nocturnal sleep quality for each participant in this study was characterised as 1. 
Number of sleep episodes per night, 2. number of wake episodes per night, 3. duration 
of wake episode, 4. duration of sleep episode movements, and 5. total sleep disrupted.  
 
Number of Sleep Episodes per Night 
The number of sleep episodes per night was defined as a number of an occurrence of 
continuity of sleep episode including wake minutes that were less than 20 minutes and 
or < 20 steps during sleeping time (326, 328), as show in Figures 2.8, 2.9 and 2.10. 
While, when the wake minutes were ≥ 20 minutes and or ≥ 20 steps during sleeping 
time; the sleeping time in this case would be consist from 2 sleep episodes as show 
Figures 2.8, 2.9 and 2.10. For each participant, from the event output file of HSC PAL 
analysis software version 2.14 were identified the number of sleep episodes per night, 
then averaged as number of sleep episodes over the number of monitoring nights. 
 
Number of Wake Episode per Night 
The number of wake episodes per night in this study was defined as a number of 
occurrences of ≥20 consecutive wake minutes and or ≥20 steps preceded and followed 
by a sleep episode during sleeping time (326, 328), as show in Figures 2.8, 2.9 and 2.10. 
For each participant, the number of wake episodes were identified from the event file 
of HSC PAL analysis software version 2.14 for each night, and was then averaged as 
number of wake episodes over the number of monitoring nights. 
 
Duration of Wake Episodes (Minutes per Night) 
Duration of wake episodes defined as total minutes per night spent during an occurrence 
of ≥20 consecutive wake minutes and or ≥20 steps during nocturnal sleeping time (326, 
Chapter II 114 
328). Duration of wake episode (i.e. time spent in wake episode) during sleep time was 
calculated from the output event file of HSC PAL analysis software version 2.4. The 
total time recorded as ‘‘walk/stepping” with ≥ 20 steps’’ and /or total time recorded as 
“standing” with ≥ 20 consecutive standing minutes in output event file of HSC PAL 
analysis software during asleep hours per night was then calculated as shown in Figures 
2.8, 2.9 and 2.10. All time spent in wake episodes were summed in minutes per night 
and was then averaged as duration of wake episode over the number of monitoring 
nights. 
 
Duration of Sleep Episode Movements (Minutes per Night) 
Duration of sleep episode movements (minutes per night) defined as duration of time 
that spent during an occurrence of < 20 consecutive wake minutes or < 20 steps during 
sleep episode (326, 328). Duration of sleep episode movements during sleep time was 
calculated from the event file of HSC PAL analysis software version 2.4. The total time 
recorded as ‘‘walk/stepping” with < 20 steps per minutes and /or as “standing” with < 
20 consecutive standing minutes during asleep hours was then calculated. For each 
participant, all time spent in sleep episode movements of participant were summed in 
minutes per night and then averaged as the duration of sleep episode movements per 
monitoring night. 
 
Total Sleep Disrupted (Minutes per Night) 
Total sleep disrupted was defined as the summed duration of wake episodes during 
sleep time in minutes per night and then averaged as the duration of total sleep disrupted 
per monitoring night (326, 328).  
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Figure 2.9: 24-h free-living worn accelerometer nocturnal sleep-related variables using one night’s data 
drawn from a single US child participating in ISCOLE, adapted from Tudor-Locke et al. (326).  
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 A)     B)     C)     D) 
 
Figure 2.10: Example of event file produced by HSC PAL analysis software v 2.14 file for one of participants show sleep quantity and quality variables. 
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2.4. Ethics Statement  
The study was approved by West of Scotland Research Ethics Committee 1 (Reference 
number 16/WS/0126) and NHS Greater Glasgow and Clyde Health Board. Parents of 
all participants provided informed written consent, and their children provided their 
informed assent -if applicable based on their age- to participate in the study prior to 
collection of any study data. 
 
2.5. Statistical Analysis 
In this study, the analysis was conducted using the IBM SPSS statistical software 
version 22 and Microsoft Office Excel 2010. Graphs were prepared using Graph Pad 
Prism version 6.00 software (San Diego, California, US). All study variables were 
screened for normality, and normally distributed data summarised as Mean (SD) while 
Median (interquartile range) were used for data not normally distributed. Since children 
with chronic disease were matched pairwise with healthy controls (for age, sex, and 
time of year) paired t-tests were used for the primary analysis which examined the 
significance of any differences between children with each particular illness vs their 
healthy controls for each of the 24-hour movement behaviours and in sleep quality 
variables. As a secondary, analysis we also compared the results in all children with 
chronic disease as a group with all healthy controls as a group using a paired t-test. 
Statistical significance was set at a cut-off value of ≤ 0.05. 
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2.6. General Results of Primary Data Collection Studies 
This section illustrated details of descriptive results of primary data collection studies 
that included results of recrutment proceses, characteristics of the participants and 
accelerometer results for children with chronic disease and their healthy controls that 
were used in both studies of next two chpaters (Chapter V and VI) 
 
2.6.1. Recruitment Process 
Of 136 potentially eligible children identified from outpatient clinics with chronic 
disease a total of 99 (73%) agreed to take part. Of 111 potential healthy control children 
eligible based on a match for age and sex 89 (80%) agreed to take part. A total of 188 
children (n=99 children with chronic disease and n=89 healthy controls) aged 3–10 
years were recruited to participate in the study after their parent had given informed 
consent and the child had given assent, if appropriate.  
 
28 children (n=19 children with chronic disease and n=9 healthy controls) were omitted 
from our study because of a number of reasons; six of the parents returned the monitor 
after 24 hours stating that the child was unhappy to continue wearing the monitor and 
asked their parents to remove it; three children were eliminated from the study because 
of loss of the monitor at their school. Another one of the monitors was accidently not 
removed when the child showered and suffered permanent water damaged. 
Additionally, twelve of the children were dropped from the study because they did not 
wear the monitor for the period of time that was considered adequate (≥ 4 days with ≥ 
10 hours of waking wear time in a 24-hour period and with ≥ 3 valid nights (i.e. valid 
night having total sleep duration ≥ 160 minutes per night) including one weekend night 
– Friday or Saturday night). Lastly, six of the children were excluded from the study 
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due to loss of contact with their family to collect the monitor from them. Thus, a total 
of 160 children met all the inclusion criteria and successfully wore the monitors for the 
required time. Further details of recruitment process are illustrated in Figure 2.11. 
 
2.6.2. Characteristics of the Participants 
Descriptive data including age, sex, weight, weight Z-score, height, height Z-score, 
BMI, BMI Z-score, BMI category and disease duration are summarised in Table 2.1. 
 
 
Figure 2.11Flow diagram of study recruitment. 
CHD, congenital heart disease; CF, cystic fibrosis; T1DM, type1diabetes mellitus; JIA, juvenile idiopathic 
arthritis. 
 
2.6.2.1. Children with T1DM and their Healthy controls 
Twenty children with T1DM (diagnosis of T1DM was made based on WHO criteria 
described in the introduction) were recruited with a mean age 7.4 years (SD=1.9) while 
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in the matched healthy controls (n=20) the mean age was 7.3 (SD=1.8). There were 11 
boys and 9 girls in each group. The mean BMI Z-score in children with T1DM was 0.3 
(SD=1.2). Seventeen (85%) children with T1DM were classified as healthy weight 
according to BMI Z-score; two (10%) were classified as overweight and one (5%) as 
obese. In their healthy matched controls, the BMI Z-score in was 0.9 (SD= 1); sixteen 
(80%) children were classified as healthy weight according to BMI Z-score; two (10%) 
were classified as overweight and two children (10%) as obese. 
 
The mean level of HbA1c in children with T1DM was 48.1 mmol/mol (SD=8.2 
mmol/mol) (range of measurements 38-61mmol/mol). Based on the revised 2015 NICE 
recommendation of HbA1c ≤ 48 mmol/mol (340), twelve (60%) of children with 
T1DM were considered to have good glycaemic control and eight (40%) children had 
poor glycaemic control at the time of recruitment (175). Multiple daily injections using 
an insulin pen were the predominant method of insulin delivery (65%). The mean 
diabetes duration in those children was 2.1 years (SD =1.4 years), with a range (1-6 
years). Further details of children with T1DM are in Table 2.2. 
 
2.6.2.2. Children with JIA and their Healthy controls 
There were twenty children with JIA (The diagnosis of JIA was made based on 
classification criteria described in the introduction) with a mean age 6.7 years (SD=2.1) 
compared with 6.7 years (SD= 2.1) in the matched healthy controls (n= 20). There were 
8 boys and 12 girls in each group. The mean BMI Z-score in children with JIA was 0.1 
(SD=1). Seventeen (85%) children with JIA were classified as healthy weight 
according to BMI Z-score; one (5%) was classified as overweight and two (10%) as 
obese. In their healthy controls, the mean BMI Z-score was 0.6 (SD=1.4); fourteen 
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(70%) children were classified as healthy weight according to BMI Z-score; five (25%) 
were classified as overweight and one child (5%) as obese as in Table 2.3.  
The children diagnosed with JIA recruited to this project were RF positive with mean 
disease duration of 3.2 years (SD=2.0) from diagnosis to the time of enrolment. Nine 
had polyarticular arthritis, eight oligoarticular arthritis, two psoriatic arthritis, and one 
patient another other arthritis subtype. Nine (45%) of the children with JIA were 
considered in remission at the time of study. All JIA participants had received biologic 
therapies, although at the time of recruitment four out of the twenty of children with 
JIA were off such treatments. We also collected a number of clinical variables about 
their joint disease activity including number of tender joint, number of swollen joint 
and other clinical variable to identify the disease severity, as well as laboratory 
parameters such as ESR, CRP and treatment. All these data are presented in Table 2.4. 
2.6.2.3. Children with CHD and their Healthy controls 
Twenty children with CHD (all post-surgery) (mean age 6.0 years (SD=2.2)) and 20 
matched healthy children (mean age 6.1years (SD = 2.1)) were studied. The mean BMI 
Z-score in children with CHD was 0.5 (SD = 1). Sixteen (80%) children with CHD 
were classified as healthy weight according to BMI Z-score; three (15%) were 
classified as overweight and one (5%) as obese. In their healthy controls, BMI Z-score 
in was 0.8 (SD = 1.1). Seventeen (85%) children were classified as healthy weight 
according to BMI Z-score; and three (15%) were classified as overweight.  
 
In children with CHD, the mean time from the last surgical procedure at the time of 
enrolment was 3.5 years (SD=2.2). Although all children had had surgery for CHD, 
nine patients were classified as having mild CHD, eight with moderate CHD and three 
patients with severe CHD, 55% of children had to had moderate-severe CHD, and 40% 
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of children with CHD were on medical treatment at the time of enrolment. Further 
details are presented in Table 2.5 and 2.6. 
2.6.2.4. Children with JIA and their Healthy controls 
Twenty children with CF had mean age 6.7 years (SD = 2.0) compared with mean age 
of 6.9years (SD = 1.9) in the 20 matched controls. Girls were slightly over represented 
(12:8 F: M) in this group. The mean BMI Z-score in children with CF was 0.2 (SD= 
2.7). Fourteen (70%) children with CF were classified as healthy weight according to 
BMI Z-score; three (15%) were classified as overweight and three (15%) as obese. In 
their healthy controls BMI Z-score was 0.2 (SD=7); nineteen (95%) children were 
classified as healthy weight and only one (5%) was classified as overweight. All 
children with CF on treatment at the time of enrolment, and had been identified by 
neonatal screening with a mean time from diagnosis at the time of study of 6.5 years 
(SD=2.0) years. Further details are presented in the Table 2.7. 
2.6.2.5. All Children with Chronic Disease (n=80) Compared with 
Healthy controls (n=80) 
Eighty children with chronic disease were recruited with a mean age 6.9 years (SD=2.0) 
while in the matched healthy controls (n=80) the mean age was 6.8 (SD=1.9). There 
were 37 boys and 43 girls in each group. The mean BMI Z-score in children with 
chronic disease was 0.3 (SD=1.5). Sixty-four (80%) children with chronic disease were 
classified as healthy weight according to BMI Z-score; nine (11%) were classified as 
overweight and seven (9%) as obese. In their healthy matched controls, the BMI Z-
score in was 0.6 (SD= 0.8); sixty- six (82%) children were classified as healthy weight 
according to BMI Z-score; eleven (14%) were classified as overweight and three 
children (4%) as obese. 
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Table 2.1: Characteristics of children with chronic disease and healthy controls. Data are presented as means and (SD)  
 
Characteristics 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
CD 
(n=80) 
HC 
(n=80) 
Age years 7.4 (1.9) 7.3 (1.8) 6.7 (2.1) 6.7 (2.1) 6.0 (2.2) 6.1 (2.1) 6.7 (2.0) 6.9 (1.9) 6.9 (2.0) 6.8 (1.9) 
Sex F:M 9: 11 9: 11 12: 8 12: 8 10: 10 10: 10 12: 8 12: 8 43: 37 43: 37 
Weight kg 25.6 (6.3) 
28.7 
(8.3) 
23.4 
(6.0) 
25.7 
(6.4) 
24.0 
(8.5) 
25.1 
(5.3) 
24.8 
(6.5) 
22.6 
(6.2) 
24.4 
(6.8) 
25.5 
(6.5) 
Weight-Z-score 0.1 (1.0) 0.8 (1.4) 0.2 (1.2) 1.1 (1.2) 0.6 (1.0) 1.4 (0.9) 0.4 (2.1) 
- 0.1 
(0.7) 
0.3 (1.3) 0.8 (0.7) 
Height cm 
122.6  
(12.8) 
125.4 
(13.2) 
119.6 
(13.7) 
123.2 
(10.0) 
117.1 
(15.6) 
118.7 
(15.3) 
119.7  
(12.5) 
117.0 
(12.8) 
119.7 
(13.6) 
121.1 
(12.8) 
Height-Z-score -0.1 (1.1) 0.4 (1.8) 0.2 (1.9) 1.2 (1.0) 0.4 (1.1) 0.5 (1.0) 0.2 (2.0) 
- 0.4 
(0.8) 
0.7 (1.0) 0.5 (0.8) 
BMI kg/m2 16.6 (2.2) 
17.8 
(2.5) 
16.2 
(1.9) 
17.3 
(2.5) 
17.0 
(2.2) 
17.2 
(1.2) 
17.3 
(3.9) 
16.2 
(1.6) 
16.8 
(2.6) 
17.1 
(2.0) 
BMI Z-score1 0.3 (1.2) 0.9 (1.0) 0.1 (1.1) 0.6 (1.4) 0.5 (1.0) 0.8 (1.1) 0.2 (2.7) 0.2 (0.8) 0.3 (1.5) 0.6 (0.8) 
BMI category2 
Normal weight n (%) 
Overweight n (%) 
Obese n (%) 
 
17 (85%) 
2 (10%) 
1 (5%) 
 
16 (80%) 
2 (10%) 
2 (10%) 
 
17 (85%) 
1 (5%) 
2 (10%) 
 
14 (70%) 
5 (25%) 
1 (5%) 
 
16 (80%) 
3 (15%) 
1 (5%) 
 
17 (85%) 
3 (15%) 
0 (0%) 
 
14 (70%) 
3 (15%) 
3 (15%) 
 
19 (95%) 
1(5%) 
0 (0%) 
 
64 (80%) 
9 (11%) 
7 (9%) 
 
66 (82%) 
11 (14%) 
3 (4%) 
Disease duration 
Years 
2.12 (1.4) - 3.2 (2.0) - 
3.5 
(2.20) 
- 6.5 (2.0) - 3.8 (1.9) - 
BMI – body mass index; CHD – congenital heart disease; CF – cystic fibrosis – JIA, juvenile idiopathic arthritis, T1DM – type1 diabetes mellitus. 
Data are presented as means and standard deviation SD unless otherwise specified.  
1Based on World Health Organization Growth Reference data from 2007 (302).  
2Based on age- and gender-specific cut-offs defined body mass index at 18.5, 25 and 30 kg/m2 at age 18 years (298, 299). 
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Table 2.2: Characteristics of children with T1DM  
 
Participants Age (yr) Gender Height (cm) Weight (kg) BMI BMI Z-score HbA
1c
 Duration Treatment 
T1DM01 7.2 F 122 28.1 15.52 -0.12 38 1.00 Insulin pen 
T1DM02 8.6 M 124 24.2 15.74 -0.11 61 2.2 Insulin pen 
T1DM03 6.3 F 117 23.6 17.24 0.95 60 1.2 Insulin pen 
T1DM04 9.4 M 139 36.1 18.68 1.19 53 1.2 Insulin pen  
T1DM05 5.8 M 121 23 15.71 0.16 56 1.7 Insulin pen 
T1DM06 8.6 F 118 20.3 14.58 -0.96 59 3.2 Insulin pen 
T1DM07 6.8 M 121 21.8 14.89 -0.50 48 4.3 Insulin pump therapy 
T1DM08 4.3 F 103.8 17.8 15.99 0.28 37 1.0 Insulin pen 
T1DM09 9.3 F 141 31.3 15.74 -0.41 53 1.4 Insulin pen 
T1DM10 6.3 F 115 24.1 18.22 1.40 48 4.2 Insulin pump therapy 
T1DM11 7.2 F 124 18.5 12.03 -2.93 50 1.5 Insulin pump therapy 
T1DM12 9.9 M 133 28.2 15.94 -0.26 51 6.0 Insulin pump therapy 
T1DM13 4.2 M 110.1 20.5 16.91 0.92 47 1.0 Insulin pen 
T1DM14 7.3 M 116.8 20.6 15.10 -0.37 43 1.0 Insulin pen 
T1DM15 7.7 M 113.2 28.1 21.93 2.64 31 1.0 Insulin pen 
T1DM16 9 M 130 35 20.71 1.96 41 1.1 Insulin pump therapy 
T1DM17 8.1 F 127 23.4 14.51 -0.92 43 2.8 Insulin pen 
T1DM18 8.4 M 135.4 31.1 16.96 0.64 38 1.0 Insulin pen 
T1DM19 3.3 F 93.8 15.6 17.73 1.28 47 1.0 Insulin pump therapy 
T1DM20 9.9 F 146.8 38.0 17.63 0.351.28 48 3.8 Insulin pump therapy 
Summary 7.4 
(1.9) 
F: M  
9:11 
122.6  
(12.8) 
25.6 
(6.3) 
16.6 
(2.2) 
0.3 
(8.2) 
48 2.12 
(1.4) 
 
BMI – body mass index; HbA1c – Haemoglobin A1c ≤ 48 mmol/mol; Duration – Disease duration.  
Summary data presented as mean and (SD)  
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Table 2.3: Characteristics of children with JIA 
 
Participants Age (yr) Gender Height (cm) Weight (kg) BMI BMI Z score Duration Treatment 
JIA01 5.5 M 116.7 21.4 15.68 0.13 4 Inflix+MTX+Rani 
JIA02 9.2 F 131.4 29.4 17.00 0.25 5 Inflix 
JIA03 8.5 F 127.1 24.5 15.17 -0.57 6 MTX 
JIA04 3.8 M 96.8 19.5 20.81 3.02 2 Etan 
JIA05 3.4 F 123.0 22.5 14.87 -0.72 7 Toci 
JIA06 5.9 F 116.2 19.3 14.29 -0.84 4.1 Etan 
JIA07 4.4 F 101.4 20.0 19.40 2.16 1.9 MTX 
JIA08 8.5 M 138.0 31.0 16.28 0.24 3.8 Off treatment 
JIA09 6.0 M 119.5 20.5 14.32 -1.01 2 Off treatment, 
JIA10 3.8 F 97.5 15.8 16.62 0.64 1.4 MTX 
JIA11 6.5 F 114.5 20.1 15.33 -0.14 4.2 Off treatment 
JIA12 8.1 F 111.3 18.6 15.01 -0.59 8 MON MTX 
JIA13 8.2 F 128.9 28.5 17.18 0.56 7 MTX 
JIA14 9.6 M 129.6 28.4 16.88 0.34 1 Off treatment 
JIA15 3 F 97.0 15.2 16.10 0.17 1.4 MTX 
JIA16 6.8 F 114.1 20.1 15.44 -0.12 4.9 Humira 
JIA17 7.9 M 128.7 24.8 14.97 -0.52 2.9 Off treatment 
JIA18 9.5 M 143.6 41.25 20.00 1.64 2.4 Etan 
JIA19 7.7 M 129.7 23.5 14.00 -1.32 1 MTX 
JIA20 7.8 F 127 24.0 14.88 -0.64 8 MTX 
Summary 6.7 
(2.1) 
F: M 
12:8 
119.6 
(13.7) 
23.4 
(6.0) 
16.2 
(1.9) 
0.1 
(1.1) 
3.2 
(2.0) 
 
BMI – body mass index; JIA - juvenile idiopathic arthritis; Etan – Etanerecept; Inflix – Infliximab; MTX- Methotrexate;  
Rani – Ranitidine. 
Summary data presented as mean and (SD)  
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Table 2.4: Clinical variables of children with JIA 
 
Participants ESR CRP TJ AJ LJ PAGA PHGA Subtype JIA Stage 
JIA 01 2 <1 2 0 0 0 0.5 Poly-articular  
JIA 02 2 <1 1 1 0 0.4 1.1 Poly-articular  
JIA 03 2 <1 3 0 0 0.1 1 Poly-articular Remission 
JIA 04 5 <1  0 0 0 0 Oligo-articular Remission 
JIA 05 2 <1 2 0 0 0.5 0.4 Poly-articular  
JIA 06 5 <1 0 0 0 1 0 Oligo-articular Remission 
JIA 07 8 4 1 0 0 0 0 Oligo-articular  
JIA 08 - <1 0 0 0 0 0 Poly-articular Remission 
JIA 09 - <1 0 0 0 0 0 Oligoarticular Remission 
JIA 10 70 52 0 0 0 0 2 Psoriatic  
JIA 11  <1 0 0 0 0 0 Oligo-articular Remission 
JIA 12 5 1 5 0 0 2 1 Poly-articular Quiescent 
JIA 13 2 <1 1 0 0 0 0 Oligo-articular  
JIA 14 - <1 2 0 0 1 0 Oligo-articular Remission 
JIA 15 15 2 2 0 0 0 0 Psoriatic  Remission 
JIA 16 5 6  0 0 0 0 Poly-articular  
JIA 17 0 <1 0 0 0 0 0 - Remission 
JIA 18 1 <1 0 0 0 0 0 Poly-articular  
JIA 19 5 <1  0 0 0.2 0 Oligo-articular  
JIA 20 11 <1 5 4 2 3 1 Poly-articular  
AJ – Active joint; CRP – C-reactive protein and the normal CRP is < 0.8mg/dl; Duration – duration of disease (years); ESR – erythrocytes  
sedimentation rate and the normal ESR is ≥20mm/hr; JIA – juvenile Idiopathic Arthritis; LJ – number of limited joint movement; PAGA – Patient global  
assessments (PAGA; where 0=best and 10=worst); PHGA – Physician global assessments (PHGA; where 0=best and 10=worst); TJ – number of tender joint. 
Summary data presented as mean and (SD).   
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Table 2.5: Characteristics of children with CHD 
 
Participants Age (yr) Gender Height (cm) Weight (kg) BMI BMI Z-score Diagnosis No. of 
surgeries 
Time from 
last surgery 
Treatment 
CHD 01 8.7 M 137.6 31.0 16.4 0.26 TGA 2 8 Sildenafil 
CHD 02 3.1 F 104.0 16.3 15.1 -0.62 TAPVR 1 3 - 
CHD 03 9.4 M 136.4 30.0 16.1 -0.03 ASD 1 9 Warfarin, 
CHD 04 4.9 F 104.2 18 16.6 0.70 ASD 1 3 - 
CHD 05 5.4 F 108 17.6 15.1 -0.25 ASD 1 2.7 - 
CHD 06 3.2 M 92.1 13.6 16.0 -0.02 TOF 1 5.6 Aspirin 
CHD 07 5.7 F 124.0 26.0 16.9 0.86 VSD 1 5.7 - 
CHD 08 7.1 F 129.4 30.0 17.9 1.11 VSD 1 2 - 
CHD 09 8.0 M 132.0 31.0 17.8 1.12 TOF 1 3.7 - 
CHD 10 3.4 M 101.0 16.5 16.2 0.16 PDA 1 2.7 - 
CHD 11 6.7 F 127.0 31.4 19.5 1.81 AVSD 2 2.2 Warfarin 
CHD 12 4.8 M 106.0 20.0 17.8 1.56 ASD 1 2 - 
CHD 13 3.9 M 104.0 19.6 18.1 1.64 Sinus 
AVSD 
1 7.9 Salbutamol 
CHD 14 9.3 F 139 46.0 23.8 2.35 Mitral 
atresia 
2 2.8 - 
CHD 15 8.7 F 135.5 35.0 19.1 1.19 HLHS 3 3.6 Warfarin 
CHD 16 8.4 F 125 23.8 15.2 -0.52 HLHS 3 2 Warfarin 
CHD 17 4.4 M 102.0 18.9 18.2 1.75 TOF 3 3.9 Aspirin 
CHD 18 6.7 M 130.0 26 15.4 -0.11 ASD 1 1 - 
CHD 19 4.3 F 102.9 15.0 14.2 -1.14 ASD 1 1.1 - 
CHD 20 4 M 101.4 15.1 14.7 -0.95 TOF 3 2.0 - 
Summary 6.0 
(2.2) 
F: M 
10:10 
117.1 
(15.6) 
24.0 
(8.5) 
17.0 
(2.2) 
0.5 
(1.0) 
- - 3.5 
(2.2) 
- 
ASD – atrial septal defect; AVSD – atrioventricular septal defect; HLHS – hypo-plastic left heart syndrome; TAPVR– total anomalous pulmonary  
venous return; TGA – transposition of the great arteries; TOF – tetralogy of fallot; VSD – ventricular septal defect.  
Summary data presented as mean and (SD).   
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Table 2.6: Distribution and classification of cardiac diagnosis in children with CHD (n=20) 
 
Cardiac Diagnosis Type of CHD Number of patients Total umber (%) 
Mild CHD   9 (45%) 
 Ventricular septal defect 2  
 Atrial septal defect 6  
 Small patent ductus arteriosus 1  
Moderate   8 (40%) 
 Tetralogy of fallot 4  
 Mitral atresia 1  
 Total anomalous pulmonary venous return 1  
 Atrioventricular septal defect 2  
Severe   3 (15%) 
 Transposition of the great arteries 1  
 Hypoplastic left heart syndrome 2  
Congenital heart disease severity was categorised in accordance with consensus guidelines (238). 
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Table 2.7: Characteristics of children with CF 
Participants Age (yr) Gender Height (cm) Weight (kg) BMI BMI Z-score FEV1 % Predicted Treatment 
CF 01 8.5 F 132.20 28.50 16.31 0.06 96 Fluc, Creon 
CF 02 4.4 M 103.00 18.00 16.97 0.99 99 
Fluc, Creon 
Mucoclear, Flixonase 
CF 03 9.2 F 138.40 36.00 18.79 0.98 111 
Fluc, Creon 
Cetirizine, Azith 
CF 04 5.6 M 115.20 22.10 16.65 0.83 96 Benz Fluc 
CF 05 5.0 M 111.90 18.20 14.53 -0.90 60 Fluc, Creon 
CF 06 5.4 M 113.00 21.20 16.60 0.80 79 - 
CF 07 5.2 F 111.60 19.20 15.42 -0.03 103 Fluc, Creon 
CF 08 9.7 M 112.00 18.60 14.83 -0.96 98 Fluc, Creon 
CF 09 9.0 F 134.00 28.25 15.73 -0.35 95 Fluc 
CF 10 8.4 F 129.7 28.4 16.88 0.37 83 
Fluc, Creon 
Azith 
CF 11 3.8 F 101.0 18.4 18.04 1.49 99 
Fluc, Movicol 
Cetirizine 
CF 12 9.1 M 93.8 15.60 16.74 -0.41 98 Benz, Creon 
CF 13 5.9 F 112.50 25.90 20.46 2.35 96  
CF 14 7.9 F 131.70 30.05 17.32 0.68 99 Dornase nebulised 
CF 15 8.0 F 132.20 29.30 16.77 0.39 99 
Creon, Fluc 
Sytron, Fultium 
CF 16 7.8 F 127.00 30.00 18.60 1.23 103 
Creon, Fluc 
Ivacaftor, Fultium 
CF 17 6.7 M 118.40 33.80 24.11 3.51 104 Creon, Fluc 
CF 18 4.3 M 106.00 18.75 16.69 0.78 97 Fluc, Creon 
CF 19 3.0 F 97.0 15.2 16.10 0.16 99 Fluc, Creon 
CF 20 6.7 F 114.1 20.1 15.44 -0.10 96 Creon 
Summary 
6.7 
(2.0) 
F: M 
12: 8 
119.7 
(12.5) 
24.8 
(6.5) 
17.3 
(3.9) 
0.2 
(2.7) 
95 
(11) 
 
 
Azith – Azithromycin; Benz- Benzylpenicillin; BMI - body mass index; CF – cystic fibrosis; Fluc – Flucloxacillin;  
Summary data presented as mean and (SD).  
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2.6.3. Accelerometer Results 
To be included in our analysis, participants had to have ≥ 4 days with ≥ 10 hours of 
waking accelerometer wear time in a 24-hour period including one weekend day. They 
also were required to have ≥ 3 valid nights (i.e. valid night having total sleep 
accelerometer monitoring duration ≥ 160 minutes per night) including one weekend 
night – Friday or Saturday night, as clarified in above in Section 2.3.3.  
 
A total of 160 participants (n = 80 in children with chronic disease (20 per group) and 
n = 80 in healthy controls groups) met the accelerometer inclusion criteria and provided 
data that were deemed suitable to include in our study. Indeed, across all groups the 
number of monitoring days and nights was ≥ 6.6 days and ≥ 6 nights of data. For each 
group the monitored waking hours per 24 h period was as follows:  
 
- In children with T1DM a mean of 13.2 h (SD 0.7) h per 24 h compared 
with 13.6 h (SD 0.6) h per 24 h in their healthy peers.  
- In children with JIA 13 h (SD 0.7) h per 24 h period and 13.9 h (SD 0.9) 
h per 24 h in their healthy peers.  
- In children with CHD a mean of 13.2 h (SD 1) h per 24 h and 13.5 h (SD 
0.6) h per 24 h in their healthy peers.  
- In children with CF mean of 13.5 h (SD 0.7) h per 24 h and 13.4 h (SD 
0.4) h per 24 h in their healthy peers, as summarised in Table 2.8.  
 
Overall, for both patients and controls the percentage of non-wear time per 24h period 
was very low (see above in section 2.3.4 for details of how non-wear time was 
calculated). For each group the mean (SD) non-wear time per 24h period was as follows 
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- children with T1DM and their healthy peers respectively 1.3% (SD 1.0) and 0.3 % 
(SD 0.6); in children with JIA and their healthy peers 1.1% (SD 1) and 0.9 % (SD 0.7); 
in children with CHD and their healthy peers 1.2 % (SD 1.4) and 0.5 % (SD 0.4); and 
in children with CF and their healthy peers 0.7 % (SD 0.6) and 0.6 % (SD 0.6). As we 
found that the non-wear time was only around 1% of total wear time per 24-hours period 
across all groups, we ignored it and analysed the recorded accelerometer data per 24h 
period.  
 
Sleep period time for each participant was determined by manual inspection of the 
event file and was timed from the last transition from standing to sitting/lying in the 
day until the first transition from sitting/lying to standing in the next day. The 
monitoring day was defined as the first transition from sitting/lying to standing as the 
start of monitoring time of the day until the first transition from sitting/lying to standing 
of the next day (described in detail in Chapter II above) that made some ‘days’ very 
slightly more or less than 24h which depended on the exact sleep offset time for each 
participant. Thus, we noted that the average missed/unaccounted time for each group 
was as follows – children with T1DM and their healthy controls an average of 16 and 
31 minutes per 24h; children with JIA and their healthy peers 21 and 12 minutes per 
24h; children with CHD and healthy peers 14 and 37 minutes per 24h; and children 
with CF and their healthy controls 45 and 34 minutes per 24h. 
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Table 2.8:Accelerometer results based on 24-hour accelerometer data in children with chronic disease and healthy controls 
 
Variables 
T1DM 
(n =20) 
HC 
(n =20) 
JIA 
(n =20) 
HC 
(n =20) 
CHD 
(n =20) 
HC 
(n =20) 
CF 
(n =20) 
HC 
(n =20) 
No. of monitoring 
days 
7.4 (0.9) 6.8 (0.9) 6.8 (1.0) 7.1 (0.7) 7.4 (0.8) 7.0 (0.9) 6.6 (1.4) 6.9 (0.6) 
No. of monitoring 
nights 
6.9 (0.4) 6.6 (0.7) 6.7 (0.7) 7.0 (0.6) 7.1 (0.9) 6.0 (0.9) 6.5 (1.5) 7.1 (0.5) 
Monitoring time 
during waking 
hours/day 
13.2 (0.7) 
13.6 
(0.6) 
13.0 (0.7) 13.9 (0.7) 13.2 (1.0) 13.5 (0.6) 13.5 (0.7) 13.4 (0.4) 
Non-wear time 
during waking time 
minutes/day 
20.4 
(13.9) 
18.1 
(10.2) 
15.8 (14.8) 12.3 (10.8) 17.7 (20.4) 7.4 (5.9) 9.8 (8.7) 9.9 (8.1) 
Non-wear time 
during sleep time 
minutes/day 
0 0 0 0 0 0 0 0 
% of total non-
wear time per 24 
hours period 
1.3 (1.0) 0.3 (0.6) 1.1 (1.0) 0.9 (0.7) 1.2 (1.4) 0.5 (0.4) 0.7 (0.6) 0.6 (0.6) 
BMI – body mass index; CHD – congenital heart disease; CF – cystic fibrosis; JIA – juvenile idiopathic arthritis; T1DM – type1 diabetes mellitus. 
Data are presented as means and standard deviation SD unless otherwise specified.  
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3.1. Introduction and Aim 
Children and adolescents with low levels of PA are at increased risk of becoming 
inactive adults, and of diseases that result from inadequate activity (79, 341). In addition 
to low PA, there is increasing concern that high levels of ST may also be common, and 
both low PA and high ST are important risk factors for chronic disease (97, 342).  
 
The MVPA recommendations was based on large bodies of generally strong and 
consistent evidence, and that this evidence has been summarised in several systematic 
and narrative reviews that a minimum of 60 minutes of MVPA every day for school-
age children and adolescents (20, 39, 281). The main argument that a level of MVPA 
below recommendations is a concern is not supported by the evidence available and 
hence the recommendations do appear to be robust. These recommendations for the 
general population are usually also considered to be applicable to children and 
adolescents with chronic disease (30, 87, 280), with an understanding that usual levels 
of MVPA might be lower in such sub-groups, and achievement of the MVPA 
recommendation would be a slower and more gradual process than in the healthy 
population (30, 343-345). 
 
Objective techniques such as accelerometry currently represent the most accurate 
methods for measuring the amount and intensity of PA and amount of ST (154, 346). 
While there have been many studies on the levels and adequacy of MVPA and ST in 
healthy children and adolescents (347-350), there are surprisingly few such studies in 
children and adolescents with chronic disease. In fact, numerous previous studies and 
national PA surveillance programs have actually excluded children and adolescents 
with chronic disease.  
Chapter III 
 
135 
 
The primary aim of the present study was therefore to examine whether children and 
adolescents with chronic disease meet the current MVPA recommendation (79, 80, 
281). Secondary aims were to examine the amount of accelerometer-measured ST in 
children and adolescents with chronic diseases, and to determine whether accelerometer 
measured MVPA and ST in children and adolescents with chronic disease were 
different from those in healthy control or comparison groups. This systematic review 
provides evidence on whether levels of MVPA are adequate and ST excessive in 
children and adolescents with chronic disease.  
 
3.2. Materials and Methods 
3.2.1. Review Governance and Registration  
A systematic review of the literature was performed in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses guidelines (285). The 
review protocol was registered on PROSPERO (registration number 
CRD42015016783), the international prospective register for systematic reviews 
(http://www.crd.york.ac.uk/ NIHR_PROSPERO) and available in Appendix I.  
 
3.2.2. Study Eligibility 
 Inclusion Criteria 
To be eligible for inclusion in the review, papers had to meet all of the following criteria 
as per PICOS principles: Population (children and adolescents aged from 0–19 years); 
Intervention or exposure: chronic childhood disease (chronic disease defined as any 
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physical health problem that lasts three months or more). The chronic diseases included 
were decided on following a scoping review and were cardiovascular disease, 
respiratory disease, diabetes type 1 or type 2, and malignancies); Comparison (where 
applicable): healthy children matched for relevant criteria (in particular age, gender); 
Outcome (accelerometer measured MVPA and/or ST of at least 3 days and 6 
hours/day). All study designs were considered eligible (cross-sectional, longitudinal, 
case-control studies and intervention studies if pre- intervention data could be 
extracted). We looked for original research studies, published in English, in peer-
reviewed journals; a detailed description of the study eligibility criteria is available in 
Appendix I. 
 
 Exclusion Criteria 
Studies that included participants with co-morbid acute or chronic medical diseases or 
conditions that may have impacted their PA were excluded. The present study aimed to 
examine the subtle impact of chronic disease on MVPA and ST, not the more obvious 
impacts from co-morbidities that preclude PA (e.g. arising from injury or acute illness 
requiring bed rest, and chronic physical limitations from e.g. cerebral palsy). Because 
of the ongoing debate about whether obesity is a disease, studies in children with 
obesity were also excluded and are the subject of a separate report.  
 
Since the aim of the review was to examine habitual levels of MVPA and ST, studies 
that measured these variables for less than 6 hours per day or over two days or less were 
excluded. Recommendations currently exist for habitual (overall) MVPA rather than 
MVPA during specific domains (e.g. the after-school period) and so studies that 
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focused only on specific periods of the day (e.g. school activity only, or outdoor activity 
only, or weekend or weekday activity only, or after-school only) were also excluded.  
 
3.2.3. Search Strategy 
The literature search was conducted using the five most relevant electronic databases: 
MEDLINE OVID; Cochrane library; EMBASE; SPORTSDiscus and CINAHL. We 
searched from the year 2000 (to increase generalisability, since levels of MVPA and/or 
ST might be different now than in the past, and because accelerometery became more 
widely used in research from the early 2000’s) up to March 2017. The literature search 
strategy used in MEDLINE is given in Table 3.1 and was adapted as required for the 
other four data- bases. Full literature search details are available in Appendix I. The 
electronic search was complemented by reference tracking (forward and backward) of 
the eligible studies.  
 
3.2.4. Study Selection 
Titles, abstracts, and full-text articles were screened in duplicate for eligibility and 
disagreements were resolved through discussions with other reviewers when required. 
Reference lists of eligible studies were examined for potentially eligible studies. 
Reasons for exclusion are summarised in the study flow diagram.  
 
3.2.5. Data Extraction and Data Synthesis 
This review used a standard form for extracting relevant information from the eligible 
studies. The systematic review identified that the eligible studies fell logically into four 
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categories: cardiovascular disease; respiratory disease; diabetes; malignancy. A fifth 
category (obesity) was identified but this is reported separately as noted above. 
Obesity was not included here because of the on-going debate about whether obesity is 
a disease or not.  
International recommendations for school-age children and adolescents specify at least 
60 minutes of MVPA every day (39, 281), but in the eligible studies the achievement 
of MVPA recommendations was never operationalised in this way. In most studies, 
only the mean or median daily MVPA was provided (rather than achievement of MVPA 
recommendations on 7/7 days), and so this was used as a proxy for achievement of 
guideline recommendations in the present study.  
 
Where suitable data for patients and healthy controls were reported, mean and standard 
deviation of MVPA and ST in minutes per day, and sample sizes for similar chronic 
disease conditions were combined in a random effects model accounting for 
heterogeneity between studies. Given the differing methods of determining MVPA 
levels obtained from accelerometers, differences in MVPA between patients and 
controls were generated as weighted standardised mean difference (SMD). While 
methodology (e.g. accelerometer model, accelerometry cut point and/or epoch) varied 
substantially between studies, within study comparisons are all based on the same 
methods. Separate meta-analyses were performed for MVPA and ST. Review Manager 
5.2 was used for the quantitative analysis (351) .Some eligible studies recruited healthy 
control participants and measured MVPA and/or ST in the same way as in their patient 
group and at the same time (referred to here as studies with controls), while other 
studies compared patient data with other studies (e.g. published data) and are referred 
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to here as studies with comparison groups; some studies simply reported patient data in 
relation to PA recommendations. 
 
Table 3.1: Search strategy used for MEDLINE database 
 
1. exp Child/ 
2. exp Adolescent/ 
3. (child* or adolesc* or teen* or youth or girl* or boy*).tw. 
4. (young adj1 (person or people)).tw. 
5. 1 or 2 or 3 or 4 
6. exp Exercise/ 
7. exp Motor Activity/ 
8. exp Sports/ 
9. exercis*.tw. 
10. physical* activ*.tw. 
11. (active adj2 (living or lifestyle)).tw. 
12. sedentary behavi?r.tw. 
13. exp Sedentary Lifestyle/ 
14. ((sedentary or sitting or screen or TV or television or computer or PC or video games) adj2 
time).tw. 
15. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. exp Obesity/ or exp Overweight/ 
17. (overweight or obes*).tw. 
18. exp Accelerometry/ 
19. exp Actigraphy/ 
20. acceleromet*.tw. 
21. actigraph.tw. 
22. activity monitor*.tw. 
23. (objective adj1 (measure* or monitor* or assess*)).tw. 
24. 18 or 19 or 20 or 21 or 22 or 23 
25. exp cardiovascular abnormalities/ or exp heart diseases/ 
26. exp Cardiovascular Abnormalities/ 
27. exp Heart Diseases/ 
28. "congenital heart disease".tw. 
29. "Atrial Septal Defect".tw. 
30. "Complete Atrioventricular Canal Defect ".tw. 
31. "Ventricular Septal Defect".tw. 
32. (Tetralogy adj2 Fallot).tw. 
33. exp Asthma/ 
34. asthma.tw. 
35. exp Respiratory Tract Diseases/ 
36. exp Respiratory Hypersensitivity/ 
37. exp Cystic Fibrosis/ 
38. (respiratory adj2 allerg*).tw. 
39. "cystic fibrosis".tw. 
40. wheez*.tw. 
41. exp Bronchopulmonary Dysplasia/ 
42. lung diseases/ or exp alpha 1-antitrypsin deficiency/ or exp "cystic adenomatoid 
malformation of lung, congenital"/ or exp hepatopulmonary syndrome/ or exp hypertension, 
pulmonary/ or exp lung diseases, fungal/ or exp lung diseases, interstitial/ or exp lung diseases, 
obstructive/ or exp lung diseases, parasitic/ or exp lung injury/ or exp lung neoplasms/ or exp 
lung, hyperlucent/ 
43. "chronic lung disease".tw. 
44. "chronic respiratory disease".tw. 
45. exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/ 
46. (diabetes adj1 mellitus).tw. 
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47. exp Leukemia/ 
48. Leukemia.tw. 
49. exp Lymphoma/ 
50. Lymphoma.tw. 
51. exp Neuroblastoma/ 
52. Neuroblastoma.tw. 
53. "Wilms’ tumor".tw. 
54. exp Central Nervous System Neoplasms/ 
55. exp Sleep Apnea Syndromes/ 
56. "sleep apnea".tw. 
57. 16 or 17 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 
39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 
or 56 
58. 5 and 15 and 24 and 57 
59. exp Adult/ 
60. 58 not 59 
61. limit 60 to (english language and yr="2000 -Current") 
https://doi.org/10.1371/journal.pone.0179429.t001 
 
3.2.6. Quality Assessment 
Eligible articles were assessed for methodological quality using a 15-item quality 
assessment scale as shown in Appendix I, collapsed to 6 items for scoring, with higher 
scores suggesting higher study quality. Each eligible study assessed independently by 
two authors (RE, JJR), and disagreements were resolved by discussion. The quality 
assessment scale was modified from the methodological quality assessment scale of 
Tooth et al. (352). This is a reliable and valid 30-item tool for assessing the quality of 
observational studies and was considered for use without modification initially. After 
careful reflection, modifications to the original scale were made to focus quality 
assessment on issues of particular importance to accelerometry measurement of PA. A 
modified Tooth tool has been used previously with several recent systemic reviews of 
PA studies with 8–17 items that were usually collapsed to a smaller number of items 
for scoring (54, 353-355). 
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3.3. Results 
3.3.1. Identification of Eligible Studies  
The PRISMA flow diagram with numbers of included and excluded articles at each 
step of the review process is provided in Figure 3.1. Table 3.2-3.5 provides a brief 
summary of all studies included in this systematic review. Of the 1592 identified 
records from the five databases, 504 were selected for full text screening and of these, 
24 met the inclusion criteria. Additionally, 1 study was identified and deemed eligible 
through searching references of eligible studies, bringing the final total to 25 eligible 
studies (7 in children with cardiovascular disease; 7 in children with respiratory disease; 
8 in children with diabetes; 3 in children with malignancies) and 11 of these 25 studies 
were suitable for inclusion in meta-analysis (4 in those with respiratory disease; 5 in 
those with diabetes; 2 in those with malignancies). All eligible studies measured 
MVPA, and 16 out the 25 eligible studies compared levels of MVPA between patients 
with chronic disease and a healthy control group (referred to here as studies with 
controls), while the other 7 eligible studies compared data from patients with data from 
previously published studies of healthy children and adolescents (referred to here as 
studies with comparison groups); and two studies simply reported patient data in 
relation to recommendations; 14 of the 25 studies also provided data on ST, and 10 of 
these 14 studies compared ST in those with chronic disease with a healthy control 
group, while another 4 eligible studies compared data from patients with data from 
previously published studies of healthy children and adolescents comparison groups.  
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Figure 3.1: The PRISMA flow diagram with numbers of included and excluded articles at each step 
of the review process. 
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Table 3.2: Descriptive characteristics and levels of moderate-to-vigorous intensity physical activity and sedentary time in children with cardiovascular disease 
 
Reference
* 
Place and 
publication 
year 
Sample group 
n, male% and 
age (yrs) 
Control group 
n, male% and 
age (yrs) 
Measurement Accelerometry 
methods 
MVPA Sedentary time 
Banks et 
al (356) 
Canada, 
2012 
n: 20, (60 % 
male) 
 
Age: mean 11.8 
(SD 3) 
N/A Actigraph MTI, 
worn above the 
iliac crest for 4 
days including 1 
weekend day 
Epoch = 60s 
MVPA cut-points not 
clearly reported. 
Median 8 (Q1 4 - Q3 11) 
min/day 
MVPA lower in patients than 
healthy comparison groups 
All patients failed to meet an 
average of 60 min/day MVPA 
N/A 
Banks et 
al (357) 
Canada, 
2013 
n: 50, (59 % 
male) 
 
Age: range 6-12 
N/A Actical, worn 
above the iliac 
crest for 7 days. 
Epoch = 15s 
MVPA > 1600 cpm 
Mean 52 (SD 20) min/day 
MVPA lower in patients than 
healthy comparison groups 
All patients failed to meet an 
average 60 min/day MVPA 
N/A 
Duncombe 
et al (358) 
Canada, 
2016 
n: 90, (54 % 
male) 
 
Age: mean 13.6 
(SD 2.7) 
N/A Actigraph GT3X, 
worn on right hip 
for 7 days during 
waking hours. 
Epoch =15s 
Evenson cut-point 
(359) 
MVPA > 2296 cpm 
Sedentary time < 100 
cpm 
Median 43 (IQ range 29 - 60) 
min/day 
MVPA similar in patients and 
healthy comparison groups 
8 % of patients achieved an 
average 60 min /day MVPA 
Median 70 (IQ range 
61 - 76) % of waking 
time sedentary 
Sedentary time 
similar in patients 
and healthy 
comparison groups 
Ewalt et al 
(360) 
USA, 2012 n: 21, (24 % 
male) 
 
Age: mean 10.7 
(SD 3.2) 
n: 21, matched 
for age and 
gender 
Actigraph 7164, 
worn on right hip 
for 7 days during 
waking hours. 
Epoch = 30s 
MVPA cut-points not 
clearly reported 
Sedentary time ≤ 50 
counts /30s 
Patients mean 71 (SD 50) 
min/day 
Control group mean 61 (SD 30) 
min/day 
MVPA difference not 
significant (p = 0.2) 
Patients mean 399 
(SD 107) min/day 
Control group mean 
406 (SD 90) min/day 
Sedentary time 
difference not 
significant (p = 0.7) 
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33 % of patients and 5 % of 
control group achieved an 
average 60 min /day of MVPA 
Gardner et 
al (361) 
Canada, 
2016 
n: 30, (46 % 
male) 
 
Age: mean 10.7 
(SD 3.2) 
N/A Actigraph GT3X, 
worn on right hip 
for 7 days during 
waking hours 
Epoch = 15s 
Evenson cut-point 
(359) 
MVPA > 2296 cpm 
Sedentary time < 100 
cpm 
Median 40 (IQ range 27 - 57) 
min/day 
25 % of patients achieved an 
average 60 min /day of MVPA 
Median 68 (IQ range 
61 - 76) % of waking 
time sedentary 
Longmuir 
et al (247) 
Canada, 
2011 
n: 63, (60 % 
male) 
 
Age: range 5 -
11 
N/A Actical, worn 
above the iliac 
crest for 7 days 
during waking 
hours 
Epoch =15s. 
MVPA > 1,600 cpm. 
Mean 51 (19) min/day 
MVPA 4 to 5 times lower in 
patients than healthy 
comparison groups 
3 % of patients achieved an 
average of 60 min per day of 
MVPA 
N/A 
McCrindle 
et al (241) 
USA and 
Canada. 
2007 
n: 147, (62 % 
male) 
 
Age: range 6 -
18 
N/A Actigraph MTI, 
worn for 4 days 
include 1 
weekend day 
during waking 
hours 
Epoch = 60s 
Freedson cut-point 
(362) 
Absolute MVPA not given. 
MVPA lower in patients than 
healthy comparison groups 
38 % of patients achieved an 
average of 60 min per day of 
MVPA 
N/A 
cpm – counts per minutes, MVPA – moderate-to-vigorous physical activity, n – number, N/A – no data included, S – second 
Data are expressed as mean (SD) unless otherwise  
Freedson MVPA cutpoint (362) calculated using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr))  
*One study (360) recruited healthy control and patient participants at the same time and measured MVPA and ST in the same way as (referred to here as studies with control 
group); five studies (241, 247, 356-358) compared patient data with other studies-previous published studies (referred to here as studies with comparison groups); and one 
study (361) reported patient data in relation to recommendations.  
* Studies are listed in alphabetic order.  
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Table 3.3: Descriptive characteristics and levels of moderate-to-vigorous intensity physical activity and sedentary time in children with chronic respiratory diseases 
 
Reference
* 
Place and 
publication 
year 
Sample group 
n, male% and 
age (yrs) 
Control group 
n, male% and 
age (yrs) 
Measurement  Accelerometry 
methods 
MVPA  Sedentary time  
Aznar et al 
(363) 
Spain, 2014 n: 47, (51 % 
male)  
Age: mean 12.0 
(SD 3.0) 
N: 39; (59 % 
male) 
 
Age: mean 12.0 
(SD 2.0) 
Actigraph 
GT3X, worn 
on right hip 
for 7 days 
during waking 
hours 
Epoch = 15s 
Evenson cut-point 
(359) 
MVPA > 2296 cpm  
Sedentary time < 100 
cpm 
Patients mean 44 (SD 28) min/day 
Control group mean 54 (SD 15) 
min/day 
MVPA significantly lower in 
patient (p < 0.02) 
2 % of patients and 34 % of 
control group achieved an average 
60 min/ day of MVPA 
Patients mean 362 
(SD 67) min/day 
Control group mean 
484 (SD 85) 
min/day  
Sedentary time was 
lower in patients (p 
< 0.001) 
Kilbride et 
al (364) 
Ireland, 
2012 
n: 16, (56 % 
male) 
 
Age: range 10 - 
12  
n: 99, (48 % 
male) 
 
Age: range 10 - 
12  
RT3 worn for 
3 days 
Epoch and MVPA cut-
points not clearly 
reported 
Sedentary time = 0 – 
99cpm  
Patients mean boys 15 (SD 3); 
girls 16 (SD 3) min/day 
Control group mean boys 23 (SD 
6); girls 15 (SD 3) min/day 
MVPA similar in patients and 
control group  
All patients failed to meet an 
average of 60 minutes/day MVPA 
N/A 
Smith et al 
(365)  
Germany, 
2016 
n: 94, (56 % 
male) 
 
Age: mean 15.6 
(SD 0.5)  
n: 590, (40 % 
male) 
 
Age: mean 15.7 
(SD 0.5)  
Actigraph 
GT3X, worn 
on right hip 
for 7 days 
during waking 
hours 
Epoch = 60s. 
Freedson cut-point 
(362) 
Patients mean boys 41 (35) 11, 
89; girls 43 (36) 14, 71 min/day 
Control group mean boys 46 (42) 
19, 89; girls 38 (34) 13, 70 
min/day 
N/A 
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Tsai et al 
(366) 
USA, 2012 n: 27, (70 % 
male) 
 
Age: range 9 - 11  
n: 27, (59 % 
male) 
 
Age: range 9 - 11  
actigraph 
(Actiwatch 64 
MM), worn 
non-dominant 
wrist for 7 
days during 
waking hours 
Epoch = 60s 
MVPA ≥ 700 cpm 
Sedentary time = 0 - 49 
cpm 
Patients mean 265 (SD 83) 
min/day  
Control group mean 308 (SD 97) 
min/day 
MVPA similar in patients and 
control group (p = 0.09) 
 
Patients and control group 
achieved an average of 60 min per 
day of MVPA 
Patients mean 87 
(SD 48) min/day 
Control group mean 
77 (SD 27) min/day  
Sedentary time 
difference not 
significant (p = 0.3) 
Vahlkvist 
et al (367) 
 
Denmark, 
2010 
n: 55  
 
Age: range 6 - 14  
n: 154  
Age: range 6 - 14  
RT3 worn for 
4 weeks 
during 24 h a 
day  
Epoch and cut-points 
not clearly reported 
Patients mean of 32 (95 % CI 5) 
min/day 
 
Control group mean 34 (95 % CI 
3) min/day 
MVPA similar in patients and 
control group  
 
Patients and control group failed 
to achieve an average of 60 min 
per day of MVPA 
Patients mean 1270 
(95 % CI 15) 
min/day 
Control group mean 
1261 (95 % CI 9) 
min/day 
Sedentary time was 
similar in patient 
and control group 
Van- Gent 
et al (368) 
Netherlands,
2007 
n: 81, (58 % 
male) 
 
Age: mean 9.4 
(SD 0.8)  
n: 202, (50 % 
male) 
 
Age: mean 9.4 
(SD 0.7)  
Pam AM 100, 
worn on hip 
for 5 days 
during waking 
hours  
Epoch = 60s  
MVPA cut-points not 
clearly reported 
Patients mean 99 (95 %, CI 80, 
118) min/day 
Control group mean 98 (95 %, CI 
85, 106) min/day 
MVPA similar in patients and 
control group  
 
Patients and control group 
achieved an average of 60 min per 
day of MVPA 
N/A 
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Yiallouros 
et al (369) 
Cyprus, 
2015  
n: 36, (64 % 
male) 
 
Age: range 8-9  
n: 99, (60 % 
male) 
 
Age: range 8 - 9  
Actigraph 
worn on wrist 
for 7 days 
during waking 
hours 
Epoch not clearly 
reported.  
MVPA > 3200 cpm  
Sedentary time  < 100 
cpm 
Patients mean 15 (95% CI 10-21) 
min/day. 
Control group mean 16 (95% CI 
14-19) min/day. 
Similar in patients and control 
group  
Patients mean 939 
(95 % CI 915 - 963) 
min/day 
Control group mean 
927 (95% CI 915 - 
938) min/day 
Similar in patients 
and control group  
cpm – counts per minutes, MVPA – moderate-to-vigorous physical activity, n – number, N/A – no data included, S – second 
Data are expressed as mean (SD) unless otherwise  
Smith et al (365): MVPA calculated as mean (Geometric mean) 5
th
, 95
th 
percentile, and Yiallouros et al (369): MVPA Calculated as geometric means (95% CI) in min/day  
Freedson MVPA cutpoint (362) calculated using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr))  
Studies recruited healthy control participants and measured MVPA and ST in the same way as in their patient participants and at the same time (referred to here as studies 
with control group) 
* Studies are listed in alphabetic order 
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Table 3.4: Descriptive characteristics and levels of moderate-to-vigorous intensity physical activity and sedentary time in children with diabetes mellitus  
 
Reference* Place and 
publication 
year 
Sample group 
n, male% and 
age (yrs) 
Control group 
n, male% and 
age (yrs) 
Measurement  Accelerometry 
methods 
MVPA  Sedentary time  
Cuenca-
Garcia et al 
(370) 
UK, 2012 n: 60, (67  % 
male) 
 
Age: mean 12.5 
(SD 2.3) 
n: 37, (54 % 
male) 
 
Age: mean 12 
(SD 2.5) 
Actigraph 
GT1M, worn 
for 7 days 
during waking 
hours  
Epoch = 60s 
MVPA ≥ 3200 cpm 
Patients mean 28 (SD 21) min/day 
Control group mean 20 (SD 11) 
min/day 
MVPA difference not significant 
(p = 0.06) 
N/A 
Kriska et al 
(105) 
USA, 2013 n: 669, (51.5% 
male) 
Age: range 10-17  
N/A Actigraph 
AM7164, 
worn on waist 
for 7 days 
during waking 
hours 
Epoch = 60s.  
MVPA Freedson 
cut-point (362) 
Sedentary time < 
100 cpm 
10-14 year old mean boys 35 (SD 
26); girls 27 (SD 18) min/ day. 
15-18 year old mean (boys 26 
(SD 24); girls 8 (SD 9) min/day 
 
MVPA low in patients than 
healthy comparison groups  
All patients failed to reach an 
average of 60 min/day MVPA 
10 - 14 year old mean 
boys 495 (SD 144); 
girls 479 (SD 141) 
min/day 
15 - 18 year old mean 
boys 526 (SD 143); 
girls 546 (SD 143) 
min/day 
MacMillan 
et al (371) 
UK, 2014 n: 40, (50 % 
male) 
 
Age: mean 11.1 
(SD 2.7) 
N/A Actigraph 
GT3X, worn 
on waist for 7 
days during 
waking hours 
Epoch =15s.  
MVPA ≥ 3200 
cpm. 
Sedentary time < 
100 cpm  
Patients mean of 43 (SD 24) 
min/day  
 
MVPA similar in patients and 
healthy comparison groups 
5 % of patients achieved an 
average of 60 min per day of 
MVPA 
Patients mean 612 
(SD 102) min/day 
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Maggio et al 
(222) 
Switzerland
, 2010 
n: 45 
 
Age: mean 10.7 
(SD 0.4) 
n: 85 
 
Age: mean 10.1 
(SD 0.3) 
Actigraph 
6471, worn for 
7 days during 
waking hours 
Epoch not clearly 
reported 
MVPA > 2000 
cpm. 
Sedentary time < 
500 cpm 
Patients mean 54 (SD 7) min/day. 
Control group mean 71 (SD 5) 
min/day 
39 % of patient and 60 % of 
control group achieved an average 
of 60 min/day of MVPA 
 
The difference not significant (p = 
0.07) 
Patients mean 77 % 
waking time 
sedentary  
Control group mean 
70 % waking time 
sedentary.  
 
Significantly higher 
in patient (p < 0.01) 
Nguyen et al 
(372) 
Canada, 
2015  
n: 16; (n = 8) 
good glycemic 
control, (n = 8) 
poor glycemic 
control 
 
Age: range 8 - 16  
n: 8 
Age: range 8 - 16  
Actigraph 
GT1, worn on 
the right hip 
for 7 days 
during waking 
hours 
Epoch = 3s 
Evenson cut-point 
(359) 
MVPA > 2296 cpm  
Sedentary time < 
100 cpm 
Patients with good glycemic 
control mean 46 (SD 16) min/day 
 
Patients with poor glycemic 
control mean 47 (SD 8) min/day 
 
Control group mean 54 (SD 28) 
min/day  
 
The difference not significant (p = 
0.07) 
N/A 
Sarnblad et 
al (373) 
Sweden, 
2005 
n: 26, (100 % 
female) 
 
Age: range 12 - 
19  
n: 49  
 
Age: range 12 - 
19  
Actigraph 
6471 worn on 
the hip for 7 
days during 
waking hours 
Epoch = 60s 
MVPA > 1952 cpm 
Sedentary time < 
100 cpm  
Patients mean of 56 (SD 20) 
min/day 
 
Control group mean 60 (SD 23) 
min/day 
 
The difference not significant (p = 
0.07) 
Patients mean 443 
(SD 60) min/day 
Control group mean 
390 (SD 27) min/day  
Significantly higher 
in patient than control 
group (P = 0.002) 
Sundberg et 
al (374)  
 
Sweden, 
2012 
n:24, (50 % male) 
 
Age: mean boys 
4.3 (SD 1.6); girls 
4.7 (SD 1.9)  
n: 26, (46.2 % 
male) 
Age: mean boys 
4.9 (SD 1.4); girls 
4.4 (SD 1.8) 
Actiheart, for 
7 days 
Epoch = 60s 
MVPA cut-point 
not clearly reported. 
Sedentary time < 
100 cpm,  
Absolute MVPA not given 
MVPA significantly lower in 
patients than the control group (p 
= 0.02) 
Absolute sedentary 
time not given 
Significantly higher 
in patient than control 
group (p = 0.03) 
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Trigona et al 
(375). 
Switzerland, 
2010.  
n: 32, (53 % 
male) 
 
Age: range 6 - 17  
n: 42, (40 % 
male). 
 
Age: range 6 - 17  
Actigraph 
6471, worn on 
hip for at least 
4 days during 
waking hours 
Epoch = 60s 
MVPA > 2000 cpm 
Patients mean 53 (95 % CI 33 - 
74) min/day 
 
Control group mean 77 (95 % CI 
58 - 97) min/day 
 
Significantly lower in patients 
than the control group (p < 0.008) 
 
35 % of patients and 57% control 
group achieved an average of 60 
min/day of MVPA 
N/A 
cpm – counts per minutes, MVPA – moderate-to-vigorous physical activity, n – number, N/A – no data included, S – second 
Data are expressed as mean (SD) unless otherwise  
Freedson MVPA cutpoint (362) calculated using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr)) 
Six studies (222, 370, 372-375) recruited healthy control participants and measured MVPA and ST in the same way as in their patient participants and at the same time 
(referred to here as studies with control group), and two studies (105, 371) compared patient data with other studies (referred to here as studies with comparison groups.  
* Studies are listed in alphabetic order. 
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Table 3.5: Descriptive characteristics and levels of moderate-to-vigorous intensity physical activity and sedentary time in children with malignancies  
 
Reference
* 
Place and 
publicatio
n year 
Sample group 
n, male% and 
age (yrs) 
Control group 
n, male% and 
age (yrs) 
Measurement Accelerometry 
methods 
MVPA Sedentary time 
Aznar et al 
(292) 
Spain, 
2006 
n: 7, (57.1 % 
male) 
 
Age: range 4 – 7  
n: 7, (57.1 % 
male) 
 
Age: range 4 –7  
Actigraph MTI, 
worn on waist 
for 7 days 
during waking 
hours  
Epoch = 60s 
MVPA Freedson cut-
point (362) 
Sedentary time ≤ 100 
cpm  
Patients mean 47 (SD 15) 
min/day 
Control group mean 72 (SD 
25) min/day 
Significantly lower in patient 
group than control group (p 
=0.04)  
0 % of patient, 57 % control 
group achieved an average of 
60 min/day of MVPA. 
Patients mean 41 (SD 
18) % of time 
sedentary  
Control group mean 42 
(SD 11) % of time 
sedentary 
Sedentary time was 
similar in patient and 
control group (p = 
0.07) 
Gotte et al 
(376) 
Germany, 
2017 
n: 28, (57 % 
male) 
Age: range 11 – 
15 
N/A Step Watch 3TM 
Monitor, worn 
for 7 days 
during waking 
hours 
Epoch = 60s 
MVPA cut-point not 
clearly reported 
Patients mean 4 (SD 5) 
min/day 
3 % (n=1) of patient achieved 
an average of 60 min/day of 
MVPA 
N/A 
Tan et al 
(75) 
Malaysia, 
2012 
n: 38  
Age: range 3 – 12  
n: 38  
 
Age: range 3 – 12  
Actical, worn on 
hip for 7 days 
during all the 
day  
Epoch = 15s  
MVPA cut off points 
not reported 
Sedentary time < 100 
cpm  
Patients mean 20 (SD 28) 
min/day 
Control group mean 168 (SD 
56) min/day 
Significantly lower in patient 
group than control group (p < 
0.01)  
Patients mean 1295 
(SD 119) min/day  
Control group mean 
925 (SD 111) min/day 
Significantly higher in 
patients than control 
group (p < 0.01) 
cpm – counts per minutes, MVPA – moderate-to-vigorous physical activity, n – number, N/A – no data included, S – second 
Data are expressed as mean (SD) unless otherwise  
Freedson MVPA cutpoint (362)calculated using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr))  
Two studies (75, 292) recruited healthy control participants and measured MVPA and ST in the same way as in their patient participants and at the same time (referred to 
here as studies with control group) and one study (376) reported patient data in relation to recommendations.  
* Studies are listed in alphabetic order. 
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3.3.2. Study Characteristics 
Study samples: Eligible study sample sizes ranged from 14 – 699 with a total of 2062 
participants with chronic disease and 1523 participants from healthy control groups. 
All studies were from high-income, developed nations. Measurement methods: A 
total of 17 out of the 25 eligible studies used the ActiGraph accelerometer to measure 
habitual MVPA and/or ST, though with a variety of different ActiGraph models and 
approaches to data collection and reduction. Of the remaining studies: three used the 
Actical (75, 247, 357); two the RT3 “Triaxial Research Tracker” (364, 367); one the 
PAM “Physical Activity Monitor” B.V. type AM 100 (368); one the Actiheart (which 
combines accelerometry and heart rate monitoring) (374); and one the Step Watch 3TM  
(376). 
 
 MVPA in Children and Adolescents with chronic Disease 
The mean reported daily MVPA accumulated by children and adolescents with chronic 
disease across the 25 eligible studies ranged between 4 (SD 4) minutes/day (376) to 
265 (SD 83) minutes/day (366). 
 
Children and adolescents with cardiovascular disease: Seven of the 25 eligible 
studies (n = 442) examined MVPA in children and adolescents previously diagnosed 
with a congenital heart defect. This included children who had received different types 
of cardiac surgery (358, 360, 361), including complex surgery such as a fontan repair 
(241, 247, 357), or cardiac transplantation (356). In all cases the patients were studied 
at least 6 months after surgery while well, clinically stable, free of acute illness, and 
living in the community. As summarised in Table 3.2, average daily MVPA in these 
studies ranged from a low of 8 (range, 4-11) min/day (356) to a high of 49 (range 39-
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60) min/day (247). In 6/7 of eligible studies reported mean daily time spent in MVPA 
in minutes and in six studies mean daily MVPA failed to reach the recommended 60 
minutes. Only 1 out of 7 eligible studies included data from a healthy control group, 
showing a higher MVPA level in the patient group compared to the healthy control 
group although the differences were not significant (360).  
 
Children and adolescents with chronic respiratory diseases: Seven of the 25 
eligible studies (n = 1013) investigated children and adolescents with chronic 
respiratory diseases; five studies in patients with asthma (365-369) and two in patients 
with cystic fibrosis (363, 364). In all cases, the children were studied while clinically 
stable, free of acute illness, and while living in the community. The mean daily MVPA 
reported ranged from 15 (SD 3) min/day (364) to 265 (SD 8) min/day (366) as 
summarised in Table 3.3. In 2/7 eligible studies (366, 368) mean daily reported MVPA 
reached or exceeded the 60 minutes recommended, though this included one study 
with exceptionally high reported levels of MVPA (30). Meta-analysis of all 4 studies 
indicated lower MVPA levels in the patient group compared to the healthy control 
group, approaching statistical significance. The standardised mean difference (SMD) 
was 0.39 (95% CI -0.80 to 0.02, p=0.06). The heterogeneity was substantial with an I2 
statistic of 68%, as shown in Figure 3.2  
 
Children and adolescents with diabetes: Eight of the 25 eligible studies (n = 1323) 
involved children and adolescents with diabetes mellitus; 7 studies in children with 
type 1 diabetes (222, 370-375) and 1 in children with T2DM (105). Again, in all cases 
the patients were studied while clinically stable and free of acute illness or diabetes 
complications, and while living in the community. As summarised in Table 3.4, the 
average daily MVPA reported for diabetic patients ranged from a low of 8 (SD 9) 
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min/day (105) to a high of 56 (SD 20) min/day (373). Of the 8 eligible studies, 7 
reported mean daily MVPA in minutes and in all 7 of these studies MVPA was < 60 
minutes. Patient MVPA was compared to healthy peers in 5 studies (222, 370, 372, 
373, 375), all of which included patients with T1DM as shown in Figure 3.3. There 
was no evidence of a statistically significant difference in MVPA in patients compared 
to healthy controls (SMD -0.70, 95% CI -1.89 to 0.48, p=0.25, n= 400). Case-control 
evidence on MVPA levels appears to be lacking for children with T2DM. 
 
Children and adolescents with malignancies: Three studies, (n = 118) examined 
MVPA in those with malignancies including one study in acute lymphoblastic 
leukaemia on maintenance treatment (292), one in acute leukemia undergoing 
induction or consolidation chemotherapy (75) and a third in children and adolescents 
with different types of childhood malignancies (376). In all of these studies, the 
participants had no other co-morbid conditions that would have been a 
contraindication for PA such as anemia, fever, or other difficulties with mobility. The 
mean daily MVPA achieved during these studies ranged from a low of 4 (SD 4) 
min/day (376) to a high of 47 (SD 15) min/day (292), as summarised in Table 3.5. In 
all three studies mean daily MVPA failed to reach the recommended 60 minutes. Two 
out the three studies included data from healthy participants and in both of these 
studies; the level of MVPA was significantly lower in children and adolescents with 
malignancies (75, 292). Figure 3.4 shows the combined result, which suggests a 
standardised mean difference of 2.2 (95% CI -4.08 to -0.26, p=0.03). Despite the 
apparent similarity between the studies the statistical heterogeneity was considerable 
with an I2 statistic of 88%. The heterogeneity noted could be due to differences in 
sample sizes, age and place of the studies, differences in the stage of treatment, or 
differences in accelerometer methodology. 
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 Sedentary Time in Children and Adolescents with Chronic 
Disease 
In this systematic review, 14 out of the 25 eligible studies reported on accelerometer 
measured ST, with a total of 1870 participants (with chronic disease n = 1325; healthy 
control group n = 545). Of the 14 studies that measured ST, the chronic diseases 
studied were as follows: cardiovascular disease - 3 studies (358, 360, 361); chronic 
respiratory diseases - 4 studies (363, 366, 367, 369); diabetes - 5 studies (105, 222, 
371, 373, 374); malignancy - 2 studies (75, 292).  
 
As summarised in Table 3.2- 3.5, the mean daily time spent sedentary in these eligible 
studies ranged from a low of 87 (SD 48) min/day (366) to a high of 1295 (SD 119) 
min/day (75). In 10 out of the 14 eligible studies, there was a healthy control group, 
and in 4/10 studies ST was significantly higher in those with chronic disease than in 
the healthy control groups (75, 222, 373, 374); in one study ST was significantly lower 
in the patient group compared to the healthy control group (363), while in 5 studies 
there was no significant group difference (292, 360, 366, 367, 369). Suitable summary 
data for combining individual study data were only available for three studies (n=355) 
in patients with chronic respiratory disease with findings indicating no statistically 
significant group difference in time spent sedentary (SMD -0.40, 95% CI -1.53 to 0.74, 
p=0.49, I2=95%) as in Figure 3.5.  
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Figure 3.2: Forest plot of the comparison of moderate-to-vigorous intensity physical activity 
between children and adolescents with chronic respiratory diseases and healthy participants. SD: 
standard deviation; Std mean difference: Standardised mean difference; IV: Inverse variance; 
Random: random effect model; CI: 95% Confidence interval. (Forest plot is kindly supplied by Dr 
Anne Martin). 
 
 
Figure 3.3: Forest plot of the comparison of daily moderate-to-vigorous intensity physical activity 
between children and adolescents with type 1 diabetes mellitus and healthy participants. SD: 
standard deviation; Std mean difference: Standardised mean difference; IV: Inverse variance; 
Random: random effect model; CI: 95% Confidence interval. (Forest plot is kindly supplied by Dr 
Anne Martin). 
 
 
Figure 3.4: Forest plot of the comparison of daily moderate-to-vigorous intensity physical activity 
between children and adolescents with malignancies and healthy participants. SD: standard 
deviation; Std mean difference: Standardised mean difference; IV: Inverse variance; Random: 
random effect model; CI: 95% Confidence interval. (Forest plot is kindly supplied by Dr Anne 
Martin). 
 
 
Figure 3.5: Forest plot of the comparison of sedentary time between children and adolescents with 
chronic respiratory diseases and healthy participants. SD: standard deviation; Std mean 
difference: Standardised mean difference; IV: Inverse variance; Random: random effect model; 
CI: 95% Confidence interval. (Forest plot is kindly supplied by Dr Anne Martin).  
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3.3.3. Study Quality Assessment 
Study quality assessment summaries are given in Table 3.6: 3 studies scored 4/6; 13 
scored 5/6; 9 scored 6/6 on study quality. Thus in general, studies were high 
methodological quality. 
 
Table 3.6: Methodological quality assessment of the included studies 
 
 Quality Assessment Criteria, Items 1-6 
*Reference 1 2 3 4 5 6 Total score 
Banks, 2012 - + + + + + 5/6 
Banks, 2013 - + + + + + 5/6 
Duncombe, 2016 + + + + + + 6/6 
Ewalt, 2012 + + + + + + 6/6 
Gardner, 2016 - + + + + + 5/6 
Longmuir, 2011 - + + + + + 5/6 
McCrindle, 2007 - + + + + + 5/6 
Aznar, 2014 - + + + + + 5/6 
Kilbride, 2012 - + + + + + 5/6 
Smith, 2016 + + + + + + 6/6 
Tsai, 2012 + + + + + + 6/6 
Vahlkvist, 2012 - - + + + + 4/6 
Van Gent, 2007 + + + + + + 6/6 
Yiallouros, 2015 + - + + + + 5/6 
Cuenca-Garcia - + + + + + 5/6 
Kriska, 2013 + + + + + + 6/6 
MacMillan, 2014 + + + + + + 6/6 
Maggio, 2010 - - + + + + 4/6 
Nguyen, 2015 - + + + + + 5/6 
Sa ̈rnblad, 2005 + + + + + + 6/6 
Sundberg, 2012 + + + + + + 6/6 
Trigona, 2010 - + + + + + 5/6 
Aznar, 2006 + + + + + + 6/6 
Gotte 2015 - + + + + + 5/6 
Tan, 2012 + - + + + + 5/6 
+ Indicates that a criterion was satisfied; − indicates that a criterion was not satisfied. 1, described of Sample 
recruitment?; 2, description of the sample.?; 3, Attrition of sample?; 4, Data collection and reduction?; 5, 
MVPA definition given?; 6, MVPA Results given?; * Studies are listed based on diseases groups.  
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3.4. Discussion  
3.4.1. Main Findings and Study Implications 
This systematic review provides evidence that children and adolescents with some of 
the common chronic childhood diseases have lower than recommended levels of 
MVPA. In most of the eligible studies, daily MVPA averaged less than the 60 
minutes/day recommended. When comparing MVPA level between patients and 
healthy control or comparison groups, the findings indicated, within the limits of the 
available data, there were no marked differences for patients with T1DM, CVD and 
chronic respiratory diseases. However, in patients with leukemia compared to healthy 
control or comparison groups daily MVPA was significantly lower. With the respect 
to sedentary time the present review found that studies fairly consistently reported that 
children and adolescents with chronic disease accumulated a high amount of ST during 
their waking hours. 
 
It should be noted that recommendations based on systematic reviews of the scientific 
evidence for MVPA state that 60 minutes per day is a minimum every day (e.g. usually 
operationalized as all 7 days in a week) (80), but adherence to recommendations was 
not operationalized in this way in any of the 25 eligible studies. We therefore used a 
mean or median daily MVPA of 60 minutes as a proxy for compliance, though this is 
conservative because in many cases where 60 minutes/day was reached as an average, 
levels of MVPA would have fallen below 60 minutes/day on at least one of the 
monitored days.  
 
Reasons for lower than recommended levels of MVPA are unclear in both children 
with chronic disease and their healthy peers. Children and adolescents with chronic 
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disease may experience an over-protective care environment, a lack of supervised 
facilities/ opportunities for PA, and/or insufficient knowledge and self-efficacy about 
the types of PA suitable for the specific disease condition (377, 378). Such socio-
environmental influences could contribute to low daily MVPA and high ST. 
Healthcare professionals, parents/caregivers and schools may need to be provided with 
adequate information and training to be able to encourage and support children with 
chronic disease to engage in regular and appropriate MVPA. However, it should also 
be noted that reported levels of MVPA among healthy peers were also generally low 
in the eligible studies, so it may be that any constraints on PA that apply to healthy 
children and adolescents also apply equally to those with chronic disease. 
 
3.4.2. Comparisons with Other Studies  
We believe that the present study is the first systematic review to ask whether or not 
levels of MVPA are adequate in children and adolescents with chronic childhood 
disease. There are therefore no directly comparable studies, but we note that in healthy 
children, and particularly in healthy adolescents, there is concern that levels of MVPA 
are generally much lower than recommended. A global analysis by Hallal et al 
suggested that less than 20% of 13-15 year olds meet the recommendation of 60 
minutes/ day of MVPA (379). A recent pooling of international accelerometry data 
from nearly 21,000 healthy children and adolescents showed typically very low levels 
of adherence to the 60 minutes/day recommendation for MVPA (289), so it is perhaps 
not surprising that levels of MVPA among those with chronic disease were also found 
to be generally low in the present study. Furthermore, because of accelerometers was 
using to measures of PA in children have only been around since the early 2000s; so 
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the direct comparisons with objective levels of PA from the past are not possible and 
evidence of PA levels declining are too limited to make that conclusion. 
We are also unaware of any previous systematic reviews of accelerometry measured 
ST among children and adolescents with chronic disease. Interpreting sedentary time 
data is even more problematic than interpreting the MVPA data in the present study 
because there are currently no evidence-based recommendations for accelerometer-
measured ST. 
 
3.4.3. Study Strengths and Limitations 
Our review had a number of strengths. It was the first review to investigate objective 
levels of MVPA and ST in children and adolescents living with childhood chronic 
disease. Secondly, there are several methodological strengths to this study: in 
particular, studies were identified from an extensive search of the published literature 
conducted in a range of databases. The broad definition of search terms applied across 
multiple databases enabled the searching and identification across many potential 
studies. Restricting eligibility to accelerometry studies was important in increasing 
confidence in the objective measurement of MVPA (348, 380-382). Finally, all 
included studies were in general rated as being of high or very high quality. 
However, there are several weaknesses worth highlighting. Firstly, as studies had to 
be published in peer-reviewed journals in English, this may have excluded some 
relevant evidence. Studies included in our review investigated MVPA and ST in 
children and adolescents with chronic childhood disease. However, we excluded some 
other common medical conditions where significant alterations in activity might have 
been expected because of the nature of the condition e.g. musculo-skeletal and 
neurological disease, and we also excluded studies of patients with acute illness or 
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injury requiring or associated with confinement or bed-rest. Future reviews should 
consider these other groups, and also consider the PA and ST of children and 
adolescents with the many chronic diseases not included in the present review. Our 
initial scoping review found that objectively measured PA data were available for only 
a few chronic disease groups and so the present review focused on those.  
 
All eligible studies were from high-income developed nations. We therefore lack data 
from low-middle income countries where the prevalence of many childhood chronic 
disease will be common and lack of resources may limit medical care (383). Most of 
the included studies were based on relatively small samples of children with chronic 
disease (n 14 - 699) and their power to estimate habitual MVPA, or to distinguish 
between MVPA of patients and comparison group participants, might have been 
limited, and their representativeness was rarely clear.  
 
Our method for assessing the quality of eligible studies has been used in variously 
adapted forms in a number of other recent accelerometry systematic reviews (54, 353-
355), and used 15 items, but the process of collapsing these 15 items to a six-item scale 
might have reduced the possibility of identifying differences in quality between 
studies. Eligible studies made comparisons with healthy peers in a wide variety of 
ways (control groups; comparison groups; reference to recommendations). Use of 
control groups was considered ideal, but restricting our synthesis to only those studies 
would have reduced a small evidence base to an even smaller evidence base, so this 
was not done. 
Further, the eligible studies varied substantially in terms of the accelerometers used, 
and even where the same accelerometer was used the methods varied in a number of 
potentially important accelerometer data reduction decisions e.g. the definition of a 
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monitoring epoch (370, 381); the number of hours and days of data constituting a valid 
data set (105, 222); MVPA and ST accelerometer cut-points; and criteria for the 
inclusion or exclusion of non-wear time (363, 371). These differences between studies 
are likely to have produced meaningful differences in MVPA and ST estimates (346) 
and they make it difficult to compare across studies. For the present review, the level 
of heterogeneity between eligible studies was high when combining data in meta-
analysis across studies. However, in the case of all eligible studies the methods used 
for patient and control/comparison groups were identical, so comparison within-
studies remain meaningful. 
 
An example of how the choice of accelerometer cut-point could affect conclusions 
reached by individual studies is that studies using lower accelerometer cut-points to 
define MVPA tended to report higher levels of habitual MVPA than those which used 
higher accelerometer cut-points to define MVPA. Tsai et al (366), for example used 
an Actigraph accelerometer cut-off of ≥ 700 counts per minute to define MVPA in 
children with asthma. This cut-off point is well below the cut-points used more 
commonly and which are more evidence based (based on calibration studies such as 
the Evenson et al cut-point of 2296 counts per minute (359); or the Puyau et al cut-
point of 3200 counts per minute (384)). The very low accelerometer cut-point used by 
Tsai et al almost certainly led to the very high estimate of 265 (SD 83) minutes of daily 
MVPA (366), and could lead to the erroneous conclusion that levels of MVPA among 
children with asthma are extremely high.   
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3.5. Conclusions 
In summary, this systematic review found that overall (habitual) MVPA levels are well 
below international recommendations in at least some groups of children and 
adolescents with chronic childhood diseases. The present review suggests that 
management of pediatric chronic conditions should place greater emphasis on MVPA, 
and patients with at least some chronic diseases are probably not currently benefiting 
from the health and non-health benefits that MVPA can bring. Time spent sedentary 
is often higher than in the comparison groups, and probably too high in many patients, 
but this is difficult to interpret in the absence of health-related recommendations for 
accelerometer measured ST in children and adolescents. This valuable information 
about the MVPA and ST levels in children with chronic disease may help to stimulate 
improving PA guidelines, and improving PA for these children. The need for more 
extensive research in this area, including intervention studies of the impact of 
increased MVPA levels on health related outcomes, is clear. 
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4.1. Introduction and Aim 
The prevalence of obesity among children and adolescents is now very high in both 
developing and developed countries (386, 387). The rising prevalence is recognised as 
a significant public health and clinical concern (73) and is attracting much research 
attention (388). Obesity is known to have a significant impact on both physical and 
psychological health and obese children and adolescents face a number of health, social, 
and psychological problems (387, 389, 390). Prevention of childhood obesity is now a 
public health priority while treatment is becoming an increasingly important clinical 
issue. 
A number of health behaviors have been associated with risks of obesity (391). Poor 
diet, lack of PA and increased ST have been linked to the development and maintenance 
of childhood and adolescent obesity (67, 392-394). Many evidence-based guidelines 
focusing on the amount of PA, particularly moderate–to-vigorous intensity physical 
activity (MVPA), required producing health benefits, have been developed. These 
guidelines commonly recommend 60 minutes of MVPA as a daily minimum (7 days in 
a week) for school-age children and adolescents (9, 80, 343, 395).  
 
Accelerometry currently represents the most accurate, inexpensive, and reliable method 
for objectively measuring both the amount and intensity of PA and amount of sedentary 
behavior (SB) (154, 346). There have been many surveys and studies on the levels and 
adequacy of MVPA in healthy-weight children and adolescents (347, 348). Since 
MVPA and SB are also important to health in those with obesity, and since obesity has 
been hypothesized to be associated with reduced MVPA (396), it is important to assess 
the extent of objectively measured time spent in MVPA and SB in obese children and 
adolescents. The primary aim of the present systematic review was therefore to review 
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the evidence on the habitual amount of time spent in MVPA by obese children and 
adolescents, and examine whether those living with obesity met the current MVPA 
recommendation for health of a minimum of 60 minutes per day (9, 30). Secondary 
aims were to examine time spent in accelerometer-measured SB by obese children and 
adolescents, and to determine whether MVPA and SB in obese children and adolescents 
were different from the non-obese peers. 
 
4.2. Materials and Methods 
4.2.1. Review Governance and Registration 
A systematic literature review was performed in accordance with the Preferred 
Reporting Items for Systematic Reviews guidelines (285). The review protocol was 
registered on PROSPERO (registration number CRD42015026882), the international 
prospective register for systematic reviews (http://www.crd.york.ac.uk/ 
NIHR_PROSPERO) and available in Appendix I. 
 
4.2.2. Literature Search 
The literature search was conducted by searching for English language peer-reviewed 
studies in the five most relevant electronic databases from 2000 up to March 2015 
(accelerometry became more widely used in research from the early 2000’s): 
MEDLINE OVID; Cochrane library; EMBASE; SPORTSDiscus and CINAHL by AM. 
The literature search in the Cochrane Central Register of Controlled Trials is shown in 
Table 4.1 and was adapted as required for the other databases. Full literature search 
details are available in Appendix I. The electronic search was complemented by 
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reference citation tracking (forward and backward) of the included studies and of 
previous reviews. 
 
Table 4.1: Search strategy used for Cochrane central register of controlled trials 
 
#1 MeSH descriptor: (Child] explode all trees 
#2 MeSH descriptor: [Adolescent] explode all trees 
#3 child* or adolesc* or teen* or boy* or girl* or youth:ti,ab, 
#4 young near/1 (person or people):ti,ab,kw  (Word variations have been searched) 
#5 #1 or #2 or #3 or #4  
#6 MeSH descriptor: [Motor Activity] this term only 
#7 MeSH descriptor: [Exercise] explode all trees 
#8 MeSH descriptor: [Sports] explode all trees 
#9 MeSH descriptor: [Sedentary Lifestyle] explode all trees 
#10 physical* activ*:ti,ab,kw  (Word variations have been searched) 
#11 exercis* or sport*:ti,ab,kw  (Word variations have been searched) 
#12 active near/2 (living or lifestyle):ti,ab,kw  (Word variations have been searched) 
#13 sedentary behavi?r:ti,ab,kw  (Word variations have been searched) 
#14 (screen or sedentary or sitting or TV or television or computer or PC or video games) near/2 
time:ti,ab,kw  (Word variations have been searched) 
#15 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14  
#16 MeSH descriptor: [Accelerometry] explode all trees 
#17 acceleromet*:ti,ab,kw  (Word variations have been searched) 
#18 actigraph*:ti,ab,kw  (Word variations have been searched) 
#19 activity near/1 monitor*.:ti,ab,kw  (Word variations have been searched) 
#20 #16 or #17 or #18 or #19  
#21 MeSH descriptor: [Overweight] explode all trees 
#22 overweight or obes*:ti,ab,kw  (Word variations have been searched) 
#23 #21 or #22 
#24 #5 and #15 and #20 and #23 
 
4.2.3. Inclusion Criteria 
To be eligible for inclusion in the review, papers had to meet all of the following criteria 
as per the PICOS principles: Population: children and adolescents aged from 0 to 
19 years as defined by World Health Organization (WHO); Intervention or exposure: 
children or adolescent classified as obese. Obesity had to be defined using an acceptable 
objective method, e.g. defined as having a body mass index (BMI) ≥ 95th percentile for 
children of the same sex and age, or defined as the equivalent of 30 kg/m2International 
Obesity Task Force (IOTF definition), or defined as obese relative to WHO BMI for 
age and sex charts; Comparison: habitual amount of time spent in MVPA and/or ST of 
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non-obese children and adolescents; Outcomes: habitual amount of time spent in 
MVPA and/or ST measured by accelerometer and reported in the form of minutes/day 
of MVPA or ST; MVPA and its relationship to the 60 minutes /day recommended. All 
study designs were considered eligible: cross-sectional, longitudinal, case-control 
studies and intervention studies were eligible if pre-intervention data could be 
extracted. 
 
4.2.4. Exclusion Criteria 
We excluded studies that included only overweight participants, combined overweight 
and obese groups, or included participants with any known barrier or limitation to 
physical activity (e.g. physical disability). Studies that used subjective methods, 
objective (e.g. doubly labelled water) or direct observation methods apart from 
accelerometer measurements were also excluded. 
 
Since the aim of the review was to examine habitual levels of MVPA and ST, studies 
that measured these variables for less than 6 h per day or over 2 days or less were 
excluded. Recommendations currently exist for habitual (overall) MVPA rather than 
MVPA during specific domains (e.g. in the after-school period) and so studies that 
focused only on specific periods of the day (e.g. school activity only, or outdoor activity 
only, or weekend activity only, or weekday activity only, or after-school only) were 
also excluded. A detailed description of the eligibility criteria is available in Appendix 
I. 
Chapter IV 
 
169 
4.2.5. Study Selection 
Titles, abstracts, and full-text articles were screened in duplicate for eligibility by RE 
and JYP and disagreements were resolved through discussions with other reviewers 
when required. Reference lists of eligible studies were examined for potentially eligible 
studies, and studies that cited eligible studies were identified and tested for eligibility. 
The reviewers were not blinded to authors or journal of publication. Reasons for 
exclusion are summarised in the study flow diagram Figure 4.1.  
 
4.2.6. Data Extraction 
A standardised data extraction form was used to populate the evidence tables by RE 
and checked by JJR and JYP. The extracted items were: first author, publication year, 
country, study design, sample group, comparison group-if applicable, accelerometer 
type, cut points for MVPA and ST, finding of MVPA (minutes/day) and ST 
(minutes/day or %) data, summary and author conclusions. International 
recommendations usually recommend the achievement of at least 60 min of MVPA 
every day, but in the eligible studies the achievement of MVPA recommendations was 
never operationalised in this way. In most studies that referred to the achievement of 
MVPA recommendations, the mean or median daily MVPA (minutes/day) was 
provided, and so this was used as a proxy for achievement of recommendations in the 
present study. 
 
4.2.7. Data Analysis and Synthesis 
We considered the data for meta-analysis but identified a substantial level of statistical 
heterogeneity between the studies (I2 statistic > 70%) that led to the decision not to 
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present the combined results of individual studies. Hence, we performed a narrative 
synthesis of the data and present the findings in tabular, textual and graphical form. 
Data were synthesised by the age and sex of the subgroups as those are factors known 
to be strongly associated with both the exposure variable, obesity, and the outcomes, 
MVPA and ST, and so might explain some of the observed findings. The age subgroup 
was categorised according to the WHO definition of children and adolescence, i.e. as 
children aged 0 to 10 years old and adolescents aged 10.1 to 19 years old. Data for boys, 
girls and mixed-sex studies are reported separately where possible.  
 
4.2.8. Quality Assessment 
Eligible articles were assessed for methodological quality using a 15-item quality 
assessment scale as shown in Appendix I, collapsed to 6 items for scoring, with higher 
scores suggesting higher study quality. Each eligible study was assessed by RE, and 
any uncertainties resolved by discussion with JJR and JYP. The quality assessment 
scale was modified from the methodological quality assessment scale of Tooth et al. 
(352). This is a reliable and valid tool for assessing the quality of observational studies. 
It was considered initially for use in its original form, which consists of over 30 items. 
The modifications to the original scale were made to focus quality assessment on issues 
of particular importance to accelerometry measurement of physical activity. The 
modified Tooth et al. tool has been used in several recent systemic reviews of physical 
activity, all of which have reduced the number of items in the quality assessment to 8 
to 17 items, which make up the quality score (54, 291, 353-355). 
 
Chapter IV 
 
171 
4.3. Results 
4.3.1. Identification of Eligible Studies 
The PRISMA flow diagram with the numbers of included and excluded articles at each 
step of the review process is provided in Figure 4.1. Table 4.2 and 4.3 provide a brief 
summary of all studies included in this systematic review. Of 1503 papers identified in 
the initial review of the five databases, 467 were selected for full-text screening and of 
these, 22 met the inclusion criteria. A further four eligible studies were identified from 
searching reference of included studies and of previous reviews, giving a total of 26 
studies which met the inclusion criteria. 
 
4.3.2. Studies Characteristics 
Of the 26 included studies: six studies involved children, 18 studies involved adolescent 
and two studies involved both children and adolescents. Further, 22/26 compared 
MVPA data in the obese with non-obese peers; 13/26 studies also provided data on 
accelerometer measured SB; 10/13 studies compared SB data in those with obesity with 
a non-obese peer. Measurement protocol: The ActiGraph was the most common 
accelerometer type used to measure habitual MVPA and/or SB, used in 20/26 studies, 
though with a variety of different ActiGraph models and approaches to data collection 
and reduction. Of the remaining six studies: three used the Actical accelerometer (397-
399); two the Triaxial Research Tracker (RT3) accelerometer (400, 401); and one the 
Actiwatch accelerometer (402).  
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Figure 4.1: The PRISMA flow diagram with numbers of included and excluded articles at each step 
of the review process.  
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4.3.3. MVPA and SB in Obese Children 
Eight eligible studies involved obese children, with a total sample size of 2138 children 
(478 obese; 131 boys, 136 girls and 211 no sex specified). Two of the eligible studies 
were clinical samples with study participants recruited from outpatient clinics. Eligible 
studies were from different nations with one study from Asia (403), three from Canada 
and USA (404-406) and four from Europe (222, 400, 407, 408), with the study 
characteristics summarised in Table 2. In four studies, MVPA data of boys and girls 
were reported separately while in the other four studies MVPA data were reported as 
mixed sex. 7/8 of eligible studies reported mean daily time spent in MVPA in minutes 
and in four studies time spent in MVPA was < 60 minutes/day. Furthermore, 2/7 of 
eligible studies obese children reached or exceeded 60 minutes of MVPA per day (405, 
406), while in one study they came close to meeting the recommendations of 60 
minutes/day of MVPA (404).  
 
In all cases time spent in MVPA in the children who were obese was compared to the 
comparison peers. In only one study was the mean time spent in MVPA similar in both 
groups (405); in three studies, time spent in MVPA was significant lower in obese 
children than in the comparison group (403, 404, 407), while in two studies time spent 
in MVPA of obese children was lower than comparison group but differences were not 
significant (222, 406). In the other 2 studies time spent in MVPA of obese children was 
different in terms of gender compared to the comparison group: Hussey et al reported 
that mean MVPA was significantly lower in obese boys but not in girls (400); while 
Vale et al reported that mean time spent in MVPA was significantly lower in obese girls 
but not in boys (408) compared to the comparison groups. 
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With respect to SB, 4/8 eligible studies reported on accelerometer-measured time spent 
in SB of obese children with a total sample size of 536 children (191 obese; 28 boys, 
32 girls and 131 no sex specified). In one study SB data of boys and girls was reported 
separately while in other the data were reported as mixed sex. Across all four eligible 
studies, mean time spent in SB was >70% of waking time (222, 400, 403, 407). In 3/4 
of the studies time spent in SB was significantly higher in the obese than the non-obese 
groups, although, in one study it was significantly higher in obese boys but not in girls 
(400). In one study time spent in SB was similar in both groups (407). 
 
4.3.4. MVPA and SB in Obese Adolescents 
Twenty of the eligible studies involved adolescents, with a total sample size of 12601 
adolescents (3045 obese; 1615 boys, 1575 girls and 195 no sex specified). Four of the 
eligible studies were clinical samples with participants recruited from outpatient clinics. 
Eligible studies were from different nations with one study from Asia (409), 11 from 
Canada and USA, and eight from Europe, with the study characteristics summarized in 
Table 3. In 12/20 studies, MVPA data of boys and girls were reported separately; in 
6/20 studies MVPA data were reported as mixed sex, while the other two studies 
involved only adolescent girls. All 20 eligible studies reported mean daily of time spent 
in MVPA in minutes and in these studies it ranged from a low of 16 (SD 4) minutes/day 
(404) to a high of 140 (SD 47) minutes/day (410). In only 2/ 20 studies did daily time 
spent in MVPA reach an average of at least 60 minutes (410, 411) in the adolescents 
who were obese. A total of 16/20 eligible studies compared time spent in MVPA of 
those with obesity with a comparison group: in 3/16 time spent in MVPA was similar 
between obese and non-obese groups, while in 10/16 mean time spent in MVPA was 
significantly lower in obese adolescents than in non-obese peers.  
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Regarding time spent in SB, nine out of the 20 eligible studies reported on 
accelerometer measured time spent in SB in obese adolescents with a total sample size 
of 5484 adolescents (1101 obese; 546 boys and 555 girls), as summarised in Table 4.2. 
In 8/9 studies, SB data of boys and girls were reported separately, and 1/9 study 
involved only adolescent girls. In 7/9 studies, mean daily time spent in SB was reported 
in minutes and in these studies it ranged from a low of 345 (SD 122) minutes/day (402) 
to a high of 731 (SD 110) minutes/day (398). In 6/9 studies there was a comparison 
group; in 2/6 studies mean daily time in SB was similar in obese and non-obese groups 
(409, 412); in 2/6 studies time spent in SB was significantly higher in those with obesity 
than in the non-obese comparison groups (402, 413), while in the other 2/6 studies it 
was higher in the obese adolescents, but not significantly so (414, 415).  
 
A graphical synthesis of the mean differences and 95% CI of time spent in MVPA by 
sex for both obese and non-obese children and adolescents is shown in Figure 4.2. A 
summary of the mean differences and 95% CI of time spent in SB by sex for both obese 
and non-obese children and adolescents is shown in Figure 4.3. 
 
4.3.5. Study Quality Assessment 
Study quality assessment summaries are given in Table 4.4. One study scored 4/6. 
Twelve studies scored 5/6 while 13 scored 6/6 on study quality. 
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Table 4.2: Overview of relevant characteristics and results of the included studies that involved child participants 
 
Reference 
* 
Place and 
publicatio
n year 
Study design Sample group Comparison 
group 
Measureme
nt 
Acceleromet
ry methods 
Finding Meet 60min/day of 
MVPA (%) and Author 
Conclusions 
Chung et 
al (404) 
United 
States, 
2012 
Data of NHANES 
2003-04 and 
2005-06) surveys 
n: 95 (47 boys, 48 
girls) obese 
participants with 
BMI ≥95th to 99th 
centile 
Age: range 6-8 
years 
n: 514 (253 
boys, 261 girls) 
participants with 
BMI ≥ 5th to 
85th centile 
Age: range 6-8 
years 
Actigraph 
7164 worn 
on the right 
hip for 7 
consecutive 
days during 
waking hours 
Epoch = 
1min 
MVPA using 
Freedson 
cut-point 
(362) 
Obese group mean 
(boys 118 (SD 6) and 
girls 83 (SD 10) 
min/day on MVPA. 
 
Comparison group 
mean (boys 129 (SD 
4) and girls 104 (SD 
4) min/day on MVPA 
97, 70 % of obese boys 
and girls achieved an 
average of 60 min/day of 
MVPA. 
 
98, 90% of the 
comparison boys and 
girls achieved an average 
of 60 min/day MVPA. 
 
MVPA was significantly 
lower in obese than 
comparison group (p < 
0.05) 
Hughes et 
al (407) 
United 
Kingdom, 
2006 
Pairwise 
comparison stud
y. 
n: 53 (25 boys, 28 
girls) obese 
participants with 
BMI ≥ 98th centile 
“Clinical sample” 
Age: mean 8.6 
(SD 2) 
n: 53 (25boys, 
28 girls) 
participants 
with BMI < 
85th centile. 
Age: mean 8.7 
(SD 2.1) years 
CSA/MTI, 
7164 worn 
on right hip 
for 7 
consecutive 
days. 
Epoch = 
1min 
MVPA > 
3200 cpm 
Sedentary 
time < 1100 
cpm 
Obese group median 
16 (range 2 -72) 
min/day on MVPA. 
 
Comparison group 
median 23 (range 7 -
77) min/day on 
MVPA. 
 
Obese group mean of 
81 (SD 7) % 
sedentary. 
 
Comparison group 
mean of 79 (SD 6) % 
sedentary. 
Obese participants failed 
to achieve an average of 
60 min/day of MVPA. 
 
MVPA was significantly 
lower in obese than 
comparison group (p 
<0.001). 
 
Sedentary time was 
similar in obese and 
comparison group 
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Hussey et 
al (400) 
Dublin, 
2007 
Cross sectional 
study 
n: 7/152 (3 boys, 
4 girls) obese; 
with BMI > 97th 
centile. 
Age: range 7-10 
years. 
n: 121/152 (43 
boys, 78 girls) 
pwith BMI > 
75th to 91th 
centile. 
Age: range 7-10 
years. 
RT3Triaxial 
acceleromete
r, worn for 4 
days. 
Epoch = 
1min 
MVPA > 
3500 cpm 
Sedentary 
time cut-
points not 
clearly 
reported 
Obese participants 
mean (boys 14 (95%, 
CI- 11, 17) and girls 
29 (95%, CI- 14, 43) 
min/day on MVPA. 
 
Comparison group 
mean (boys 39 (95%, 
CI-33, 45) and girls 
24 (95%, CI- 22, 27) 
min/day on MVPA. 
 
Obese participants 
mean of (boys 1046 
(95%, CI- 934, 1157) 
and girls 935 (95%, 
CI- 795, 1075) 
min/day sedentary. 
 
Comparison group 
spent mean of (boys 
928 (95%, CI-901, 
955) and girls 963 
(95%, CI- 941,985) 
min/day sedentary. 
Obese participants failed 
to achieve an average of 
60 min/day of MVPA. 
 
MVPA was significantly 
lower in obese boys than 
comparison group (p 
<0.05). 
 
Sedentary time was 
significantly higher in 
obese boys than 
comparison group (p 
<0.05). 
Maggio et 
al (222) 
Switzerland
, 2010 
Cross sectional 
study 
n: 45/209 obese 
participants with 
BMI > 97th centile 
“Clinical sample” 
Age: mean 9.1 
(SD 0.3) years 
n: 85 
participants with 
BMI <90th 
centile 
Age: mean 10 
(SD 0.3) years 
 
Actigraph 
6471, worn 
on right hip 
for 7 
consecutive 
days 
Epoch not 
clearly 
reported 
MVPA > 
2000 cpm 
Sedentary 
time < 500 
cpm 
Obese group mean 60 
(SD 3) min/day on 
MVPA. 
 
Comparison group 
mean 71 (SD 5) 
min/day on MVPA. 
 
52% of the obese 
participants achieved an 
average of 60 min/day of 
MVPA. 
 
60% of the comparison 
group achieved an 
average of 60 min/day 
MVPA. 
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Obese participants 
mean 71% of time 
sedentary 
Comparison group 
mean of 70 % of time 
sedentary 
 
MVPA was lower in 
obese than comparison 
group, but not 
significantly (p=0.07). 
 
Sedentary time was 
significantly higher in 
obese than comparison 
group (p < 0.01). 
Metallinos
-Katsaras 
et al (406) 
United 
States, 
2007 
Cross sectional 
study 
n: 21 obese 
children with 
BMI ≥ 95th centile 
Age: range 2-5 
years 
n: 35 children; 
BMI < 95th 
centile 
Age: range 2-5 
years 
CSA 7164, 
worn on the 
hip for 7 
consecutive 
days 
Epoch= 1 
min 
MVPA cut-
points not 
clearly 
reported 
Obese group mean 
269 (SD not given) 
min/day on MVPA. 
 
Comparison group 
mean of 277 (SD not 
given) min/day on 
MVPA. 
Obese participants 
exceeded an average of 
60 min/day of MVPA. 
 
MVPA was lower in 
obese than comparison 
group but, not significant 
(p >0.05 
Thompson 
et al (405) 
Canada, 
2005 
Cross sectional 
study 
n: 112 (56 boys, 
56 girls) obese 
participants with 
BMI ≥ 95th centile 
Age: mean 8 (SD 
0.3) years 
n: 341 (177 
boys, 164 girls) 
participants with 
BMI ≤ 85th  
centile 
Age: 3, 7 and 11 
years old 
Actigraph 
7164, worn 
on the hip for 
7 
consecutive 
days 
Epoch = 
1min 
MVPA using 
Freedson 
cut-point 
(362) 
Obese group mean 
(boys 172 (SD 58) 
and girls 157 (SD 52) 
min/day on MVPA. 
 
Comparison group 
mean (boys 179 (SD 
63) and girls 165 (SD 
51) min/day on 
MVPA. 
Obese participants and 
comparison group 
exceeded an average of 
60 min/day of MVPA. 
 
MVPA was similar in 
obese and comparison 
group. 
Vale et al 
(408) 
Portugal, 
2013 
Cross sectional 
study 
n: 59/607 obese 
children with 
BMI defined 
according to the 
IOTF criteria 
Age: mean 5.1 
(SD 0.8) years 
n: 425/607 
children with 
BMI defined as 
non-overweight, 
non-obese 
according to the 
IOTF criteria 
Age: range 4-6 
years 
ActiGraph 
GT1M, worn 
on the hip for 
7 
consecutive 
days 
Epoch = 5 s 
MVPA ≥ 
1680 cpm 
Absolute MVPA not 
clearly given 
 
MVPA was significantly 
lower in obese girls than 
comparison group (p < 
0.01), but not in boys 
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Wafa et al 
(403) 
Malaysia, 
2014 
Cross sectional 
study 
n: 86 obese 
participants with 
BMI ≥ 95th 
centile 
Age: median 9.5 
(IQR 8,11) years 
n: 86 
participants with 
BMI < 85th 
centile matched 
for age and 
gender 
ActiGraph 
GT1M, worn 
for 5 
consecutive 
days 
Epoch not 
reported 
MVA >3200 
cpm 
Sedentary 
time <1100 
cpm 
Obese group median 
5 (IQR – 0, 32) 
min/day on MVPA. 
 
Comparison group 
median 9 (IQR – 0, 
55) min/day on 
MVPA. 
 
Obese group spent an 
average of 90 % of 
time sedentary. 
 
Comparison group 
spent an average of 
88 % of time 
sedentary 
 
Obese participants failed 
to achieve an average of 
60 min/day of MVPA. 
 
Comparison group failed 
to achieve an average of 
60 min/day of MVPA. 
 
MVPA was significantly 
lower in the obese than in 
the comparison group (p 
< 0.001) 
 
Sedentary time was 
significantly higher in the 
obese group than in the 
comparison group (p < 
0.001) 
BMI – body mass index; cpm – counts per minutes; IOTF – International Obesity Task Force criteria; MVPA – moderate- vigorous physical activity; n – number; S – second. 
Data are expressed as mean, (SD) unless otherwise.  
Freedson MVPA cutpoint (362) using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr)). * Studies are 
listed in alphabetic order.  
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Table 4.3: Overview of relevant characteristics and results of the included studies that involved adolescent participants 
 
Reference * Place and 
publication 
year 
 Sample group Comparison 
group 
Measurement Accelerometry 
methods 
Findings Meet 60min/day of 
MVPA (%) and 
Author 
Conclusions 
Butte et al 
(402) 
United 
States, 2007 
Cross 
sectional 
study. 
n: 473 (247 
boys, 226 girls) 
obese 
participants with 
BMI ≥ 95th 
centile 
Age: mean 10.8 
(SD 3.8) years 
n: 424 (194 
boys, 230 girls) 
participants with 
BMI <95th 
centile 
Age: mean 10.8 
(SD 3.8) years 
Actiwatch, 
worn on the 
right hip for 
24 hours for 3 
consecutive 
days 
Epoch = 1min. 
Sedentary time 
and MVPA cut-
points not 
clearly reported 
Obese mean (boys 88 
(SD 50) and girls 74 
(SD 46) min/day on 
MVPA. 
 
Comparison group 
spent mean of (boys 96 
(SD 57) and girls 79 
(SD 57) min/day on 
MVPA. 
 
Obese group spent 
mean of (boys 357 (SD 
118) and girls 345 (SD 
122) min/day) 
sedentary 
 
Comparison group 
spent mean of (boys 
305 (SD 121) and girls 
308 (SD 131) min/day) 
sedentary. 
62% of all 
participants (obese 
and comparison 
group) achieved an 
average of 60 
min/day of MVPA. 
 
MVPA was lower in 
obese than 
comparison group 
but not significant 
 
Sedentary time was 
significantly higher 
in obese than 
comparison group 
(P = 0.001) 
Chung et al 
(404) 
United 
States, 2012 
Data of 
NHANES 
2003-04 and 
2005-06) 
surveys 
n: 185 (92 boys, 
93 girls) obese 
participants with 
BMI ≥95th to 
99th centile 
Age: range 12-
17 years 
n: 987 (489 
boys, 498 girls) 
participants with 
BMI ≥ 5th to 
85th centile 
Age: range 12-
17 years 
Actigraph 
7164 worn on 
the right hip 
for 7 
consecutive 
days during 
waking hours 
Epoch = 1min 
MVPA used 
Freedson cut-
point (362) 
Obese group mean of 
(boys 34 (SD 4) and 
girls 16 (SD 4) min/day 
on MVPA. 
 
Comparison group 
mean (boys 40 (SD 3) 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was 
significantly lower 
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and girls 22 (SD 2) 
min/day on MVPA. 
in obese than 
comparison group 
(p < 0.05) 
Decelis et al 
(414) 
Malta, 2012 Cross 
sectional 
study. 
n: 34/187 (19 
boys, 15 girls) 
obese 
participants with 
BMI defined 
according to the 
IOTF criteria 
Age: range 11-
12 years 
n: 106/187 (53 
boys, 53 girls) 
participants with 
BMI defined as 
non-overweight 
and non-obese 
according to the 
IOTF criteria. 
Age: range 11-
12 years 
Actigraph 
GT3X, worn 
on right hip 
for 5 days 
during waking 
hours 
Epoch not 
defined. 
Sedentary time 
≤ 727 cpm and 
MVPA ≥ 2912 
cpm 
Obese group mean 
(boys 30 (SD 13) and 
girls 19 (SD 8) 
min/day) on MVPA. 
 
Comparison group 
mean (boys 44 (SD 16) 
and girls 26 (SD 9) 
min/day) on MVPA. 
 
Obese group mean 
(boys 638 (SD 95) and 
girls 619 (SD 106) 
min/day) sedentary 
 
Comparison group 
mean (boys 654 (SD 
93) and girls 664 (SD 
93) min/day) sedentary. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
11% of comparison 
group achieved an 
average of 60 
min/day MVPA 
 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p < 0.05) 
 
Sedentary time was 
higher in obese than 
comparison group, 
but not significant. 
Decelis et al 
(415) 
Malta, 2014 Cross 
sectional 
study. 
n: 113/810 (59 
boys, 54 girls) 
obese 
participants with 
BMI defined 
according to the 
IOTF criteria 
Age: range 10- 
11 years 
n: 534/810 (254 
boys, 280 girls) 
participants with 
BMI defined as 
non-overweight 
and non-obese 
according to the 
IOTF criteria 
Age: range 10- 
11 years 
Actigraph 
GT3X, worn 
on right hip 
for 5 days 
during waking 
hours 
Epoch = 10 s. 
Sedentary time 
< 100 cpm and 
MVPA > 2296 
cpm. 
Obese group mean 
boys 49 (SD 19) and 
girls 38 (SD 12) 
min/day on MVPA. 
Comparison group 
mean boys 61 (SD 22) 
and girls 44 (SD 15 
min/day on MVPA. 
 
Obese group mean 
boys 553 (SD 94) and 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA 
 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p < 0.05). 
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girls 610 (SD 125) 
min/day sedentary. 
 
Comparison group 
mean boys 582 (SD 
113) and girls 603 (SD 
97) min/day sedentary. 
Sedentary time was 
higher in obese than 
comparison group, 
but not significant 
Ekelund et 
al (412) 
Sweden, 
2002 
Case control, 
cross 
sectional 
design study. 
n: 18 (8 boys, 10 
girls) obese 
participants with 
BMI defined 
according to the 
IOTF criteria 
Age: mean 
(boys 18.1 (SD 
1.1), girls 17.3 
(SD 1.9) years 
n: 18 (8 boys, 10 
girls) 
participants with 
BMI defined as 
non-overweight 
and non-obese 
according to the 
IOTF criteria.  
Age: mean (boys 
18.2 (SD 1.1), 
girls 17.3 (SD 
1.9) years. 
CSA 7164, 
worn on lower 
part of the 
back (L 4–5) 
for 14 days. 
Epoch= 15s 
Sedentary time 
<100 cpm and 
MVPA cut-
points not 
clearly reported 
Obese group mean 
boys 58 (SD 30) and 
girls 60 (SD 28) 
min/day on MVPA. 
 
Comparison group 
mean boys 82 (SD 36) 
and girls 98 (SD 58) 
min/day on MVPA. 
 
Obese group mean 
boys 421 (SD 33) and 
girls 465 (SD 132) 
min/day sedentary. 
 
Comparison group 
mean boys 414 (SD 81) 
and girls 397 (SD 69) 
min/day sedentary. 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p < 0.05). 
 
MVPA was similar 
in obese girls and 
boys (p < 0.05) 
Sedentary time was 
similar in obese and 
comparison group. 
Gyllenham-
mer et al 
(416) 
United 
States, 2013 
Cross 
sectional 
study. 
n: 37 obese girls 
with BMI ≥ 95th 
centile 
Age: mean 15.5 
(SD 1.1) years. 
No comparison 
group 
Actigraph 
GT1M, worn 
on the right 
hip for 7 
consecutive 
days. 
Epoch = 1min, 
SB =100 cpm 
and MVPA cut-
points not 
clearly 
reported. 
Obese girls mean 28 
(SD 18) min/day on 
MVPA. 
 
Obese participants 
spent 63% (SD 7.) 
sedentary. 
Obese girls failed to 
achieve an average 
of 60 min/day of 
MVPA. 
 
MVPA was lower in 
obese girls 
compared to 
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published data from 
healthy adolescents. 
Kitzman-
Ulrich et al 
(399) 
United 
States, 2010 
Randomized 
trial ACT 
(Active by 
Choice 
Today) data 
at baseline 
used here. 
n: 242/669 (98 
boys, 144 girls) 
obese 
participants with 
BMI > 95th 
centile 
Age: mean 11.4 
(SD 0.7) years. 
n: 314/ 669 (138 
boys, 176 girls) 
participants with 
BMI < 85th 
centile 
Age: mean 11.4 
(SD 0.7) years. 
Actical, worn 
on the right 
hip for 7 days 
all day 
Epoch = 1 min. 
Sedentary time 
and MVPA cut-
points not 
clearly 
reported. 
Obese participants 
mean boys 46 (SD 20) 
and girls 36 (SD 15) 
min/day on MVPA. 
 
Comparison group 
mean boys 65 (SD 27) 
and girls 46 (SD 20) 
min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p<0.05). 
Maggio et 
al (417) 
Switzerland, 
2014 
Case control 
study 
n: 24 (12 boys, 
12 girls) obese 
participants with 
BMI ≥ 97th 
centile. “Clinical 
sample” 
Age: mean 13.9 
(SD 1.2) years 
n: 25 (12 boys, 
13 girls) 
participants with 
BMI <90th 
centile 
Age: mean 13.2 
(SD 1.7) years. 
Actigraph 
GT1M, worn 
for at least 4 
days. 
Epoch, MVPA 
cut-points not 
clearly 
reported, and 
Sedentary time 
<500 cpm 
Obese participants 
mean 43 (SD 19) 
min/day on MVPA. 
 
Comparison group 
mean 58 (SD 30) 
min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
MVPA was 
significantly lower 
in obese than 
comparison group 
(P = 0.01) 
MVPA was similar 
in obese girls and 
boys (p < 0.05). 
Martins et 
al (418) 
Portugal, 
2015 
Cross 
sectional 
baseline 
study. 
n: 131 (48 boys, 
83 girls) obese 
participants with 
BMI defined 
according to the 
IOTF criteria 
Age: mean 10.3 
(SD 3.6) years. 
No comparison 
group 
Actigraph 
GT3x, worn 
for 7 
consecutive 
days. 
Epoch= 1 min. 
Sedentary time 
=0-100 cpm 
and MVPA cut-
points not 
clearly 
reported. 
Obese participants 
mean boys 65 (SD 28) 
and girls 51 (SD 22) 
min/day on MVPA. 
 
Obese participants 
mean boys 575 (SD 
108) and girls 562 (SD 
82) min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA 
 
MVPA was lower in 
obese participants 
compared to 
published data from 
healthy children and 
adolescents. 
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MVPA was 
significantly lower 
in obese girls than 
obese boys (p < 
0.05) 
McMurray 
et al (419) 
United 
States, 2008 
Baseline data 
of 
Randomized 
controlled 
TAAG “Trial 
of Activity 
for 
Adolescent 
Girls” 
n: 184/1021 
obese girls with 
BMI ≥ 95th 
centile 
Age: range 11-
14 years 
n: 645/1021 
participants with 
BMI < 85th 
centile 
Age: range 11-
14 years 
Actigraph 
MTI, worn for 
6 consecutive 
days 
Epoch = 30 s. 
MVPA cut-
points not 
clearly reported 
Obese girls mean 21 
(SD 2) min/day on 
MVPA. 
 
Comparison group 
mean 25 (SD 1) 
min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was 
significantly lower 
in the obese than the 
comparison group 
(p=0.01). 
Page et al 
(410) 
United 
Kingdom, 
2005 
Cross 
sectional 
study. 
n: 25 (14 boys, 
11 girls) obese 
participants with 
BMI ≥ 99th 
centile. “Clinical 
and non clinical 
sample” 
Age: mean 10.5 
(SD 0.8) years 
n: 108 (54 boys, 
54 girls) 
participants with 
BMI < 99th 
centile. 
Age: mean 10.5 
(SD 0.8) years 
Actigraph 
7164, worn on 
the waist for 7 
consecutive 
days 
Epoch and 
MVPA cut-
points not 
clearly 
reported. 
Obese participants 
mean boys 140 (SD 47) 
and girls 105 (SD 48) 
min/day on MVPA. 
 
Comparison group 
mean boys 176 (SD 52) 
and girls 149 (SD 52) 
min/day on MVPA. 
Obese participants 
exceeded an average 
of 60 min/day of 
MVPA 
 
MVPA was 
significantly lower 
in obese compared 
to comparison 
group (p=0.02) 
Peart et al 
(420) 
United 
States, 2011 
Combined 
data of cross 
sectional 
NHANES 
(2003-04, 
2005-06) 
surveys 
n: 434/2368 
(217 boys, 217 
girls) obese 
participants with 
BMI ≥ 95 
centile 
Age: mean 15.4 
(SD 2.2) years 
n: 1469/ 2368 
(749 boys, 720 
girls) 
participants with 
BMI < 85th 
centile 
Age: mean 15.4 
(SD 2.2) years 
Actigraph 
7164, worn on 
hip over 7 
day. 
Epoch= 1 min 
MVPA≥ 1500 
cpm. 
Obese participants 
mean 28 (SD 35) 
min/day on MVPA. 
 
Comparison group 
mean 32 (SD 29) 
min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was lower in 
obese than 
comparison group 
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but not significantly 
(p >0.05). 
 
MVPA was similar 
in obese boys and 
girls. 
Ruiz et al 
(413) 
10 centers in 
9 European 
countries, 
2011 
Cross 
sectional 
study. 
n: 104/2200 (45 
boys, 59 girls) 
obese 
participants with 
BMI ≥ 95th 
centile 
Age: median 
14.9 (IQR 12.8 – 
15.8) years. 
n: 1592/2200 
(870 boys, 722 
girls) 
participants with 
BMI < 85th 
centile 
Age: median 
14.9 (IQR 12.8 – 
15.8) years. 
Actigraph 
GT1M, worn 
lower back for 
7 consecutive 
days. 
Epoch= 15 s 
Sedentary time 
< 100 and 
MVPA ≥ 2000 
cpm. 
Obese participants 
mean boys 60 (95%, 
CI- 53, 68) and girls 44 
(95%, CI- 38,50) 
min/day on MVPA. 
 
Comparison group 
mean boys 67, (95%, 
CI- 65, 69) and girls 51 
(95%, CI- 49,52) 
min/day on MVPA. 
 
Obese participants 
mean boys 68% and 
girls 71%) sedentary. 
 
Comparison group 
mean boys 69% and 
girls 72%) sedentary. 
MVPA was 
significantly lower 
in obese boys than 
comparison boys 
group (p=0.002). 
 
Sedentary time was 
significantly higher 
in obese girls than 
comparison girls 
group (p=0.006) 
Shoup et al 
(421) 
United 
States, 2008 
Cross 
sectional 
study. 
n: 85 obese 
participants; 
BMI ≥ 99th 
centile 
“Clinical 
sample” 
Age: mean 10.6 
(SD 1.4) years 
n: 92 
participants with 
BMI ≥85th and 
<95th  centile 
matched for age 
Actigraph 
7164, worn on 
waist for 7 
consecutive 
days 
Epoch and 
MVPA cut-
points not 
clearly reported 
Obese participants 
mean 54 (SD 22) 
min/day on MVPA. 
 
Comparison group 
mean 59 (SD 30) 
min/day on MVPA. 
40% (n = 34) of the 
obese group 
achieved an average 
of 60 min/day on 
MVPA 
 
40% (n=35) of the 
comparison group 
achieved 60 
min/day of MVPA. 
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MVPA was similar 
in obese and 
comparison group. 
St George et 
al (397) 
United 
States, 2013 
Baseline data 
of ACT 
Randomized 
trial (Active 
by Choice 
Today). 
n: 484/1,422 
(203 boys, 281 
girls) obese 
participants with 
BMI ≥ 95th 
centile 
Age: mean 11.3 
(SD 0.6) years 
n: 684/1,422 
(321 boys, 363 
girls) 
participants with 
BMI < 85th 
centile 
Age: mean 11.4 
(SD 0.6) years 
Actical, worn 
on the right 
hip for 7 
consecutive 
days 
Epoch= 1 min 
MVPA used 
Puyau cut-point 
(384) 
Obese participants 
spent mean of 37 (SD 
22) min/day on MVPA. 
 
Comparison group 
spent mean of 47 (SD 
28) min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p<0.01) 
Starkoffet al 
(398) 
United 
States, 2014 
Cross 
sectional 
study. 
n: 16 (5 boys, 11 
girls) obese 
participants with 
BMI ≥ 95 
centile 
“Clinical 
sample” 
Age: mean 14.8 
(SD 1.5) years. 
No comparison 
group 
Actical, worn 
on the right 
hip for 5 days 
during waking 
time 
Epoch = 1min 
Sedentary time 
and MVPA cut-
points not 
clearly reported 
Obese participants 
mean (boys 26 (SD 36) 
and girls 19 (SD 17) 
min/day on MVPA. 
 
Obese participants 
mean boys 731 (SD 
110) and girls 726 (SD 
98) min/day) on 
sedentary. 
12.5% of the obese 
group achieved an 
average of 60 
min/day of MVPA. 
 
MVPA was lower in 
obese participants 
compared to 
published data from 
healthy adolescents. 
Thompson 
et al (405) 
Canada, 2005 Cross 
sectional 
study. 
n: 171 (93 boys, 
78 girls) 
participants with 
BMI ≥ 95th 
centile 
Age: range 12-
16 years 
n: 716 (327 
boys, 389 girls) 
participants with 
BMI ≤ 85th 
centile 
Age: range 12-
16 years 
Actigraph 
7164, worn on 
the hip for 7 
consecutive 
days. 
Epoch = 1min 
MVPA used 
Freedson cut-
point (362) 
Obese group mean 
boys 53 (SD 26) and 
girls 48 (SD 25) 
min/day on MVPA. 
 
Comparison group 
mean boys 58 (SD 30) 
and girls 47 (SD 24) 
min/day on MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
Comparison group 
failed to achieve an 
average of 60 
min/day of MVPA 
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MVPA was similar 
in obese and 
comparison group. 
Trost et al 
(43) 
United 
States, 2001 
Cross 
sectional 
study. 
n: 54 obese 
participants with 
BMI ≥ 95th 
centile 
Age: mean 11.4 
(SD 0.6) years 
n: 133 non obese 
with BMI< 95th 
centile 
Age: mean 11.4 
(SD 0.6) years 
CSA 7164, 
worn on right 
hip for 7 
consecutive 
days 
Epoch = 1min 
MVPA used 
Freedson cut-
point (362) 
Obese participants 
mean 70 (SD 6) 
min/day on MVPA. 
 
Comparison group 
mean 82 (SD 4) 
min/day on MVPA. 
Obese participants 
achieved an average 
of 60 min/day of 
MVPA. 
 
Comparison group 
achieved an average 
of 60 min/day of 
MVPA. 
 
MVPA was 
significantly lower 
in obese than 
comparison group 
(p < 0.001). 
Vanhelst et 
al (401) 
France, 2013 Cross 
sectional 
study. 
n: 56 obese 
participants with 
BMI ≥ 97th 
centile 
“Clinical 
sample” 
Age: mean 12.8 
(SD 2.9) years. 
No comparison 
group 
RT3 worn on 
right hip up to 
21 
consecutive 
days 
Epoch = 1min 
Sedentary time 
= 0 - 40 cpm 
and MVPA cut-
points not 
clearly reported 
Participants mean 22 
(SD 12) min/day on 
MVPA. 
Obese participants 
failed to achieve an 
average of 60 
min/day of MVPA. 
 
MVPA was lower in 
obese participants 
compared to 
published data from 
healthy children and 
adolescents. 
Wang et al 
(409) 
Chine, 2013 Cross 
sectional 
“large-scale 
study” 
n: 175/2163 
(115 boys, 60 
girls) obese 
participants with 
BMI defined 
n: 1709/2163; 
808 boys; 901 
girls with BMI 
defined as non-
overweight, non-
obese according 
ActiGraph 
GT3X, worn 
on right hip 
for 7 
consecutive 
days 
Epoch = 1min. 
Sedentary time 
< 100 cpm and 
MVPA cut-
points not 
clearly reported 
Obese group mean 
boys29 (SD 18) and 
girls 24 (SD 13) 
min/day on MVPA. 
 
7 % of obese boys 
achieved 60 
min/day of MVPA. 
 
10 %, 2 % of 
comparison boys 
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according to the 
IOTF criteria 
Age: mean 
13.41 (SD 2.25) 
years. 
to the IOTF 
criteria 
Age: mean 
13.41 (SD 2.25) 
years 
Comparison group 
mean of boys 35(SD 
19) and girls 22 (SD 
14) min/day on MVPA. 
 
Obese group spent 
mean of (boys 480 (SD 
107) and girls 490 (SD 
89) min/day) sedentary. 
 
Comparison group 
spent mean of (boys 
521 (SD 113) and girls 
533, (SD 103) min/day) 
sedentary. 
and girls achieved 
an average of 60 
min/day of MVPA 
 
MVPA was similar 
in obese and 
comparison groups 
 
Sedentary time was 
similar in obese and 
comparison groups 
 
BMI – body mass index; cpm – counts per minutes; IOTF – International Obesity Task Force criteria; MVPA – moderate- vigorous physical activity; n – Number; S – Second. 
Data are expressed as mean, (SD) unless otherwise stated.  
Freedson MVPA cutpoint (362) using the following equation: METS = 2.757 + (0.0015 x counts/min) – (0.08957 x age (yr)) – (0.000038 x counts/min x age (yr)).  
* Studies are listed in alphabetic order. 
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Figure 4.2: Forest plot of the comparison of moderate-to-vigorous intensity physical activity between 
children and adolescents with obesity and non-obese participants by sex.  
SD: standard deviation; CI: 95% Confidence interval (Forest plot is kindly supplied by Dr Anne Martin). 
 
 
 
Figure 4.3: Forest plot of the comparison of sedentary time between children and adolescents with obesity 
and non-obese participants by sex.  
SD: standard deviation; CI: 95% Confidence interval (Forest plot is kindly supplied by Dr Anne Martin). 
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Table 4.4: Methodological quality assessment of the included studies  
 
 Quality Assessment Criteria, Items 1-6 
Study, year* 1 2 3 4 5 6 Total score 
Butte et al, 2007 + + + + + + 6/6 
Chung, 2012 + + + + + + 6/6 
Decelis, 2012 + + + + + + 6/6 
Decelis, 2014 + + + + + + 6/6 
Ekelund, 2002 - + + + + + 5/6 
Gyllenhammer, 
2013 
- + + + + + 5/6 
Hughes, 2006 - + + + + + 5/6 
Hussey, 2007 + + + + + + 6/6 
Kitzman-Ulrich, 
2010 
+ + + + + + 6/6 
Maggio, 2014 + + + + + + 6/6 
Maggio, 2010 - - + + + + 4/6 
Martins, 2015 - + + + + + 5/6 
McMurray, 
2008 
+ + + + + + 6/6 
Metallinos-
Katsaras, 2007 
+ + + + + + 6/6 
Page, 2005 - + + + + + 5/6 
Peart, 2011 + + + + + + 6/6 
Ruiz, 2011 + + + + + + 6/6 
Shoup, 2008 - + + + + + 5/6 
St George, 2013 - + + + + + 5/6 
Starkoff, 2014 - + + + + + 5/6 
Thompson, 2005 - + + + + + 5/6 
Trost, 2001 - + + + + + 5/6 
Vale, 2013 + + + + + + 6/6 
Vanhelst, 2013 - + + + + + 5/6 
Wafa, 2014 - + + + + + 5/6 
Wang, 2013 + + + + + + 6/6 
+ Indicates that a criterion was satisfied; − indicates that a criterion was not satisfied. 1, described of Sample 
recruitment?; 2, description of the sample.?; 3, Attrition of sample?; 4, Data collection and reduction?; 5, 
MVPA definition given?; 6, MVPA Results given?;  
 
* Studies are listed in alphabetic order. 
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4.4. Discussion 
4.4.1. Main Findings and Study Implications 
Our systematic review provided evidence that is both clear and fairly consistent, and 
from relatively high study quality accelerometer-based studies that obese children and 
adolescents spend lower daily amounts of time spent in MVPA than non-obese peers. 
In most of the eligible studies, daily time spent in MVPA averaged less than the 60 
minutes/day recommended in many guidelines. 
 
In the methodology of the studies, it is noteworthy that the precise accelerometer 
methodology was often not stated clearly, or sometimes not stated at all, in the eligible 
studies particularly in the cut-off to define MVPA (Table 4.2 and 4.3). However, mean 
of time spent in MVPA were broadly similar within studies that employed comparable 
accelerometer methods. For example, in the two eligible Actigraph studies which used 
a cut-off of 2000 counts per minutes (cpm) to define MVPA (Maggio et al (222) , age 
4-17 years old, and Ruiz et al (413), age 12-17 year olds) mean daily time spent in 
MVPA was 60 minutes/day in the obese boys in the sample studied by Ruiz et al (413), 
and 60 minutes/day in the obese boys studied by Maggio et al (222). Both of these 
studies might suggest the tentative conclusion that time spent in MVPA is relatively 
high in adolescents who are obese, possibly suggesting that adolescence and/or obesity 
do not present major barriers to MVPA. In contrast, three of the eligible Actigraph 
studies used higher MVPA cut-offs which ranged between 2912cpm in 11-12 year olds 
(Decelis et al (414)); 3200cpm in 8 and 9 year olds respectively (Hughes et al (407) 
and Wafa et al (403)). These studies found mean daily time spent in MVPA was 30 
minutes in obese boys and 19 minutes in obese girls (414) and a median of 16 minutes 
for both sexes combined in the study by Hughes et al (407) and 5 minutes/day in the 
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study by Wafa et al (403). The majority of obese children and adolescents achieved 
means of < 30 minutes of daily time spent in MVPA in studies with cut-offs of ≥ 2912 
cpm (400, 406, 407, 410, 411).  
 
Further, it should be noted that recommendations for MVPA state that 60 minutes per 
day is a minimum every day (e.g. usually operationalized as 7 days in a week) (39, 
281, 422), but adherence to recommendations was never operationalized in this way 
in any of the 26 eligible studies. We therefore used a mean or median daily MVPA of 
60 minutes as a proxy for adherence, though this is conservative because in many 
individuals where 60 minutes MVPA/day was reached as an average, time spent in 
MVPA would have fallen below 60 minutes/day on at least one of the monitored days. 
 
With respect to ST the present review found that studies fairly consistently reported 
that obese children and adolescent accumulated a high amount of sedentary time 
during their waking hours, ranging typically between 65-90 % of their monitoring 
time: 10 hours was the mean daily sedentary time in all 13/26 studies, which reaches 
or exceeds typical Actigraph measured levels of sedentary time in North-American 
adults from surveys such as NHANES. All eligible studies, which had comparison 
groups found sedentary time, were fairly consistent with no marked differences 
between obese and non-obese peers. 
 
In the present systematic review, the level of heterogeneity between eligible studies 
made it impossible to combine data in a meta-analysis. The heterogeneity noted could 
be due to differences in place of the studies, differences in the way obesity was defined 
(different BMI cut-off points and different reference data), or differences in 
accelerometer models and methodology. Therefore, we narratively synthesized the 
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differences in the time spent in MVPA and ST between obese and control groups by 
age and sex. 
 
4.4.2. Comparisons with Other Studies 
We believe that the present study is the first systematic review to ask whether or not 
levels of accelerometer measured MVPA are adequate in obese children and 
adolescents, and whether time spent in MVPA and sedentary time differed between 
obese and comparison groups based on accelerometer data. There are therefore no 
directly comparable studies. However, our findings are consistent with some studies 
on the correlates and determinants of objectively MVPA (423, 424), and consistent 
with a growing belief that obesity is associated with reduced MVPA. Low MVPA is 
probably both a cause of obesity (low activity increases risk of the obesity) and a 
consequence of obesity (obesity lowers activity level), i.e., “bidirectional causation”, 
(65, 66, 396).  
 
4.4.3. Review and Evidence Strengths and Weaknesses 
The evidence considered by our review had a number of strengths. Firstly, it 
investigated the accelerometer-measured time spent in MVPA and SB of obese 
children and adolescents, with clear definitions of obesity so that samples included in 
the review were not contaminated by the inclusion of overweight but non-obese 
individuals. Secondly, there are several methodological strengths to this study. Studies 
were identified from an extensive search of the published literature conducted in a 
range of databases, over the last 15 years, covering the time when accelerometers 
started to become available and popular in PA research and more recently SB research. 
The broad definition of search terms applied across multiple databases enabled the 
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searching and identification across many potential studies with no limitations on place 
of publication, sample size or country of origin. Restricting eligibility to studies using 
accelerometry was important in increasing confidence in the measurement of MVPA 
(348, 380-382). The included studies were in general rated as being of high or very 
high methodological quality with respect to their accelerometry methods. Also, in 
some cases the eligible studies were based on large, nationally representative samples 
or surveys another strength in terms of generalizability.  
 
There were some sources of weakness in our systematic review. Firstly, since studies 
had to be published in peer-reviewed journals in English, this may have excluded 
relevant evidence. The generalisability of review results is subject to certain limitation; 
for instance, eligible studies in our systematic review were from high-income nations, 
and we lack data from low-middle income countries. Most of the included studies were 
based on relatively small samples of obese children and adolescents with a total (n = 
14739 participants; n = 3523 obese) and their power to estimate habitual MVPA might 
have been limited, and thus the extent to which the results observed are generalizable 
to the general obese paediatric population is unclear. Our method for assessing the 
quality of eligible studies has been used in variously adapted forms in a number of 
other recent accelerometry systematic reviews (54, 353-355) and used 15 items, but 
the process of collapsing these 15 items to a six-item scale might have reduced the 
possibility of identifying differences in quality between studies. 
 
Eligible studies generally obtained MVPA and ST data using the ActiGraph 
accelerometer, but methods used varied between studies. Methodological differences 
include: the definition of epoch, the number of hours and days of data constituting a 
valid/acceptable data set, MVPA and ST cut-points, and the choice of non-wear 
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criteria. These methodological variation tends to produce meaningful differences in 
MVPA and ST estimates between studies (346) and also make it difficult to compare 
across studies. However, while there were multiple differences between studies in 
accelerometry methodology (e.g. in epochs, cut-points, handling of non-wear time, 
duration of accelerometry monitoring), in all cases the methods were the same within 
studies between the obese and non-obese comparison groups, so these methodological 
differences probably had limited effect on the ability of studies to identify differences 
in MVPA and ST between the obese and non-obese. Finally, the validity of 
accelerometry (in particular hip-worn accelerometry, the method in almost all eligible 
studies) to determine ST is less well established than the validity of this placement for 
measurement of MVPA (425). Hip-worn accelerometers are not generally designed to 
measure posture, and devices which include inclinometers may provide improved 
measurement. Accelerometers are used widely to measure ST though, and there is 
some evidence of validity for group-comparisons as here (obese vs non-obese 
comparisons) (30, 346). 
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4.5. Conclusions 
In summary, the data presented in our review demonstrated that a high percentage of 
obese children and adolescents do not achieve the minimum amount of 60 minutes per 
day MVPA that is recommended in guidelines and tended to spend what appears to be 
the vast majority of their waking hours in SB. Obese children and adolescents were 
less physically active and more sedentary compared to comparison groups. The present 
review supports the hypotheses that the obese children and adolescents are both less 
physically active and more sedentary than the non-obese peers (though cannot test 
whether they were less active or more sedentary before becoming obese). 
 
Given the many and varied health and non-health benefits of MVPA in children and 
youth (20, 38) and emerging evidence that ST influences health outcomes in children 
and adolescents (426, 427), the present review highlights the need to focus on 
increasing MVPA and reducing ST among obese children and adolescents, and the 
importance of raising these issues in clinical settings as part of treatment for obesity. 
However, there is a need for more research on children, and for more 'dose-response' 
evidence. As well, more intervention studies were warranted to examine the treatment 
of childhood and adolescent obesity should clearly involve a focus on increasing 
MVPA and reducing SB as recommended in multiple evidence based treatment and 
prevention guidelines published in recent years. 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER V 
24-Hour Movement Behaviours in Children with Chronic 
Disease Compared to Healthy Children 
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5.1. Introduction and Aim 
There is growing concern about low level of PA in children and adolescents (14, 150, 347, 
428). Many fail to meet current recommendations for a minimum of 60 minutes of MVPA 
daily (79). In addition to low PA, there is increasing concern that high level of SB may also 
be common. Both low PA and high SB are important risk factors for cardiovascular disease, 
chronic diseases and mortality in adults (342, 344, 429, 430), as well associated with 
cardiovascular disease risk factors in children and adolescents, especially in their obesity 
(431) and metabolic risk profile (432). Most previous research on levels of PA and SB has 
focused on healthy children. Children with chronic disease have often been excluded from 
such research, with presence of a chronic disease being a common exclusion criterion, and 
they have either been excluded from or under-represented in public health surveillance of 
physical activity (291).  
 
Our recent systematic review of objectively measured MVPA in children with chronic 
disease found a relatively small amount of evidence (25 eligible studies across all groups 
with chronic disease and across all of childhood and adolescence). Habitual MVPA in 
children with chronic disease was consistently well below the recommended minimum of 
60 minutes per day and they accumulated a high amount of ST. However, MVPA in 
children with chronic disease though was not very much lower than in healthy control or 
comparison groups with the exception of children being treated for malignancy.(291).  
 
It is clear that there are no easy solutions to these serious and interlinked public health 
issues of low PA and increased SB and it is acknowledged that a range of strategies is likely 
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to be required. One commonly used strategy has been to try to find ways to increase overall 
PA and reduced ST. 
 
Recently, Chaput et al, have argued that focusing on MVPA while ignoring other 
components of movement behaviours limits our understanding of how various ‘activities’ 
interact together to impact children’s health (22). This has led to a growing realisation that 
an integrated approach that includes all movement/non-movement behaviours extending 
from sleep through to MVPA (“24-Hour movement behaviours”) might be a better way 
forward. Each of these behaviours may interact with PA and each may have an important 
influence on child health, development, and well-being (131, 132). This developing 
realisation has led to national Canadian and Australian evidence-based guidance for 24-
hour movement behaviours in children and adolescents published in 2016 and 2017 (131, 
132, 322). International (WHO) evidence-based guidance for the under 5s is currently 
under development and should be published in early 2019 (83). 
 
The 24-hour movement behaviours concept is so new that it has not been applied to 
studying children with chronic disease to date. In order to start to address this research 
deficit, we aimed carry out a case-control observational study to investigate 24-hour 
movement behaviours (sitting/lying, PA, standing, and sleep) for 5-7 days in children with 
common chronic childhood disease and test whether there are differences between children 
with chronic disease and their healthy peers. 
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5.2. Methods and Participants  
The methods and participant recruitment procedures were described in detail in Chapter II. 
In brief, the sample comprised 160 participants in total: children with chronic disease 
(n=80) and healthy controls (n=80) matched for age and sex. We investigated children with 
four common chronic diseases: 20 with TIDM, 20 with JIA, 20 with CHD, and 20 with CF 
as described in Chapter II. Patients were recruited from the outpatient clinics at Royal 
Hospital for Children, Glasgow, UK. Our healthy control children were obtained from 
nursery/schools, and children of staff members and friends.  
 
The study was approved by West of Scotland Research Ethics Committee 1 (Reference 
number 16/WS/0126) and NHS Greater Glasgow and Clyde Health Board (Appendix II). 
Parents of all participants provided informed written consent, and their children provided 
their informed assent - if applicable - to participate in the study prior to collection of any 
study data. 
 
Sex, age, height, weight, disease duration and a number of clinical variables related to each 
disease were recorded at the start of the study. BMI was then calculated from the height 
and weight measures (kg/m2). Anthropometric measurements and clinical variables were 
described in details in Chapter II. 
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5.3. Statistical Analyses 
In this study, all variables (anthropometric data, sitting/lying, PA, standing, and sleep 
behaviours) were checked for normality. Normally distributed data were summarised using 
mean (SD), while median and interquartile range were used for any data that were not 
normally distributed. Since children with chronic disease were matched pairwise with 
healthy controls (for age, sex, and time of year), and data on differences between pairs were 
normally distributed. Paired t-tests were used for the primary analysis that examined the 
significance of any differences between children with each particular illness vs their 
healthy controls for each of the 24-hour movement behaviours. As a secondary analysis we 
also compared the results in all children with chronic disease as a group with all healthy 
controls as a group using a t-test. Statistical significance was set at a cut-off value of ≤ 
0.05. Details of the study power calculation are described in detail in Chapter II section 
2.2.4.  
 
5.4. Results 
The details of the recruitment process, accelerometer results, characteristics of participants 
and summary details of the study participants are described in Chapter II Section 2.6. 
5.4.1. 24-Hour Movement Behaviours in Children with Chronic Disease 
and Healthy Controls 
Tables 5.1 and 5.2 and Figures 5.1, 5.2, 5.3 and 5.4 show summarised 24-hour movement 
behaviours (PA, standing, sedentary “sitting”, and sleep behaviours) for the children with 
chronic disease compared to healthy controls. 
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 Sedentary Time in Children with Chronic Disease and Healthy 
Controls 
All ST components (total sitting time, sitting percentage per 24 h period, and number of 
breaks (Up transitions) which reflected the number of sitting bouts) are shown in Table 5.1 
and Figures 5.1, 5.2, 5.3 and 5.4. 
Children with T1DM and their healthy controls group: there was no significant 
difference in sitting time between the two groups (paired t-test p = 0.33), as shown in Figure 
5.1-A. The mean (SD) of total number of breaks (Up transitions) which reflected to total 
number of sitting bouts in children with T1DM was lower compared to healthy peers, a 
difference that was close to significance (paired t-test p = 0.08).  
Children with JIA and their Healthy Controls: again there was no significant difference 
in sitting time between the two groups (paired t-test p = 0.77), as shown in Figure 5.1-B. 
Children with JIA had significantly lower of total number of breaks (Up transitions) 
compared to healthy controls (paired t-test p = 0.002). 
Children with CHD and their healthy controls group: there was no significant 
difference in sitting time between the two groups although the difference was close to 
significance (paired t-test p = 0.06), as shown in Figure 5.1- C. Those with CHD had a 
lower number of breaks (Up transitions) which compared to healthy controls, but this 
difference in the number of breaks was not significant (paired t-test p = 0.36). 
 
Children with CF and healthy controls group: There was a significant difference in 
sitting time between the two groups (paired t-test p = 0.02), as shown in Figure 5.1-D. The 
number of breaks (Up transitions) which reflected to number of sitting bouts per 24 h in 
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children with CF was lower compared to healthy peers, but this difference in the number 
of breaks (Up transitions) was not significant (paired t-test p = 0.52). 
 
All Children with Chronic Disease (n=80) Compared with Healthy Controls (n=80) 
Finally, as a secondary analysis we compared children in the chronic disease group with 
their matched healthy control group. There was a significant difference in sitting time 
between the two groups (paired t-test p = 0.01), as shown in Figure 5.2. The total number 
of breaks in sitting (posture transitions) was lower compared to healthy peers, a difference 
that was significance (paired t-test p = 0.001). Thus, children with chronic disease sat for 
longer with more prolonged periods of sitting than their healthy controls.  
 
 Standing in Children with Chronic Disease and Healthy Controls 
Standing time was expressed as total amount of time spent in standing. Standing time and 
standing as a percentage per 24 h period are shown in Table 5.1 and Figures 5.1, 5.2, 5.3 
and 5.4. 
Children with T1DM and their healthy controls groups: the time spent in standing was 
lower in diabetic children compared to healthy peers, but the difference was not statistically 
significant (paired t-test p = 0.15). 
 
Children with JIA and their healthy controls groups: Children with JIA spent lower 
time in standing compared to their healthy peers spent. The difference between children 
with JIA and healthy controls for standing time was significant (paired t-test p =0.02). 
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Children with CHD and their healthy controls groups: the time spent in standing was 
lower in children with CHD than healthy peers, but the difference between two groups was 
not significant (paired t-test p =0.22). 
 
Children with CF and their healthy controls groups: The standing time was lower in 
children with CF compare to healthy. There was a significant difference in the time spent 
standing between two groups (paired t-test p = 0.0002). 
 
All Children with Chronic Disease (n=80) Compared with Healthy Controls (n=80): 
Children with chronic disease spent lower time in standing and the difference between two 
groups was statistically significant (paired t-test p = 0.0001). 
 
 Physical Activity in Children with Chronic Disease and Healthy 
Controls 
PA data expressed in two ways: 1) total amount of time spent in PA; 2) PA percentage per 
24 h period and 3) number of steps per day as shown in Tables 5.1 and 5.2 and Figures 5.1, 
5.2, 5.3 and 5.4. 
Children with T1DM and their healthy controls groups: the difference in time spent in 
PA between children with T1DM and healthy control groups was significant (paired t-test 
p =0.04). Further, the activPAL measured step counts per 24 h period in children with 
T1DM compared with healthy controls and difference in step count between the groups 
was close to being significant (paired t-test p = 0.09). 
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Children with JIA and their healthy controls groups: Children with JIA spent lower 
time in PA compared to healthy peers, a difference that was not statistically significant 
(paired t-test p = 0.16). Steps measured by the activPAL in children with JIA and healthy 
controls group and the difference in step count between the groups was not significant 
(paired t-test p = 0.26). 
 
Children with CHD and their healthy controls groups: The difference in the time spent 
in PA was significant (paired t-test p = 0.01) between two groups. While, the difference in 
step count between the groups was significant (paired t-test p = 0.02). 
 
Children with CF and their healthy controls groups: There was no significant 
difference between the two groups in the time spent in PA (paired t-test p = 0.73). Also, 
the difference in step count between the groups was not significant (paired t-test p = 0.84). 
 
All Children with Chronic Disease (n=80) Compared with Healthy Controls (n=80): 
The difference in time spent in PA between children with chronic disease and healthy 
controls was significant (paired t-test p =0.001). Further, the difference in step count 
between the groups was also significant (paired t-test p = 0.01). This overall, children with 
chronic diseases had lower PA levels and lower measured step count levels. 
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 Sleep Duration in Children with Chronic Disease and Healthy 
Controls 
Tables 5.1 and 5.2 and Figures 5.1, 5.2, 5.3 and 5.4 summarises sleep time variables in 
children with chronic disease compared to healthy controls. Other sleep variables are 
presented in chapter VI. 
 
Children with T1DM and their healthy controls groups: The difference in sleep 
duration between children with T1DM and healthy controls was not significant (paired t-
test, p=0.12). Children with JIA and their healthy controls groups: The difference in 
sleep duration between children with JIA and healthy controls was significant (paired t-test 
p = 0.0007). Children with CHD and their healthy controls groups: The difference in 
sleep duration of children with CHD and healthy controls was not statistically significant 
(paired t-test p =0.52). Children with CF and their healthy controls groups: The 
difference in sleep duration between-groups was not significant (paired t-test p =0.30). It 
was noted that this was the only chronic disease group where sleep duration was slightly 
shorter than controls. All Children with Chronic Disease (n=80) Compared with 
Healthy Controls (n=80): The difference in sleep duration between children with chronic 
disease and healthy controls was significant (paired t-test, p=0.001). This overall, children 
with chronic diseases had significant prolonged sleep duration than healthy controls. 
 
5.4.2. 24-Hour Movement Data Comparisons with Recommendations 
The activPAL can make objective measures of the amount of time spent in PA, of the 
number of steps per day (as a proxy for physical activity), of the time spent in sleep, and 
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of the time spent sedentary (sitting/lying down), and time spent standing but not moving. 
Of these behaviours, there are currently paediatric guideline recommendations only for 
number of steps per day and time spent in sleep. Number of steps per day and time spent 
asleep were therefore compared against the appropriate age-specific recommendations: in 
children aged 4-6 years for steps per day the recommendation is 10,000 - 14,000 steps/day; 
In boys aged 6-11years 13,000 - 15,000 steps per day and in girls 6-11years 11,000 - 12,000 
steps per day in girls to achieve an average of 60 minutes per day of MVPA (86). For sleep 
duration, the recommendation in children aged 3-4 years is 10-13 h per night, and in 
children aged 5-13 years 9-11 h per night, with consistent bed and wake-up times (131, 
132). 
In both our chronic disease and healthy control groups mean steps per 24h period were 
below the recommendations. A total of 49/160 participants (n=20 in children with chronic 
disease and 29 in healthy control groups) met the step count recommendations. From each 
group the number of individuals who met the step count recommendations was as follows 
three (one boy and two girls) in children with T1DM and four girls in their healthy peers; 
eight (four boys and four girls) in children with JIA and nine (two boys and seven girls) in 
their healthy control group; four (one boy and three girls) in children with CHD and eight 
(three boys and five girls) in their healthy control group; and five (one boy and four girls) 
children with CF and eight (five boys and three girls) in their healthy control group, as 
summarised in Table 5.4. 
 
Mean duration of sleep was within recommendations for all four-groups both for the 
children with chronic diseases and for their four healthy control groups. For the individual 
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level data, a total of 23 participants (n=10 in children with chronic disease and 13 in healthy 
control groups) were below the sleep recommendation. For each group the numbers not 
meeting the sleep recommendations were as follows three (one boy and two girls) in 
children with T1DM; and four (two boys and two girls) in their healthy peers, five (two 
boys and three girls) in healthy control of JIA group, three (two boys and one girl) in CHD 
and two (one boy and one girl) in their healthy peers, four (two boys and two girl) in CF 
and two (one boy and one girl) in their healthy control groups; were had short sleep duration 
“below” the sleep recommendation as summarised in Table 5.4. 
 
In Summary,  
In children with T1DM, although, there were no significant differences between patient 
and controls for sedentary, standing and sleep time, they had greater time spent sedentary 
with lower number of breaks (meaning more prolonged sitting bouts), less standing time 
with slightly longer sleep time than their healthy controls. While, time spent in PA was 
significant lower in children with T1DM, with lower step counts (but not significantly 
lower) compared to healthy controls. 
 
Children with JIA had slightly greater sedentary time with significantly lower number of 
breaks in sitting (more prolonged sitting bouts), significantly lower standing time, and 
significantly longer sleep time than their healthy controls. Also, they were less physically 
active (in both time spent in PA and step counts) than their healthy controls although but 
the differences did not reach significance.  
 
Chapter V 
 
 
209 
 
Children with CHD had greater ST lower number of breaks (i.e. prolonged sitting bouts) 
and less standing time with longer sleep time than their healthy peers, (but not significant). 
Children with CHD were significantly less physically active (in terms of both time spent 
in PA step counts) than healthy controls.  
 
For children with CF there was little difference in terms of PA and step counts between 
them and their healthy controls. However, they were significantly more sedentary with 
lower number of breaks than their healthy controls and spent significantly less time 
standing than their healthy peer, Children with CF were the only chronic disease group to 
have slightly shorter sleep times compared to healthy controls.  
 
These apparently small but consistent differences in the children within the individual 
chronic disease groups and their matched controls become more obvious when the children 
with chronic diseases are considered as a group. In children with chronic disease, there 
were significant differences between patients and controls for time spent sedentary, 
standing, PA and asleep. Patients had greater time spent sedentary with significantly lower 
number of breaks in sedentary time (meaning more prolonged sitting bouts), and less 
standing time with slightly longer sleep time than their healthy controls. Time spent in PA 
as measured by activPAL accelerometry was significantly lower in the children with 
chronic disease than the controls, and patients also had significantly lower step counts 
compared to healthy controls. 
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Table 5.1: 24-hour movement behaviours variables in children with chronic disease and their healthy control; data are presented as means and (SD) 
 
Variables 
CD 
(n=80) 
HC 
(n=80) 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
Time spent 
sitting h 
8.1 (1.4)  
* 
7.4 (0.9) 
* 
8.3 (1.7) 7.8 (0.8) 7.6 (1.1) 7.4 (1.0) 8.1 (1.7) 7.4 (0.9) 
8.1 (1.0)  
* 
7.2 (0.9) 
* 
% of sitting 
per 24 h 
33.3 (5.8) 30.8 (3.7) 34.5 (7.3) 
32.6 
(3.1) 
31.5 (4.7) 31 (4.5) 33.9 (7.1) 30.9 (3.7) 33.7 (4.2) 30.0 (3.6) 
No of sitting 
bouts 
245 (68) 
** 
277 (88) 
** 
210 (56) 243 (93) 
236 (75) 
** 
319 (87) 
** 
241 (61) 298 (82) 249 (31) 261 (83) 
           
Time spent 
standing h 
3.1 (0.7) 
*** 
3.7 (0.7) 
*** 
3.2 (0.7) 3.5 (0.6) 
3.2 (0.9) 
* 
3.8 (0.8) 
* 
3.2 (0.8) 3.6 (0.5) 
2.9 (0.5)
 
*** 
3.7 (0.7) 
*** 
% of stand per 
24 h 
12.9 (3) 15.4 (2.9) 13.3 (3) 
14.5 
(2.3) 
13.3 (3.8) 15.9 (3.2) 13.4 (3.2) 15 (2.1) 12.1 (2.1) 15.4 (3.1) 
           
Time spent in 
PA h 
2.1 (0.8) 
** 
2.5 (0.4) 
** 
1.7 (0.7) 
* 
2.2 (0.4) 
* 
2.3 (0.9) 2.6 (0.3) 
1.9 (0.9) 
* 
2.5 (0.4) 
* 
2.4 (0.7) 2.4 (0.4) 
% of PA per 
24 h 
8.7 (3.3) 10.4 (1.6) 7.2 (3) 9.1 (1.6) 9.5 (3.7) 10.8 (1.3) 8 (3.7) 10.4 (1.8) 10.0 (3.1) 10.2 (1.8) 
No steps per 
24h 
9,485 
(4,148) 
* 
10,959 
(2,024)  
* 
8201 
(3231) 
9903 
(1657) 
10428 
(4139) 
11608 
(1561) 
8533 
(4712) 
* 
11249 
(2320) 
* 
11395 
(4169) 
11050 
(2128) 
           
Time spent in 
sleep h 
10.1 (0.8) 
** 
9.7 (0.6) 
** 
10.2 (0.7) 9.7 (0.6) 
10.4 (0.8) 
*** 
9.5 (0.5) 
*** 
10.2 (0.9) 9.7 (0.5) 9.7 (0.9) 9.9 (0.5) 
% of sleep per 
24 h 
42.1 (3.3) 40.4 (2.8) 42.5 (2.9) 
40.4 
(2.8) 
43.3 (3.2) 39.6 (2.1) 42.5 (3.9) 40.6 (2.1) 40.4 (2.8) 41.2 (2.2) 
CD – chronic disease; CHD – congenital heart disease; CF – cystic fibrosis; JIA – juvenile idiopathic arthritis; h – hour; T1DM – type1 diabetes mellitus.  
Combined data represented total children with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), and F: M 43: 37) as one group and total healthy controls n=80,  
mean age 6.8 (SD=1.9) and F: M 43: 37) as one group. Further details of characteristics data in Chapter II and Table 2.1. 
Data are presented as means and standard deviation SD unless otherwise specified.  
Paired t test compared between children with chronic disease and healthy children control age and sex matched; * P=< 0.05, ** P=< 0.005 and ***P= <0.0005   
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Table 5.2: 24-hour movement behaviours variables comparisons with recommendations in children with chronic disease and healthy controls.  
 
Variables 
CD 
(n= 80) 
HC 
(n= 80) 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
No. of participants 
meeting steps 
recommendation 
20 29 3 4 8 9 4 8 5 8 
No. of participants 
NOT meeting sleep 
recommendation 
10 13 3 4 0 5 3 2 4 2 
CHD – congenital heart disease; CF – cystic fibrosis; JIA, – juvenile idiopathic arthritis; T1DM – type1 diabetes mellitus.  
Combined data represented total children with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), and F: M 43: 37) as one group and total healthy controls n=80,  
mean age 6.8 (SD=1.9) and F: M 43: 37) as one group. Further details of Characteristics data in Chapter II and Table 2.1. 
Steps recommendations per day 10,000- 14,000 steps/day in children aged 4-6 years, 13,000- 15,000 steps per day in boys and 11,000- 12,000 steps per day in girls aged 6-
11 years old (86); 
Sleep duration recommendations 10- 13 h per night in children aged 3-4 years, and 9- 11 h per night in children aged 5-13 years, with consistent bed and wake-up times  
(131, 132). Data are presented as number. 
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A)      B) 
  
C)      D) 
 
Figure 5.1: Difference in 24-Hour movement behaviours (Sitting/lying, PA; physical activity, stand, and sleep) 
variables for children with chronic disease compared to healthy controls.  
A) Between children with T1DM (type 1 diabetes mellitus) (n=20) and their healthy control (n=20) groups;  
B) Between children with JIA juvenile idiopathic arthritis (n=20) and their healthy control (n=20) groups;  
C) Between children with CHD (congenital heart disease) (n=20) and their healthy control (n=20) groups;  
D) Between children with CF (cystic fibrosis) (n=20) and their healthy control (n=20) groups;  
Values presented with a mean ± SD and dots represent the participant. Paired t test compared between 
children with chronic disease and healthy children control age and sex matched; * significant difference and 
P=< 0.05, ** P=< 0.005 and ***P= <0.0005. 
 
 
Figure 5.2: Difference in 24-Hours movement behaviours (Sitting/lying, PA; physical activity, stand, and 
sleep) variables for total children with chronic disease (CD n=80) compared to total healthy controls (HC 
n=80). Combined data represented total children with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), 
and F: M 43: 37) as one group and total healthy controls n=80, mean age 6.8 (SD=1.9) and F: M 43: 37) as 
one group. Values presented with a mean (SD) and dots represent the participant. Paired t test compared 
between children with chronic disease and healthy children control age and sex matched; * significant 
difference and P=< 0.05, ** P=< 0.005 and ***P= <0.0005.   
0
200
400
600
800
T
im
e
 (
m
in
/d
a
y
)
Sitting Stand PA Sleep
*
HC
T1DM
0
200
400
600
800
T
im
e
 (
m
in
/d
a
y
)
Sitting Stand PA Sleep
*
***
HC
JIA
0
200
400
600
800
T
im
e
 (
m
in
/d
a
y
)
Sitting Stand PA Sleep
*
HC
CHD
0
200
400
600
800
T
im
e
 (
m
in
/d
a
y
)
Sitting Stand PA Sleep
***
*
HC
CF
0
200
400
600
800
T
im
e
 (
m
in
/d
a
y
)
Sitting Stand PA Sleep
**
HC
CD
*
***
**
Chapter V 
 
213 
A) TIDM – HC   Ai) TIDM 
   
B) JIA–HC   Bi) JIA 
   
C) CHD– HC   Ci) CHD 
   
D) CF– HC   Di) CF 
   
Figure 5.3: Pie chart represented the distribution of 24-hour movement behaviours in children with chronic 
disease and their healthy controls groups; A-D is healthy control groups (n=20/group) of TIDM; JIA; CHD 
and CF, while, Ai-Di is represent children with chronic disease (n=20/group) of TIDM; JIA; CHD and CF 
respectively. Abbreviations: CHD, congenital heart disease; CF, cystic fibrosis; JIA, juvenile idiopathic 
arthritis; T1DM, type1 diabetes mellitus; NM, non-wear time. 
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 A) HC     Ai) CD 
   
Figure 5.4: Pie chart represented the distribution of 24-hour movement behaviours in: A- total healthy 
controls (HC n=80, mean age 6.8 (SD=1.9) and F: M 43: 37) as one group, while, Ai- is represent total children 
with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), and F: M 43: 37) as one group; NM - non-wear 
time. Further details of participants characteristics data in Chapter II and Table 2.1 Values presented with a 
mean (SD)  
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5.5. Discussion 
5.5.1. Main Findings and Study Implications 
The intense recent interest in the new paradigm of ‘24-hour movement behaviours’ in 
children has not yet extended to children with chronic disease of childhood. There are 
currently few published data on these behaviours for children, particularly school-age 
children (132, 133) and even fewer data from children with any of the common chronic 
diseases of childhood. Since the release of the Canadian 24-Hour movement guidelines 
for children and adolescents in 2016 (school age children and adolescents) and 2017 
(the under 5s) (131, 132), our study appears to be the first to quantify 24-hour 
movement behaviours in children with common childhood diseases, and to test for 
differences in the time spent in the behaviours between those children and healthy 
controls.  
 
The present study suggests that for at least some groups with chronic disease 24-hour 
movement behaviours may differ substantially from recommendations and differ 
slightly but systematically from their healthy peers. The most obvious concerns in the 
present study relate to the greater ST in children with chronic disease, although the 
differences from healthy controls are small and were significant only in the CF group 
and nearly so in the CHD group. In addition, the number of breaks (Up transitions) was 
consistently lower in those with chronic disease compared to healthy controls, meaning 
that children with chronic disease had more prolonged sitting bouts compared to healthy 
control groups. Again differences between disease groups and healthy controls were 
small and here were only significant only in children with JIA and nearly so T1DM 
groups. Standing time was lower in children with chronic disease and significantly 
lower in those with JIA and CF than in their healthy controls.  
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Children with chronic disease were consistently less active than their healthy controls, 
in both the time spent in PA and step counts, although again the difference between 
chronic disease groups and controls were small with significantly lower time spent in 
PA in the T1DM and CHD groups, and significantly lower step counts in CHD. Except 
in children with CF, time spent in asleep was slightly greater in children with chronic 
disease compared to healthy peers but with a significant difference only in JIA and their 
healthy control groups.  
 
When data from the four groups of controls and four groups with chronic disease were 
combined children with chronic disease had significantly greater time spent sedentary 
with significant lower number of breaks with significant less standing time with 
significant longer sleep time than their healthy controls. Children with chronic disease 
were significantly less active than their healthy controls, reflected both in the time spent 
in PA and step counts. Twenty-four hour movement behaviours were generally slightly 
more favourable in the healthy controls than in the patient groups.  
 
The analysis combining data of the different patient groups is exploratory. The 
similarity in findings between patient groups and controls (e.g. generally slightly lower 
levels of PA and slightly higher levels of ST) across all four of the patient groups makes 
it tempting to conclude that any potential ‘effects’ of chronic disease may be similar, 
but further research would be needed to establish this. We combined data form four 
different disease groups all of whom were stable and free living at the time of 
recruitment. However, while it is important to acknowledge that different mechanism 
may be operating within the different groups, nevertheless they did all share the label 
and had the met the characteristics specified to be labelled as having a chronic illness 
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“Chronic illness in children and adolescents could be defined as any physical, 
emotional, or mental health problem that lasts at least three months, and affects a 
child’s physical appearance and/ or growth and daily normal activities and results in 
frequent hospitalisations with regular therapy and sometimes unpleasant procedures, 
with home and medical care (166). “ 
 
There are no either evidence based or consensus expert opinion paediatric 
recommendations for total sedentary time and standing time. Lately, it is has become 
widely believed, based mostly on adult studies, that standing is better for 
cardiometabolic health than sitting, and breaking up long periods of sitting with 
standing is good for cardiometabolic health (433-435). It is not at present certain that 
these possible benefits of standing also apply to children. However, it is at least 
probable that underlying biological mechanisms are likely to apply to both children and 
adults, and behavioural norms around sitting and standing may be established in 
childhood. There is increasing interest in time spent standing in childhood, interest that 
includes a number of intervention studies where ‘standing breaks’ in the classroom have 
been the main intervention (436). Hopefully, this will result in a clearer and more 
substantial evidence base about whether time spent standing is indeed important for 
health outcomes in children. 
 
Therefore, my study included time standing as an early empirical exploration of the 
topic. For example, it seemed potentially important to highlight that children stand for 
quite long periods in each 24-hour day, as shown by my study, yet most previous 24-
hour movement behaviour studies in children have ignored/not presented time spent 
standing. 
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Hopefully, the significance of time spent standing might become clearer as more 
evidence comes to light on the possible benefits of standing (or at least not sitting) in 
children in future. 
 
5.5.2. 24-Hour Movement Behaviours Data Comparisons with 
Recommendations 
Whether children with chronic disease and their healthy peers meet 24-hour movement 
behaviours recommendation is an interesting and important question and deserves 
further investigations. As we noted above, currently there are no either evidence based 
or consensus expert opinion paediatric recommendations for total sedentary time and 
standing time. Therefore our study focused on step counts per day and sleep duration 
since these have widely used recommendations for children in the public domain (86, 
131, 132). Our results showed that in all groups, both patients and controls, step counts 
were much lower than age-specific recommendations per day (86). Only 30.6% of 
participants (12.5% in children with chronic disease and 18.1% in healthy control 
groups) met the step count recommendations per day. 
 
 The next part of our study addressed meeting sleep duration recommendations. Here, 
in both chronic disease and healthy control groups mean duration of sleep was within 
the range 9-11 h of sleep per night with consistent bed and wake-up times, in accordance 
with what is recommended (131, 132). However, 14.4 % of participants (6.3 % in 
children with chronic disease and 8.1% in healthy control groups) did not meet the sleep 
duration recommendation, and they slept less than recommended.  
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5.5.3. Comparisons with Other Studies  
As noted above, the novelty of the 24-hour movement behaviours paradigm, 
particularly as it applies to children with chronic disease, makes comparison between 
the present study and other studies problematic. We are unaware of any studies of 
compliance with new 24-hour recommendations in school-age children. Our recent 
systematic reviews found that levels of MVPA were lower than recommended in 
children with chronic disease, though typically not lower than control groups except in 
children with malignancy and children with obesity (291, 385).  
 
The present study data on PA are broadly consistent with those findings, in that levels 
of PA (measured both as time spent moving by the activPAL and the step counts) in the 
patients were generally lower than those of the controls, though the differences were 
generally small and were not always significant in the sample size we used of n = 20 
pairs.  
 
Furthermore, our findings are somewhat consistent with previous research that 
examined these behaviours, particularly MVPA, in children with chronic disease. Our 
systematic review showed that children with chronic disease had more inactive 
lifestyles than their peers (i.e. spent less time in PA and more time in SB). As an 
example, one study included in our review was that of Maggio et al who carried out a 
cross-sectional study to examine MVPA and ST in children with childhood disease 
focused on obesity, JIA and T1DM groups compared to healthy children, with 209 
children and adolescents aged 4.8 to 17.9 years: 45 were obese, 48 had T1DM, 31 had 
JIA and 85 were healthy. MVPA and ST were assessed by using an uniaxial 
accelerometer (ActigraphTM). They found that ST was significantly greater in those 
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with chronic disease and MVPA was lower in children with childhood disease (but only 
significantly in JIA) compared to the healthy control group (222).  
 
Taken together with our recent systematic reviews it seems likely that levels of 
objectively measured PA among many groups of children with chronic disease – at least 
for those who are relatively well - are lower than recommended, though probably not 
much lower than their healthy peers.  
 
While the children recruited to patient groups in the present study were relatively well 
and living as outpatients, they and their families were presumably still living with a 
substantial burden imposed by their chronic disease. For example, in children with 
T1DM, although 60% (n=12) with good glycaemic control, there was 40% (n=8) were 
considered to have poor glycaemic control at the time of recruitment with an average 
of duration 2.1 years from diagnosis to the time of enrolment in the study. Further, 35% 
were on insulin pump therapy, a complex treatment, with the others on insulin multiple 
injections per day. All children with JIA had been receiving treatment with biological 
therapies with a mean 3.2 years disease duration from diagnosis to the time of 
enrolment. However, four out of the twenty of children with JIA were off treatment at 
the time of recruitment. All children in the group with CHD had received cardiac 
surgery, with a mean time from the last surgical procedure at the time of enrolment of 
3.5 years (SD=2.2) years, while 55% (n=11) children had moderate-severe CHD and 
most had more than one cardiac operation. Further, forty per cent (n=8) of CHD 
children were still on medical treatment at the time of enrolment. Children with CF 
were on treatment with the mean time from diagnosis to study enrolment of 6.5 years 
(SD=2.0) years, where most of them had diagnosis with CF in early their life following 
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neonatal screening “within a few months after their birth” and were being frequently 
admitted to the hospital to receive systemic treatment.  
 
While the disease severity ranged from mild/moderate to severe among the children 
with chronic disease in the present study, all were attending school and being treated as 
outpatients. Therefore, the lack of large differences in PA and the other 24-hour 
movement behaviours between chronic disease versus control groups is perhaps a 
reflection of the normalisation of low levels of PA and high levels of ST among healthy 
contemporary children rather than exceptionally impaired PA in the chronic disease 
group (156, 158, 437). 
 
5.5.4. Study Strengths and Limitations 
This study had several strengths and limitations that warrant discussion. The main 
interest of the present study was the novelty of the research questions and population, 
with a paucity of 24-hour movement data in general. This lack of data has been even 
greater in children with chronic disease. Further strengths were our ability to make 
objective measures of so many of the behaviours (time spent sitting, standing, moving, 
and sleeping), to control for the key known determinants of these behaviours at this age 
(age, gender, season (158, 289, 290)), and to make pair-wise comparisons of the 
behaviours with closely matched healthy controls. The participants were composed of 
boys and girls with children with chronic disease and their healthy control groups and 
they were closely matched for age and sex matched-to avoid influences of age and sex 
on PA and sedentary behaviours (289). Previous research reported that younger 
children are more active than older children, with a decline in activity with increasing 
age (289, 290). Evidence from longitudinal studies has shown that SB increases with 
Chapter V 
 
222 
age and becomes less fragmented (longer bouts of sitting time), and also that the 
increase in sedentary time displaces time spent in PA (158, 438).  
 
We were also able to allow for the fact that children spend a good deal of time standing 
and not moving. Time spent standing has generally not been considered in previous 
studies, and possibly misclassified as other forms of movement behaviour in previous 
studies. Furthermore, a highly standardised measurement protocol was used. In 
addition, the 24-hour movement behaviours were measured across a sufﬁcient number 
of days and nights to obtain a reliable assessment of the participants’ usual sedentary, 
standing, PA and sleep behaviours by using ActivPALTM accelerometer, a small device 
that has been validated for such studies. Thus, we believe our results provide a valid 
and reliable picture of 24-hour movement for the children with chronic disease and 
healthy children across 7 days. 
 
The limitations of the present study included the fact that children with chronic disease 
were recruited from a hospital setting. However, these children were attending routine 
follow-up appointments because of their chronic disease and were apparently fairly well 
at the time of recruitment. Our results focused on four of the chronic childhood chronic 
disease groups and their generalisability to other chronic disease groups in children is 
not yet known. It is not clear if differences in 24-hour movement behaviours could be 
detected among groups of children with other chronic diseases such as children with 
malignancies or another musculoskeletal disease, or with even more severe/advanced 
forms (or during disease exacerbations) of diseases in the present study, and this 
requires future work. Furthermore, in our study the participants aged range 3-10 years, 
a relatively young age when taking account of the fact that differences in activity are 
Chapter V 
 
223 
only likely to increase as children move into adolescence. Thus additional research will 
be required to investigate whether similar findings are found in younger or older 
children with these or other chronic diseases.  
 
The most important limitation was inability to measure MVPA in the present study, as 
there are currently no algorithms for converting activPAL-measured movement to 
MVPA in school-age children. Although a few studies in adults have suggested 
stepping cadence of >100 and >70 steps/min as equivalent to MVPA using the 
activPAL3 (439), there is no valid and reliable data that this would be suitable for 
children of mean age around 6 years. Janssen et al have provided evidence validity of 
using a cut-point ≥1418 counts per 15s to measured MVPA from activPAL in young 
children aged 4-6 years. Despite the broader age ranges in our study (from 3-10 years 
with mean age 6.9 and 6.8 for children with chronic disease and healthy peers), we 
initially thought the Janssen cut-point might be suitable to use with our participants to 
estimate MVPA levels. Unfortunately, the results show there was discrepancy between 
their MVPA level and number of steps/day. Since this means that the cut-points was 
not evidence based I did not present this result in the original thesis and presented in 
Appendix III Table 2.  
 
A further weakness was our inability to measure screen-time – a subset of sedentary 
behaviour. Again, there are currently no objective methods available for measuring 
screen time exposure in children and the accuracy of subjective (parent-report) methods 
is unknown as suggested by the recent systematic review by Prince et al (312). If and 
when these methodological difficulties can be overcome, then more comprehensive 
experimental investigations of 24-hour movement behaviours will become possible. 
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The high degree of compliance with the activPAL measurement protocol in the present 
study suggests that future studies of time spent in PA, SB, and sleep, should be practical 
with a single device, but enhancements to our existing device-based approaches to 
reflect the limitations highlighted would be desirable. 
 
The high degree of compliance with the activPAL measurement protocol in the present 
study suggests that future studies of time spent in PA, SB, and sleep, should be practical 
with a single device, but enhancements to our existing device-based approaches to 
reflect the limitations highlighted would be desirable.  
 
Finally, in a post hoc analysis of our data we calculated using the data we collected that 
a minimum of 16-20 pairs would be required to have a 80% power of detecting a 
difference in PA and SB between children with chronic disease and healthy peers with 
a significance level of 5%, but in fact some of the differences between groups were 
relatively small and much larger studies may be required to determine the significance 
of differences between some of the groups in future studies. The statistical significance 
of some of the differences may in fact be of secondary importance - the main findings 
of the present study may be more relevant because of the biological/clinical significance 
of the observed low levels of PA, high levels of ST, with apparently adequate levels of 
sleep in children with and without chronic disease during early-mid childhood. If 
sustained, the tracking of such low levels may lead to cumulative effects in the longer 
term.  
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5.6. Conclusions 
In conclusion, the present study suggests that 24-hour movement behaviours in children 
with chronic disease give cause for some cause for concern and may be generally 
slightly worse than in their healthy peers. Those with chronic disease tended to spend 
slightly more time sedentary with lower number of breaks in their sitting, and with less 
time standing and less time in PA with lower step counts per 24 h period but and with 
longer sleep duration than controls. The fact that the findings for sleep were different 
in children with CF who were only chronic disease group to have slightly shorter sleep 
duration then their healthy peers – suggests that individual characteristics of each 
chronic disease may have different impact on 24 hour movement behaviours. 
 
Optimising levels of the 24-hour movement behaviours should potentially confer a 
number of benefits for child health, development, and wellbeing (132) and so 
improving 24-hour movement behaviours should be considered as part of the 
management of many common childhood chronic diseases in future. Methods to 
normalising 24-hour movement behaviours will require large scale empirical testing. 
At present, further, future research efforts should aim to examining 24-hour movement 
behaviours in larger sample sizes, should extend measures to screen time and MVPA if 
possible, and also children with other chronic diseases should be considered for future 
studies. 
  
 
 
 
 
 
 
 
 
 
CHAPTER VI 
Sleep Behaviour in Children with Chronic Disease 
Compared to Healthy Children 
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6.1. Introduction and Aim 
Sleep is a ‘naturally recurring resting state in which the human body is not active and 
the mind is unconscious’ (109). During sleep, most human systems are in an anabolic 
state, building up the immune, nervous, skeletal and muscular systems (119). Sleep is 
also important for the mental processes of learning as well as the maintenance of 
emotional and mental wellbeing of the individual (112, 125). Healthy sleep requires 
adequate duration of sleep, appropriate timing of going to sleep (sleep onset) and 
waking (sleep offset), and freedom from disturbance during sleep (112). Like PA and 
nutrition, sleep has an important role in growth and physical and mental development 
and health in children and adolescents (114, 125, 440).  
 
Lack of sleep (in terms of timing and duration) and poor sleep quality (in terms of sleep 
interruption by awake episodes) has been shown to have significant impacts on daytime 
functioning and mood in otherwise healthy children (441, 442). A number of 
epidemiological reports have linked inadequate sleep duration with increased risk of 
chronic disease and rate of premature mortality in adults (111). Part of this association 
might be mediated by obesity, as that has also been associated with short and long sleep 
duration (119, 443). Further, it is obvious from many observational studies that 
suboptimal sleep - insufficient or poor quality sleep - is associated with impairments in 
cognition, behaviour, performance, and well-being in children and adolescents (139, 
442, 444, 445). It is also associated with poor physical health outcomes, including 
hypertension, cardiovascular disease, diabetes, obesity, and cancer in adults and 
children (121-123, 446-448). 
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In contemporary society, it is recognised that there has been a secular decline in sleep 
duration in children (449). However, the causes of this decline are not well understood. 
Later bedtimes with largely unchanged wake time are one possibility (118, 450). 
National and international bodies such as the National Sleep Foundation have 
recommended 10-13 hours of sleep per night for preschool children and 9–11 hours of 
sleep per night for school-aged children to maximise general health and well-being 
(451). These recommendations for the population are usually also considered to be 
applicable to children with chronic diseases (131, 132), Indeed, the United States 
Centres for Disease Control and Prevention in 2011 recommended 10 -12 hours of sleep 
per night for school-aged children with chronic disease (452).  
 
Measurement of sleep in young children continues to be challenging. Subjective 
measures such as sleep diaries and parental questionnaires are widely used methods of 
assessing child and adolescent sleep and are relatively easy to use and inexpensive. 
Some clinical research has used objective methods such as polysomnography, 
considered the gold standard of objective sleep measurement, in children and 
adolescent. Because it is complex, time consuming and expensive, polysomnography 
is mainly used in experimental studies that include clinical populations. Alternative 
objective methods such as accelerometry currently represent a more readily available 
accurate and convenient objective tool for measuring sleep in terms of both quantity 
and quality of sleep (453). Accelerometry has been shown to produce more consistent 
and accurate measurement of sleep than subjective methods (138, 309). 
 
While there have been many studies on sleep, both on quantity and quality, in healthy 
children (454, 455), there are surprisingly few studies in children with chronic disease 
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and so differences in sleep in children with chronic disease compared to healthy 
children particularly using objective methods of measurement such as accelerometry 
(128, 129). This part of our work was undertaken to investigate sleep quantity – 
particularly sleep timing (in terms of sleep onset/offset), and sleep duration - and sleep 
quality in children with chronic diseases. In particular, we wished to investigate 
whether children with chronic disease differed from healthy controls and whether both 
met the current sleep duration recommendations (131, 132) using objective 
measurements (activPALTM micro accelerometer). 
 
6.2. Methods and Participants  
6.2.1. Recruitment Process and Participants 
The data used in this study were also collected in the 24-hour movement behaviours in 
children with chronic disease compared to healthy controls groups study described in 
Chapter V. The procedures for recruitment were described in chapter II. In brief, there 
were 160 participants in total: (n=80) children with chronic disease recruited from 
outpatient clinics at the Royal Hospital for Children, Glasgow, UK; and (n=80) healthy 
control group children recruited from local schools and nurseries. We investigated 
children from four groups of children with common chronic diseases: 20 with TIDM, 
20 with JIA, 20 with CHD, and 20 with CF. The study had a paired design, with each 
patient matched with a healthy control child, matched for age, gender, and time of 
measurement as these have been identified in previous studies as the main influences 
on PA, SB and sleep in children. (289, 290). 
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The study was approved by West of Scotland Research Ethics Committee 1 (Reference 
number 16/WS/0126) and NHS Greater Glasgow and Clyde Health Board. Informed 
consent was obtained from the parents/guardians of all participants, and children 
provided their informed assent -if applicable - to participate in the study prior to 
collection of any study data. 
 
Sex, age, disease duration and a number of clinical variables related to each disease 
were recorded at the start of the study. Height and weight were measured to 0.1cm and 
0.1kg respectively, and Body Mass Index (BMI) was then calculated from the height 
and weight measures (kg/m2) and expressed relative to age and sex using the UK 1990 
BMI reference data (298, 299). Details of the anthropometric measurements and the 
clinical variables collected were described in detail in Chapter II. 
 
6.2.2. Measurement of Sleep Behaviour Variables – Sleep Quantity 
and Quality - Using the ActivPAL 
Sleep time was measured objectively using an activPAL™ micro monitor (PAL 
Technologies Ltd., Glasgow, UK). Children were asked to wear the monitor 
continuously for 24 h a day over seven consecutive days and nights. Data from the 
activPALTM micro were downloaded using activPAL Professional (Version 7.2.32 
software) and processed manually using the activPAL™ HSCPAL software files. To 
be included in our analysis, participants had to have ≥ 4 days with ≥ 10 hours of waking 
wear time in a 24-hour period including one weekend day, and have ≥ 3 valid nights 
(i.e. valid night having total sleep duration ≥ 160 minutes per night (326)) including 
one weekend night – either Friday or Saturday night. The reason for these inclusion 
criteria was to attempt to get a measure of usual sleep. 
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For each participant, information on sleep onset and offset, sleep time (duration) and 
sleep quality variables were extracted and calculated by using event file of the HSC 
PAL analysis software version 2.14, more details provided in Chapter II. 
 
6.3. Statistical Analyses  
All study variables were screened for normality, and normally distributed data 
summarised either as mean (SD) for normally distributed data or as median 
(interquartile range) for data that were not normally distributed. Since children with 
chronic disease were matched pairwise with healthy controls (for age, sex, and time of 
year), paired t-tests were used to test the significance of any differences between 
children with particular illness vs their healthy controls for each of the sleep behaviour 
(quantity and quality) components. Then all children with chronic disease were tested 
compared with their healthy controls for each of the sleep behaviour (quantity and 
quality) components. 
 
Statistical significance was set at a cut-off value of ≤ 0.05. Details of the study power 
calculation are described in detail in Chapter II section 2.2.4. 
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6.4. Results 
The details of the recruitment process, accelerometer results, characteristics of 
participants and summary details of the study participants are described in Chapter II 
Section 2.6. 
6.4.1. Nocturnal Sleep Behaviour Variables in Children with Chronic 
Disease and Healthy Controls 
Tables 6.1 and 6.2 summarises the nocturnal sleep behaviour (quantity and quality) 
variables measured objectively of children with chronic disease compared to healthy 
controls. 
 Sleep Quantity Variables in Children with Chronic Disease 
and Healthy Controls 
Sleep quantity measures (Sleep onset, sleep offset, sleeping time “sleep duration per 
24h period”, sleep percentage per 24 h period and number of participants meeting the 
sleep recommendation per night) are shown Table 6.1. 
 
The mean time of nocturnal sleep duration in children with chronic disease compared 
to healthy controls was significant in children with JIA was significant (paired t-test p 
= 0.0007), but the difference was not significant in children with T1DM (paired t-test 
p=0.12), in children with CHD (paired t-test p =0.52) and in children with CF (paired 
t-test p =0.30). As well, the difference between all children with chronic disease (n=80) 
compared with healthy controls (n=80) in sleep duration was significant (paired t-test 
p=0.001). 
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 Sleep Quality in Children with Chronic Disease and Healthy 
Controls 
Table 6.2 presents sleep quality-related variables obtained from 24 h thigh-worn 
accelerometry data in all children with chronic disease and healthy controls. 
 
Children with T1DM and their Healthy Controls 
Our results showed that, six (30%) children with T1DM accumulated sleep in a single 
episode, ten (50%) in two episodes, while four (20%) had three or more episodes per 
night. Thus six (30%) of children with T1DM had no wake episodes per night, ten 
(50%) had one wake episode per night and four (20%) of children had two or more 
wake episodes per night. In their matched controls, seventeen (85%) accumulated sleep 
in a single episode and the other three (15 %) had two sleep episodes per night. Thus, 
seventeen (85%) of healthy controls had no wake episodes, three (15 %) of the healthy 
control group had only one wake episode per night and none of the controls had more 
than one wake episode per night.  
 
Next, we looked at quality of sleep in children with T1DM and control group in relation 
to duration of nocturnal sleep disruption per night (average total wake time per night). 
Mean total disrupted sleep duration in children with T1DM was 17 minutes (SD 20 
minutes) per night compared to controls with an average 5 (SD 7 minutes) per night. 
The difference was significant (paired t-test p = 0.03). 
 
Children with JIA and their Healthy Controls 
Seven (35%) of children with JIA accumulated sleep in a single episode, eleven (55%) 
in two sleep episodes, and two (10%) in three sleep episodes per night. Thus seven 
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(35%) of the children with JIA had no wake episodes, eleven (55%) one wake episode, 
and two (10%) of JIA children had two wake episodes per night. In comparison, 
eighteen (90%) of healthy controls accumulated sleep in a single episode, and two 
(10%) in two sleep episodes and thus eighteen (90%) of healthy controls had no wake 
episode and two (10%) of them had one wake episode.  
 
With regards to the duration of total sleep disrupted in children with JIA compared to 
healthy controls, children with JIA had an average of 13 minutes (SD 22 minutes) per 
night disrupted compared to healthy children who had an average of 7 minutes (SD 5 
minutes) disrupted per night. This difference was not significant (paired t-test p = 0.20).  
 
Children with CHD and their Healthy Controls 
In children with CHD, two (10%) accumulated sleep in one episode, seven (35%) in 
two episodes and eleven (55%) in three or more sleep episodes. Thus, two (10%) 
children with CHD had no wake episodes per night, seven (35%) had one wake episode 
per night and eleven (55%) had two or more wake episodes per night. While in healthy 
controls, sixteen (80%) accumulated sleep in a single episode and four (20%) in two 
sleep episodes. Therefore, sixteen (80%) of the healthy controls had no wake episode 
and four (20%) of healthy controls had one wake episode per night.  
 
In term of duration of total sleep disrupted in children with CHD and healthy control, 
there was a significant difference in total disrupted sleep duration, in children with CHD 
mean 24 minutes (SD 30 minutes) per night and healthy control group mean 6 minutes 
(SD 4 minutes) per night (paired t-test p = 0.01). 
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Children with CF and their Healthy Controls 
Three (15%) of children with CF accumulated sleep in one episode per night, five (25%) 
in two episodes and twelve (60%) in three or more episodes per night. Only three (15%) 
of children with CF had no wake episodes, five (25%) had one wake episode and twelve 
(60 %) had two or more wake episodes per night. Seventeen (85%) of healthy controls 
accumulated sleep typically in a single episode and three (15%) in two episodes per 
night and thus seventeen (85%) healthy controls had no wake episodes and three (15%) 
had one wake episode.  
 
Additionally, the duration of total sleep disrupted per night in children with CF was a 
mean of 24 minutes (SD 13 minutes) per night while in the healthy controls the mean 
was 5 minutes (SD 5 minutes) per night. The difference between the two groups was 
significant (paired t-test p = 0.0001).  
 
All Children with Chronic Disease (n=80) Compared with Healthy Controls 
(n=80) 
Our results showed that, eighteen (23%) children with chronic disease accumulated 
sleep in a single episode, thirty-three (41%) in two episodes, while sixteen (20%) had 
three episodes, thirteen (16%) had four or more episodes per night. Thus eighteen (23%) 
children with chronic disease had no wake episodes per night, thirty-three (41%) had 
one wake episode per night, sixteen (20%) of children had two and thirteen (16%) had 
three or more wake episodes per night. In their matched healthy controls, sixty-eight 
(85%) accumulated all sleep time in a single episode and eleven (14%) had two sleep 
episodes per night, the other one (1%) had three sleep episodes per night. Thus, sixty-
eight (85%) of healthy controls had no wake episodes per night, eleven (14%) of the 
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healthy control group had only one wake episode per night and one (1%) of the controls 
had two wake episodes per night. 
 
Next, we evaluated the quality of sleep in children with chronic disease and controls as 
measured by the duration of nocturnal sleep disruption per night (average total wake 
time per night). Mean total disrupted sleep duration in children with chronic disease 
was 20 minutes (SD 22 minutes) per night compared to controls with an average 6 (SD 
5 minutes) per night. The difference between groups was significant (paired t-test p = 
0.0001). 
 
6.4.2. Comparisons of Sleep Duration with Recommendations 
As noted in Chapter V, on average the sleep duration across all groups – children with 
chronic disease and healthy control groups - was within current guideline 
recommendations (i.e. sleep duration 10 - 13 h per night in children aged 3-4 years, and 
9 - 11 h per night in children aged 5-13 years, with consistent bed and wake-up times 
(131, 132)). However, 23 participants (n=10 in children with chronic disease, and 
(n=13) in healthy control groups) did not meet the sleep duration recommendation. 
From each group those not meeting the sleep duration recommendation were as follows: 
three (boy and two girls) in children with T1DM and four (two boys and two girls) in 
their healthy peers, five (two boys and three girls) in healthy control of JIA group, three 
(two boys and girl) in CHD and two (boy and girl) in their healthy peers, four (two boys 
and two girls) in CF and two (boy and girl) in their healthy control groups; was below 
the sleep recommendation as summarised in Table 6.1. 
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In summary, these observations suggest that sleeping time in children with chronic 
disease is generally longer and starts slightly earlier than in their healthy peers except 
in those with CF. There are also slightly more wake episodes due to disrupted sleep 
time in children with chronic disease compared to the healthy age and sex matched 
children and the amount of disturbed sleep in each group was significantly greater than 
in the healthy children except in JIA group. However, in the present study the overall 
duration of sleep was similar between the healthy control and chronic disease groups, 
and in the main children appeared to be meeting current sleep duration 
recommendations. 
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Table 6.1: Nocturnal sleep quantity-related variables based on 24-hour accelerometer data in children with chronic disease and healthy controls. Data are presented as means and 
standard deviation (SD) 
 
Variables 
CD 
(n=80) 
HC 
(n=80) 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
Sleep onset hr:mm 
21:16 
(01:03) 
21:45 
(01:13) 
21:32 
(01:13) 
21:41 
(01:34) 
20:54 
(00:56) 
22:17 
(00:50) 
20:43 
(01:26) 
21:23 
(01:38) 
21:57 
(00:40) 
21:40 
(00:52) 
Sleep offset hr:mm 
07:45 
(00:44) 
07:53 
(00:31) 
07:59 
(00:33) 
07:52 
(00:22) 
07:34 
(00:39) 
07:50 
(00:38) 
07:42 
(01:08) 
08:04 
(00:38) 
07:45 
(00:37) 
07:48 
(00:26) 
Time spent in sleep 
h 
10.1 (0.8) 
** 
9.7 (0.6) 
** 
10.2 (0.7) 9.7 (0.6) 
10.4 (0.8) 
*** 
9.5 (0.5) 
*** 
10.2 (0.9) 9.7 (0.5) 9.7 (0.9) 9.9 (0.5) 
% of sleep per 24 h 42.1 (3.3) 40.4 (2.8) 42.5 (2.9) 40.4 (2.8) 43.3 (3.2) 39.6 (2.1) 42.5 (3.9) 40.6 (2.1) 40.4 (2.8) 41.2 (2.2) 
No of Not meeting 
sleep 
recommendation 
10 13 3 4 0 5 3 2 4 2 
CD – chronic disease; CHD – congenital heart disease; CF – cystic fibrosis; T1DM – type1diabetes mellitus; JIA – juvenile idiopathic arthritis.  
Combined data represented total children with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), and F: M 43: 37) as one group and total healthy controls n=80, mean age 6.8 
(SD=1.9) and F: M 43: 37) as one group. Further details of participants characteristics data in Chapter II and Table2.1. 
Data are presented as means and standard deviation SD unless otherwise specified. 
Paired t test compared sleep period time between children with chronic disease and healthy children control age and sex matched; * significant difference and P< 0.05, ** P< 0.005 and 
***P= <0.0005. 
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Table 6.2: Nocturnal sleep quality-related variables based on 24-hour accelerometer data in children with chronic disease and healthy controls. Data are presented as means 
and standard deviation (SD) 
Variables 
CD 
(n=80) 
HC 
(n=80) 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
NO. of sleep 
episode 
1 sleep episodes: 
2 sleep episodes: 
3 sleep episodes: 
≥ 4 sleep episodes: 
 
18 (23%) 
33 (41%) 
16 (20%) 
13 (16%) 
 
68 (85%) 
11 (14%) 
1 (1%) 
0 
 
6 (30%) 
10 (50%) 
2 (10%) 
2 (10%) 
 
17 (85%) 
3 (15%) 
0 
0 
 
7 (35%) 
11 (55%) 
2 (10%) 
0 
 
18 (90%) 
2 (10%) 
0 
0 
 
2 (10%) 
7 (35%) 
6 (30%) 
5 (25%) 
 
16 (80%) 
3 (15%) 
1 (5%) 
0 
 
3 (15%) 
5 (25%) 
6 (30%) 
6 (30%) 
 
17 (85 %) 
3 (15%) 
0 
0 
NO. of wake 
episode: 
0 wake episode: 
1 wake episodes: 
2 wake episodes: 
≥ 3wake episodes: 
 
18 (23%) 
33 (41%) 
16 (20%) 
13 (16%) 
 
68 (85%) 
11 (14%) 
1 (1%) 
0 
 
6 (30%) 
10 (50%) 
2 (10%) 
2 (10%) 
 
17 (85%) 
3 (15%) 
0 
0 
 
7 (35%) 
11 (55%) 
2 (10%) 
0 
 
18 (90%) 
2 (10%) 
0 
0 
 
2 (10%) 
7 (35%) 
6 (30%) 
5 (25%) 
 
16 (80%) 
3 (15%) 
1 (5%) 
0 
 
3 (15%) 
5 (25%) 
6 (30%) 
6 (30%) 
 
17 (85 %) 
3 (15%) 
0 
0 
Duration of wake 
episode minutes 
11.2 (13.2) 1.4 (2.1) 9.9 (13.8) 1.3 (2.0) 5.5 (9.2) 1.6 (2.5) 12.1 (17.6) 0.9 (1.8) 17.3 (12.5) 1.6 (1.9) 
Duration of sleep 
episodemovement 
minutes/night 
8.4 (13.1) 4.7 (4.3) 7.1 (8.9) 4.1 (5.6) 7.7 (20.1) 5.4 (3.7) 11.5 (16.4) 5.4 (3.9) 7.1 (7.1) 3.8 (4.0) 
Total sleep 
disrupted 
minutes/ night 
19.6 (21.9) 
*** 
6.1 (5.4) 
*** 
17 (20.8) 
* 
5.4 (7.1) 
* 
13.2 (22.9) 6.9 (5.0) 
23.6 (30.7)  
** 
6.4 (4.5) 
** 
24.4 (13.3) 
*** 
5.4 (5.1) 
*** 
Abbreviations: CD – chronic disease; CHD – congenital heart disease; CF – cystic fibrosis; T1DM – type1diabetes mellitus; JIA – juvenile idiopathic arthritis.  
Combined data represented total children with chronic disease (CD n=80, mean age 6.9 years (SD=2.0), and F: M 43: 37) as one group and total healthy controls n=80, mean age 6.8 
(SD=1.9) and F: M 43: 37) as one group. Further details of participants characteristics data in Chapter V and Table 5.1. 
Data are presented as means and standard deviation SD unless otherwise specified. Paired t test compared total sleep disrupted time between children with chronic disease and healthy 
children control age and sex matched; * significant difference and P< 0.05, ** P< 0.005 and ***P= <0.0005. 
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6.5. Discussion  
6.5.1. Main Findings and Study Implications 
Despite considerable recent interest in the sleep quantity and quality in children, there 
are currently few published data (453), and there are even fewer data from children 
with any chronic disease using objective measurement (128, 129). Thus, our study 
appears to be the one of the first to attempt to quantify sleep behaviour in children with 
common childhood diseases using accelerometry to provide an objective measure, and 
to test for differences in the quantity and quality of sleep between those children with 
chronic disease and healthy controls.  
 
Our findings show that overall children with T1DM, JIA and CHD slept longer than 
age and sex matched healthy controls, though differences between groups were 
significant in only the JIA group. Differences between chronic disease and healthy 
control groups were fairly small and appear to have been due to differences in 
bedtimes, with healthy children apparently going to bed around forty minutes later 
than children with chronic disease, and with both groups waking up at around the same 
time. The cause of earlier sleep onset in children with chronic disease is not 
understood. It could be either a consequence of the disease itself or socially 
conditioned by the parents, questions which will require further research. 
Taken together, these observations suggest that objectively measured overnight sleep 
duration differs slightly but significant between children with chronic disease and 
healthy These small and generally significant differences observed in the present study 
will have to be tested in larger studies to confirm if they are real and reproducible. In 
all groups recommended sleep times were achieved on average, so there was no major 
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concern over sleep duration. 
The next part of our study addressed sleep quality in children with chronic disease 
compared to healthy controls. This study noted several striking ﬁndings regarding the 
difference in quality of sleep between children with chronic disease and healthy 
children control age and sex matched. First of all, although, the sleep duration in 
children with chronic disease was generally slightly longer than in control groups 
except in children with CF, in all groups it was more disrupted than in healthy children: 
eighteen (23 %) of the children with chronic disease compared with sixty-eight (85 %) 
of healthy controls accumulated sleep in a single episode. Thus, 77 % of children with 
chronic disease had at least one wake episode per night and most of them had more 
than two wake episodes per night, while 10 % healthy control had one wake episode 
and only 5 % had two wake episodes per night. Furthermore, children with chronic 
disease in the present study had longer duration of disruption than age and sex matched 
healthy controls, though differences between groups were significant only in the CHD 
and CF groups.  
 
Previous studies of sleep and sleep disorders in children and adolescents suggested 
that causes of sleep disturbance can be emotional (e.g., anxiety) or behavioural 
dysregulation (e.g., bedtime refusal), interfering with sleep or further exacerbating 
underlying sleep disruption (113, 456). Our study suggests that children with chronic 
disease appear to have more sleep disturbances when compared to healthy controls. 
As noted briefly in Chapter I, these differences in the patients groups compared to the 
controls might relate to the disease itself and/or disease severity. In diabetic children 
with poor glyceamic control for example, the high level of blood sugar might affect 
sleep by dehydration prompting the child to get up for regular glasses of water, and 
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more frequent urination, also low blood sugar levels could cause shakiness, dizziness 
and sweating, and all these could affect their sleep quality. In children with JIA, pain 
might be the main contributor to sleep disturbance (200, 223), and the effects of 
medication might also have an influence (most of the participants with JIA in our study 
were on biological treatment (128)). In our study sample children with CF had stable 
lung disease with good lung function and nutritional status making it unlikely that gas 
exchange abnormalities were the main cause for sleep disruption. Whether nocturnal 
cough accounted for the disturbance will require further study (129). However, at 
present, all these possible reasons for the observed differences are hypothetical and 
will require furthermore detailed studies. 
 
6.5.2. Comparisons with Recommendations 
The mean sleep duration in children with chronic disease and healthy control groups 
was within the range 10 - 13 h per night in children aged 3-4 years, and 9 - 11 h per 
night in children aged 5-13 years, with consistent bed and wake-up times and in 
accordance with what is recommended for children (131, 132). However, 14.4 % of 
participants (6.3 % in children with chronic disease and 8.1% in healthy control 
groups) did not meet the sleep duration recommendation and slept less than 
recommended amount. 
 
6.5.3. Comparisons with Other Studies  
We believe that the present study is the first study to ask whether objectively measured 
levels of sleep are adequate in children with chronic childhood disease. Hence there 
are no directly comparable studies, but we note that our findings are somewhat 
inconsistent with previous research examining sleep timing and duration in healthy 
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children objectively. One particular example is in the International Study of Childhood 
Obesity Lifestyle and the Environment (326) study. ISCOLE was a cross-sectional 
study, which included 6106 children aged 9-11 years from sites in Australia, Brazil, 
Canada, China, Colombia, Finland, India, Kenya, Portugal, South Africa, United 
Kingdom and United States of America. Sleep duration was assessed by using 24-h 
waist-worn accelerometers (GT3X+, ActiGraph LLC) over seven consecutive days. 
They reported that average sleep onset was at 20:18, sleep offset at 07:07, with sleep 
duration averaging 8.8 hours per night. Fifty seven point seven per cent of the healthy 
children accumulated less than recommended sleep duration and 7.8% accumulated 
more than recommended sleep (326), so in total around two thirds of the ISCOLE 
participants did not meet sleep duration recommendations. The methodological 
difference between the present study (activPAL based) and the ISCOLE study 
(ActiGraph GT3X+ based) might be important, as well as differences in the ages of 
the samples in ISCOLE (9-11 years) and the present study (3-10 years).  
Together, these data provide preliminary evidence that there may be a difference in 
sleep quantity and sleep quality between healthy children and those with chronic 
disease in mid-childhood. It is recommended that this be confirmed in different age 
groups, and different chronic diseases.  
 
6.5.4. Study Strengths and Limitations 
The main strength of the present study was in answering the research questions in a 
novel but important population vis. groups of children with common chronic disease. 
Further strengths are that our study investigated objective sleep behaviour (quantity 
and quality parameters) in children living with childhood chronic disease compared to 
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closely match healthy controls so that the main influences on the behaviours (age, sex, 
time of year) were all controlled for by the paired design.  
 
In addition, there are several other methodological strengths to this study: the 
participants were diverse and were composed of children with chronic disease and 
healthy children, both male and female. Further, the measures of sleep were detailed 
and quantitative due to the objective measurement methods used, and our ability to 
make objective measures of sleep behaviours (quantity and quality parameters). The 
most practical method was used rather than a gold standard method. There were 
practical constraints on my time and the equipment available, and the issue of burden 
to participating families was important too. Polysomnography was not a feasible 
option in our study; and of the alternatives, objective measurements are more accurate 
than using a subjective methods (self-reports/parent reports) (286, 310, 311) (286, 310, 
311); self-reports tend to underestimate night awakenings and overestimate sleeping 
time and thus might not convey as accurate or complete a picture of children’s sleep 
(457). A highly standardised measurement protocol was used and the sleep behaviours 
(sleep quantity and quality) were measured across a sufﬁcient number of nights to 
obtain a reliable assessment of the participants’ usual sleep behaviours by using 
ActivPALTM accelerometer. Family and child compliance with the activPAL protocol 
was very high, at least for those families who met study inclusion criteria and whose 
data could be retained. Moreover, the methods used were the same between patient 
and control groups and so any methodological biases in sleep variables probably apply 
fairly equally to both groups so between-group comparisons can be made. Thus, we 
believe our results provide a reasonably valid and reliable picture of sleep behaviour 
for the children with chronic disease and healthy children across 7 days. However, the 
gold standard methods would be needed to confirm our conclusions. 
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The study also had some limitations. The study design was cross-sectional, and 
antecedent-consequent relationships could not be made in regards to the associations 
observed. Further, the combined analysis was exploratory data and can only provide 
preliminary evidence. However, these children were children with a history of a 
chronic disease who were attending follow-up appointments but were apparently 
healthy and living at home at the time of recruitment. It is also important to 
acknowledge the possibly limited generalisability of our findings to other groups of 
children with different chronic diseases, or to children with the same chronic diseases 
as recruited to the present study, but with more severe/advanced forms of disease (or 
during disease exacerbations) is not known at present. Although, in each group of 
children with chronic disease in our study there was a spectrum of illness with a 
number of children at the more severe end of the spectrum, in children with more 
severe chronic disease there might be significantly less sleep time and poorer sleep 
quality, than observed in the present study. In our study the participants age range-
covered childhood did not include either adolescence or early childhood so 
generalisability to chronic disease effects on sleep in younger or older disease groups, 
or to different chronic diseases is not possible. To address this, it would be advisable 
to replicate this research with these methods in children from different age groups and 
with these and other chronic diseases. A further limitation included the fact that there 
is no currently available methodology that applies automated measurements to young 
school age children.   
 
Finally, our power calculations suggested that 160 participants – 80 children with 
chronic disease and 80 children healthy controls would be sufficient, but in fact some 
of the differences within the individual disease categories when considered separately 
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were small. Larger studies may be required to determine the significance of differences 
between some of the groups. However, the statistical significance or otherwise of some 
of the differences may in fact be of secondary importance - the main findings of the 
present study probably relate to the biological/clinical significance of the observed in 
those with chronic disease had apparently adequate levels of sleep with slightly lower 
sleep quality than their peers due to more time in wakefulness during the night rather 
than less time spent in bed, at least during early-mid childhood. Small differences 
sustained over long time periods, as children get older may have a significant 
cumulative impact in relation to longer-term health. 
 
6.6. Conclusions 
In conclusion, the present study provides evidence that there may be slight but 
systematic differences in both sleep quantity and quality between children with chronic 
disease and healthy children. In children with chronic disease generally slept longer 
and started sleeping slightly earlier than in their healthy peers, except in children with 
CF. Sleep is also more disrupted sleep in those with chronic disease than healthy 
children. Future efforts aimed at examining sleep quantity and quality in children with 
other common chronic disease should be considered. 
 
 
  
 
 
 
 
 
 
 
CHAPTER VII 
GENERAL DISCUSSION 
 
Chapter VII 
 
248 
7.1. General Discussion 
Recent evidence-based guidelines (131-133) have concluded that PA, SB and sleep 
have important roles in the physical development of children and impact on health 
outcomes in childhood and in adulthood (14, 112). Several epidemiological studies in 
children have reported that low levels of PA and insufficient sleep in children are 
linked with unfavourable health outcomes e.g. obesity and development of chronic 
diseases such as diabetes and cardiovascular diseases in later life (97, 440, 456, 458, 
459).  
 
Low levels of PA are associated with significant exposure to prolonged periods of SB, 
especially in relation to watching television or playing computer games. Increasing 
PA is often considered as the most important principal intervention for primary and 
secondary disease prevention. Some studies have even shown that regular PA during 
treatment for cancer may help adult patients better tolerate treatment-induced side 
effects with improved quality of life (75).  
 
The developing paradigm of 24-hour movement behaviours suggests that the focus on 
PA needs to broaden to consider the whole 24-hour day even in interventions. Viewed 
like that other possibilities than just promoting PA emerge for consideration e.g. 
focusing on reducing SB by swapping some ST for PA and/or sleep (460). The 
paradigm is new and researchers have only recently begun to consider movement 
across the 24-hour period and so there is limited evidence on it, including how best to 
analyse 24-hour data (461). 
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In children with chronic disease, too, there is concern about the amount of PA, 
particularly MVPA, and ST. In our systematic review (Chapter III) across all of 
childhood and adolescence that children with chronic disease accumulated low level 
of MVPA, consistently below the recommended minimum level of 60 minutes per day 
in most of the eligible studies. Compared to healthy children, there were no marked 
differences for patients with T1DM, CVD and chronic respiratory diseases, while in 
those with leukaemia MVPA was significantly lower. Further, children with chronic 
disease accumulated a high amount of ST during their waking hours (291).  
 
Levels of MVPA and ST are also important to health in children and adolescents, and 
unfavourable levels of MVPA and ST may be both causes and consequences of 
obesity. In our second systematic review (Chapter IV), a high percentage of obese 
children and adolescents did not achieve the minimum amount of 60 minutes per day 
MVPA (39), and MVPA levels in children and adolescents with obesity were 
consistently slightly lower than children from healthy control or comparison groups. 
Additionally, all eligible studies, which had comparison groups, found ST was fairly 
consistent, with no marked differences between obese and non-obese peers (385) 
 
Our findings from both systematic reviews provided valuable information about levels 
of MVPA and ST in children and adolescent with chronic disease including in those 
with obesity that may help to stimulate improving PA guidelines, and improving PA 
level for these children. These reviews also call attention to focus on increasing MVPA 
and reducing ST among children and adolescents with chronic disease and those with 
obesity, and the importance of raising these issues in clinical settings as part of their 
treatment. Treatment of those children should clearly involve a focus on increasing 
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MVPA and reducing ST as recommended in multiple evidence based treatment and 
prevention guidelines published in recent years for healthy children (39, 281, 462).  
 
In 2014, the concept of 24-hour movement behaviours began to be used. This sought 
to take account of the fact that only a small amount of any child’s days is involved in 
MVPA – typically around 5%. Further, the different movement behaviours are 
believed to interact and impact on physical health and development in combination 
(22). A small body of research is emerging that quantifies all of the various movement 
behaviours (PA, SB, and sleep) in 24-hour period in healthy children, particularly in 
preschool and school age children (131-133). Collectively, some studies provided 
evidence on compliance of young children to the new 24-hour movement guidelines. 
These suggest that only a small proportion of young children meet the overall 
guidelines e.g. only 10-13% of preschool-aged children were found to meet the new 
24-hour movement guidelines for the early years (133, 463-465). In the recent study 
by Walsh et al (461) of 4,500 United States children aged from 8-11years, only 5 % 
of primary school-age children met all three guidelines, 51% participants met the sleep 
recommendation while 18% met the PA recommendation, as measured by self/parent 
report (461). However, at present, there is very limited evidence about 24-hour 
movement behaviours in children with chronic childhood illnesses, and so the 
adequacy of levels of 24-hour movement behaviours in children with chronic disease 
is unknown.  
 
In order to start to address this research deficit, our aim in (Chapter V) of the present 
thesis was to evaluate the 24-hour movement behaviours in children with chronic 
childhood diseases, focusing on four common chronic childhood disease groups. We 
also explored whether there are differences in levels of 24-hour movement behaviours 
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in those children and their healthy peers. We found that, there were small systematic 
differences between children with chronic diseases in their individual groups and 
healthy matched controls. These were made more obvious when the children with 
chronic disease were compared as a single group with their healthy controls. The most 
important finding obtained from this study was that there were significant differences 
between children with chronic disease and healthy controls for time spent sedentary, 
standing, PA and sleep. Those with chronic disease had greater time spent sedentary 
with significant lower number of sedentary breaks, less standing time with slightly 
longer sleep time than their healthy controls. Time spent in PA was significant lower 
(in both PA time and steps counts) in children with chronic disease compared to 
healthy controls. ST was consistently higher in children with chronic disease, though 
the number of breaks in sitting, reflecting the more prolonged sitting bouts was 
consistently lower in those with chronic disease compared to healthy controls. 
Standing time was also was consistently lower in children with chronic disease. The 
mean time spent in PA and step counts per day were consistently lower in the children 
with chronic disease compared to healthy controls, and 29/80 controls met the daily 
step count recommendations. Time spent asleep was slightly greater in the children 
with chronic disease. 
 
The next study (Chapter VI) examined sleep behaviour (quantity and quality of sleep) 
in children with common chronic childhood diseases. In this study, possibly somewhat 
surprisingly, it was found that sleep duration was consistently slightly longer in those 
with T1DM, JIA and CHD than in age- and sex- matched healthy controls. This 
difference could be due to the time of the sleep onset. Children with chronic disease 
in the present study apparently started to sleep on average around forty minutes earlier 
than their healthy controls, with both groups waking up at around the same time. Sleep 
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disruption was consistently greater in those with chronic disease, reaching significance 
in T1DM, CHD and CF groups. However, mean sleep duration on a group level (both 
in in children with chronic disease and healthy control groups) was within usual 
recommendations (131, 132).  
 
Taken together our activPAL-based studies suggest that among the children with the 
chronic diseases studied compared with matched controls there was a lower PA level, 
higher ST amount, but an apparently adequate amount of sleep although sleep was 
slightly more disrupted in those with chronic disease. In addition, levels of PA were 
lower than recommended in current guidelines for both groups.  
 
Reasons for differences between patient and control groups are unclear. Several prior 
studies had suggested a number of reasons for lower levels of PA in children and 
adolescent with chronic disease including a relation to disease activity or 
cardiorespiratory functional disability (61). However, Fereday et al, had demonstrated 
that, the participation in PA in children with T1DM, with asthma and with cystic 
fibrosis was not hindered by the chronic condition itself (466).  
 
In our studies, in all cases children with chronic disease were recruited while relatively 
well and clinically stable, free of acute illness, and living in the community and 
attending schools/pre-school. The disease severity in the sample ranged from 
mild/moderate to severe, and in the children who had disease for many years (or in 
those with CHD who had cardiac surgery), this could have affected the ability of those 
children to engage in PA (e.g. to play actively, or to be active in sport or during school 
physical education) and could theoretically lead to lowering PA levels, with reduced 
PA being replaced by more ST. Alternatively, lower levels of MVPA in children with 
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chronic disease might be due in part to parental over-protective care as they might see 
their child as especially “vulnerable”, leading to them not permitting their child with 
chronic disease to be engaged in PA to the same extent as their healthy peers (377, 
378), or they may perceive that spending time indoors engaging in ST is a safer option 
and parents may encourage that. Also, at schoolteachers might be more concerned 
about children with chronic disease playing and engaging in activity programmes 
compared to their healthy peers. Indeed, a lack of supervised facilities and 
opportunities for PA, with insufficient knowledge about the suitable types of PA for 
the specific disease condition could be one reason for lowering the PA levels among 
children and adolescents with chronic disease (377, 378). It seems most likely that 
both physio-pathologic as well as issues of socialisation into sport and activity are 
active and contribute to the observed levels of activity.  
 
The low levels of PA among the patient groups suggest that there is a need to address 
this, perhaps by providing disease-specific rehabilitation programmes aimed at 
increasing PA. Such programmes should involve children/adolescents, parents and 
other caregivers, General practitioner and other Healthcare professionals. It would 
probably be helpful if families and all health professionals were able to encourage and 
support children with chronic disease to engage in regular and appropriate PA.  
 
As noted earlier in the thesis there has been a lack of attention in the PA research 
community on children and adolescents with chronic disease. For many years national 
and global Active Healthy Kids Report Cards (467) have attempted to report on and 
increase levels of PA among the general population of children and adolescents. 
Increasing PA levels in children with chronic disease could be achieved through a 
similar knowledge exchange effort aimed at children with chronic disease rather than 
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the general population. One very recent pioneering example of this –from 2018- can 
be found in the Dutch Active Healthy Kids Report Card for those with chronic disease 
(468). This sort of report card for children or adolescents with chronic disease would 
provide useful information for the clinician regarding recommendations and 
contraindications for PA, and both parents and affected children/adolescents could 
gain reassurance about PA, exercise and participation in sport (468). Further, the report 
card emphasises the important role, which parents and family have an increasing the 
PA levels and reducing ST in this group of children. Report cards and disease-specific 
rehabilitation programmes could help parents, family and other caregivers to improve 
their child’s PA, possibly by including a simple 24-hour perspectives that provides 
examples such as the trading of indoor time for outdoor activity, so replacing SB with 
PA.  
 
Further, the variety of childhood chronic diseases makes it difficult to speculate as to 
what future chronic disease guidelines might look like, or the extent to which they 
might need to be disease-specific. Even within childhood chronic disease there is such 
variety in disease severity and other factors (e.g. age) that developing disease specific 
guidance would not be easy also speculated that a good deal of evidence on 
associations between movement behaviours and health outcomes in chronic disease 
groups would be needed to establish if disease specific recommendations were needed. 
We are a long way from having that sort of evidence just now. most recent 24 hour 
movement guidelines and physical activity guidelines state that they are applicable for 
children with chronic disease, while recommending that a healthy professional should 
be consulted for additional guidance (132) such that (a) such children might have to 
reach recommendations gradually, and (b) the limitations of the chronic disease, and 
safety issues, should be considered when families are trying to reach the 
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recommendations. I hope this work will start to highlight that a more secure evidence 
base is needed for such recommendations 
 
However, the thesis data shows that in healthy children too, there is high probability 
that levels of the 24-hour movement behaviours will get worse with age - PA declines 
and SB goes up with age and increasing SB displaces PA and eventually sleep too by 
the time of adolescence (156, 158, 437). Thus it is likely that levels of all the 24hour 
movement behaviours would be likely to change (at least on average) if the children 
with chronic disease studied in this thesis were studied again when older. Levels of 
movement behaviours in the present study may actually be relatively favourable 
because of the relatively young age of the study participants. 
 
One of the implications from the present study is that it suggests that the activPALTM 
is a good tool for objective measurement of many of the 24hour movement behaviours 
and so could be more widely used in paediatric populations in future. The activPAL 
has not been used to any great extent to measure 24-hour movement behaviours 
previously. However, it cannot measure all of the 24-hour movement behaviours - as 
noted in the individual studies/chapters as it does not currently measure MVPA, screen 
time, and cannot differentiate between sitting and lying postures. These are important 
limitations and future studies should try to measure these behaviours, though methods 
to do so are not very practical at present. The validity of the simple and widely used 
self or parent report measures -e.g. parent reported screen time – is unclear at the 
moment. A further complication of interpretation of thesis findings is that there are no 
national or international guidelines for time spent in standing and total ST. However, 
thesis data provide preliminary evidence that there may be small but clear differences 
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in 24-hour movement behaviours between children with chronic childhood disease and 
their healthy peers.  
 
As noted above, the field of 24 movement behaviours is quite new and there are new 
developments in data analysis as well as in measurement methods underway. In future 
studies we would like to consider use of 'compositional analysis'. This is a statistical 
approach that explores the integrated time spent in the 24-hour movement behaviours 
(sleep, sedentary behavior, physical activity – light, moderate and vigorous) (433, 
469). 
 
“Compositional analysis is about changing how we conceptualize data from 
the standard real space to the constrained simplex space perspective. This 
requires that we abandon thinking of each behavior as an independent variable 
and, instead, view them as relative to the other ones (470). “ 
 
Compositional analysis provides a different approach to analysis, which might be 
informative, but as this approach is new and complex, and there was limited time, there 
was not the chance to use this analysis in the present thesis, so for the author this is a 
technique for the future. 
 
For all the studies in this thesis, we instructed our participants to maintain their usual 
daily PA and sleep habits during the study, but they might have altered their habits as 
a consequence of taking part. It is currently not clear whether or to what extent children 
and families change their 24-hour movement behaviours when taking part in studies, 
but PA studies using accelerometry are not considered to be affected by ‘reactivity’ 
(471, 472). 
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 The limited age range and number of chronic disease groups included in the thesis 
studies mean that to increase generalisability, further research with more participants 
and in different age group also with different chronic childhood diseases will be 
needed. Further, as disease activity and functional disability could be a reason for 
lower PA levels and sleep disturbance in those with chronic disease (and in our study 
disease activity was mostly mild/moderate), it would be advisable to replicate this 
work with patients with more active and more severe disease to increase understanding 
of the association between different disease severities and 24-hour movement 
behaviours. If the 24-hour movement behaviours deteriorate a lot in older children 
and/or as their disease progresses that might provide useful information, which could 
help in the clinical management of those children and could help them and their parents 
balance the disease burden with a healthier lifestyle.  
 
Future research efforts should also include the possibility of interventions for some or 
all of 24h movement behaviours, and in a wider range of groups of children with 
chronic disease. 
 
To gain a better understanding of 24-hour movement behaviours in children with 
chronic diseases to future reviews should consider other groups of disease such as 
musculo-skeletal and neurological disease, and also, should investigate the factors 
impacting on the behaviours in these populations (correlates or determinants of the 24-
hour movement behaviours). 
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7.2. Conclusions and Relevance 
Several conclusions can be drawn from this work. The systematic literature reviews 
showed that levels of MVPA in children and adolescents with chronic disease and in 
those with obesity appear to be well below recommendations, although similar to those 
of their contemporary healthy peers (except for children with malignancies and with 
obesity). Children with chronic disease tend to spend the majority of their waking 
hours sedentary and their ST is often higher than in their healthy peers. Thus, a 
substantial effort and appropriate disease intervention strategies are likely to be 
required to increase MVPA and reduce ST among children with chronic disease.  
 
The systematic review findings were somewhat consistent with our finding in the 
studies of objectively measured 24-hour movement behaviours in children with 
chronic disease and their healthy peers. This study suggests that for at least some 
groups with chronic disease 24-hour movement behaviours may differ substantially 
from recommendations and differ slightly but systematically from their healthy peers.  
 
The most obvious concerns in the present study arising from differences between 
patient and control groups relate to the greater ST in children with chronic disease, and 
the evidence that the number of sitting bouts was consistently lower (more prolonged 
sitting bouts) in those with chronic disease. Also, children with chronic disease were 
consistently less active than their healthy controls, operationalised both in the 
accelerometer-measured time spent in PA and in the step counts, and time spent in 
sleep was slightly longer in children with chronic disease. Sleep duration was generally 
within recommended values but there was evidence that sleep in children with chronic 
disease was slightly more disrupted compared to the healthy controls. Finally, it is 
becoming clear that optimising levels of 24-hour movement behaviours should confer 
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a number of benefits for child health, development, and wellbeing and so there is a 
need for further research with a clinical focus on these behaviours in those with chronic 
disease (131-133). 
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APPENDIX I 
Search strategies of systematic literature reviews 
The search strategies that used to search in the electronic databases: Medline, 
Cochrane library, EMBASE, SPORT Discus and CINAHL  
A. EMBASE (ovid):  
1. exp Child/ 
2. exp Adolescent/ 
3. (child* or adolesc* or teen* or youth or girl* or boy*).tw. 
4. (young adj1 (person or people)).tw. 
5. 1 or 2 or 3 or 4 
6. exp Exercise/ 
7. exp Motor Activity/ 
8. exp Sports/ 
9. exercis*.tw. 
10. physical* activ*.tw. 
11. (active adj2 (living or lifestyle)).tw. 
12. sedentary behavi?r.tw. 
13. exp Sedentary Lifestyle/ 
14. ((sedentary or sitting or screen or TV or television or computer or PC or video 
games) adj2 time).tw. 
15. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. exp Obesity/ or exp Overweight/ 
17. (overweight or obes*).tw. 
18. exp Accelerometry/ 
19. exp Actigraphy/ 
20. acceleromet*.tw. 
21. actigraph.tw. 
22. activity monitor*.tw. 
23. (objective adj1 (measure* or monitor* or assess*)).tw. 
24. 18 or 19 or 20 or 21 or 22 or 23 
25. exp cardiovascular abnormalities/ or exp heart diseases/ 
26. exp Cardiovascular Abnormalities/ 
27. exp Heart Diseases/ 
28. "congenital heart disease".tw. 
29. "Atrial Septal Defect".tw. 
30. "Complete Atrioventricular Canal Defect ".tw. 
31. "Ventricular Septal Defect".tw. 
32. (Tetralogy adj2 Fallot).tw. 
33. exp Asthma/ 
34. asthma.tw. 
35. exp Respiratory Tract Diseases/ 
36. exp Respiratory Hypersensitivity/ 
37. exp Cystic Fibrosis/ 
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38. (respiratory adj2 allerg*).tw. 
39. "cystic fibrosis".tw. 
40. wheez*.tw. 
41. exp Bronchopulmonary Dysplasia/ 
42. lung diseases/ or exp alpha 1-antitrypsin deficiency/ or exp "cystic adenomatoid 
malformation of lung, congenital"/ or exp hepatopulmonary syndrome/ or exp 
hypertension, pulmonary/ or exp lung diseases, fungal/ or exp lung diseases, 
interstitial/ or exp lung diseases, obstructive/ or exp lung diseases, parasitic/ or exp 
lung injury/ or exp lung neoplasms/ or exp lung, hyperlucent/ 
43. "chronic lung disease".tw. 
44. "chronic respiratory disease".tw. 
45. exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/ 
46. (diabetes adj1 mellitus).tw. 
47. exp Leukemia/ 
48. Leukemia.tw. 
49. exp Lymphoma/ 
50. Lymphoma.tw. 
51. exp Neuroblastoma/ 
52. Neuroblastoma.tw. 
53. "Wilms’ tumor".tw. 
54. exp Central Nervous System Neoplasms/ 
55. exp Sleep Apnea Syndromes/ 
56. "sleep apnea".tw. 
57. 16 or 17 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 
37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 
or 52 or 53 or 54 or 55 or 56 
58. 5 and 15 and 24 and 57 
59. exp Adult/ 
60. 58 not 59 
61. limit 60 to (english language and yr="2000 -Current") 
 
B. Cochrane Central Register of Controlled Trials:  
#1 MeSH descriptor: [Child] explode all trees 
#2 MeSH descriptor: [Adolescent] explode all trees 
#3 child* or adolesc* or teen* or boy* or girl* or youth:ti,ab,kw  (Word variations 
have been searched) 
#4 young near/1 (person or people):ti,ab,kw  (Word variations have been 
searched) 
#5 #1 or #2 or #3 or #4  
#6 MeSH descriptor: [Motor Activity] this term only 
#7 MeSH descriptor: [Exercise] explode all trees 
#8 MeSH descriptor: [Sports] explode all trees 
#9 MeSH descriptor: [Sedentary Lifestyle] explode all trees 
#10 physical* activ*:ti,ab,kw  (Word variations have been searched) 
#11 exercis* or sport*:ti,ab,kw  (Word variations have been searched) 
#12 active near/2 (living or lifestyle):ti,ab,kw  (Word variations have been 
searched) 
#13 sedentary behavi?r:ti,ab,kw  (Word variations have been searched) 
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#14 (screen or sedentary or sitting or TV or television or computer or PC or video 
games) near/2 time:ti,ab,kw  (Word variations have been searched) 
#15 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14  
#16 MeSH descriptor: [Accelerometry] explode all trees 
#17 acceleromet*:ti,ab,kw  (Word variations have been searched) 
#18 actigraph*:ti,ab,kw  (Word variations have been searched) 
#19 activity near/1 monitor*.:ti,ab,kw  (Word variations have been searched) 
#20 #16 or #17 or #18 or #19  
#21 MeSH descriptor: [Overweight] explode all trees 
#22 overweight or obes*:ti,ab,kw  (Word variations have been searched) 
#23 MeSH descriptor: [Heart Defects, Congenital] explode all trees 
#24 "Congenital Heart Disease":ti,ab,kw  (Word variations have been searched) 
#25 "Atrial Septal Defect" or "Coarctation of the Aorta" or "Complete 
Atrioventricular Canal defect" or "Ventricular Septal Defect" or "Tetralogy of 
Fallot":ti,ab,kw  (Word variations have been searched) 
#26 MeSH descriptor: [Hypertension] explode all trees 
#27 hypertension:ti,ab,kw  (Word variations have been searched) 
#28 high near/1 (blood pressure):ti,ab,kw  (Word variations have been searched) 
#29 MeSH descriptor: [Cardiomyopathies] explode all trees 
#30 Cardiomyopath*:ti,ab,kw  (Word variations have been searched) 
#31 MeSH descriptor: [Respiratory Tract Diseases] explode all trees 
#32 respirator* near/1 disease*:ti,ab,kw  (Word variations have been searched) 
#33 asthma*:ti,ab,kw  (Word variations have been searched) 
#34 respiratory near/1 allerg*:ti,ab,kw  (Word variations have been searched) 
#35 MeSH descriptor: [Sleep Apnea Syndromes] explode all trees 
#36 sleep near/1 apnea:ti,ab,kw  (Word variations have been searched) 
#37 pulmonary near/1 hypertension:ti,ab,kw  (Word variations have been searched) 
#38 MeSH descriptor: [Cystic Fibrosis] explode all trees 
#39 "cystic fibrosis":ti,ab,kw  (Word variations have been searched) 
#40 "Broncho-pulmonary dysplasia":ti,ab,kw  (Word variations have been 
searched) 
#41 "Bronchopulmonary dysplasia" or "Broncho pulmonary dysplasia":ti,ab,kw  
(Word variations have been searched) 
#42 MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees 
#43 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees 
#44 "diabetes mellitus" or diabet*:ti,ab,kw  (Word variations have been searched) 
#45 MeSH descriptor: [Leukemia] explode all trees 
#46 MeSH descriptor: [Lymphoma] explode all trees 
#47 MeSH descriptor: [Neuroblastoma] explode all trees 
#48 MeSH descriptor: [Wilms Tumor] explode all trees 
#49 Leukemia or Lymphoma or Neuroblastoma or "Wilms’ tumors":ti,ab,kw  
(Word variations have been searched) 
#50 MeSH descriptor: [Central Nervous System Neoplasms] explode all trees 
#51 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or 
#32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or 
#44 or #45 or #46 or #47 or #48 or #49 or #50  
#52 #5 and #15 and #20 and #51 
 
 
 
C. SportDiscus: 2000 – 1st March 2015 
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S56 S6 AND S21 AND S25 AND S52 Limiters - Published Date: 20000101-
20151231; Peer Reviewed; Language: English; Publication Type: Academic Journal  
S55 S6 AND S21 AND S25 AND S52 Limiters - Published Date: 20000101-
20151231; Language: English  
S54 S6 AND S21 AND S25 AND S52 Limiters - Published Date: 20000101-
20151231  
S53 S6 AND S21 AND S25 AND S52  
S52 S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR 
S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR 
S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR  
S51 DE "CANCER"  
S50 DE "LEUKEMIA"  
S49 AB Leukemia or Lymphoma or Neuroblastoma or "Wilms’ tumor"  
S48 AB diabetes mellitus  
S47 DE "DIABETES in children" OR DE "DIABETES in youth"  
S46 AB "pulmonary hypertension"  
S45 AB "sleep apnea" or "cystic fibrosis" or "Broncho-pulmonary dysplasia" or 
"Bronchopulmonary dysplasia" or "Broncho pulmonary dysplasia"  
S44 DE "CYSTIC fibrosis"  
S43 DE "SLEEP apnea syndromes in children"  
S42 AB "chronic lung disease"  
S41 AB wheez*  
S40 AB asthma*  
S39 AB respiratory N1 (disease* or allerg*)  
S38 DE "ASTHMA in children"  
S37 DE "RESPIRATORY diseases" OR DE "RESPIRATORY allergy" OR DE 
"RESPIRATORY obstructions"  
S36 DE "CARDIOMYOPATHIES"  
S35 AB high N1 (blood pressure)  
S34 AB hypertension  
S33 DE "HYPERTENSION"  
S32 AB "Atrial Septal Defect" or "Coarctation of the Aorta" or "Complete 
Atrioventricular Canal defect" or "Ventricular Septal Defect" or "Tetralogy of Fallot"  
S31 AB "congenital heart disease"  
S30 DE "AORTIC coarctation"  
S29 DE "CONGENITAL heart disease" OR DE "HYPOPLASTIC left heart 
syndrome" OR DE "TETRALOGY of Fallot"  
S28 AB overweight or obes*  
S27 DE "OBESITY in children"  
S26 DE "OVERWEIGHT children" OR DE "OVERWEIGHT teenagers"  
S25 S22 OR S23 OR S24  
S24 AB activity N1 monitor*  
S23 AB acceleromet* or actigraph  
S22 DE "ACCELEROMETERS"  
S21 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 
OR S17 OR S18 OR S19 OR S20  
S20 AB (computer or PC) N1 time  
S19 AB (TV or television) N1 time  
S18 AB screen N1 time  
S17 AB sitting N1 time  
S16 AB sedentary N1 time  
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S15 AB sedentary behavi?r*  
S14 DE "SEDENTARY lifestyles"  
S13 DE "SEDENTARY behavior in children"  
S12 AB active N2 (living or lifestyle) 
S11 AB exercis* or sport*  
S10 AB physical* activ*  
S9 DE "SPORTS"  
S8 DE "EXERCISE" OR DE "ABDOMINAL exercises" OR DE "AEROBIC 
exercises" OR DE "ANAEROBIC exercises" OR DE "AQUATIC exercises" OR DE 
"ARM exercises" OR DE "BACK exercises" OR DE "BREATHING exercises" OR 
DE "BREEMA" OR DE "BUTTOCKS exercises" OR DE "CALISTHENICS" OR 
DE "CHAIR exercises" OR DE "CHEST exercises" OR DE "CIRCUIT training" OR 
DE "COMPOUND exercises" OR DE "DO-in" OR DE "EXERCISE -- 
Immunological aspects" OR DE "EXERCISE adherence" OR DE "EXERCISE for 
children" OR DE "EXERCISE for girls" OR DE "EXERCISE for men" OR DE 
"EXERCISE for middle-aged persons" OR DE "EXERCISE for older people" OR 
DE "EXERCISE for people with disabilities" OR DE "EXERCISE for women" OR 
DE "EXERCISE for youth" OR DE "EXERCISE therapy" OR DE "EXERCISE 
video games" OR DE "FACIAL exercises" OR DE "FALUN gong exercises" OR 
DE "FOOT exercises" OR DE "GYMNASTICS" OR DE "HAND exercises" OR DE 
"HATHA yoga" OR DE "HIP exercises" OR DE "ISOKINETIC exercise" OR DE 
"ISOLATION exercises" OR DE "ISOMETRIC exercise" OR DE "ISOTONIC 
exercise" OR DE "KNEE exercises" OR DE "LEG exercises" OR DE 
"LIANGONG" OR DE "METABOLIC equivalent" OR DE "MULAN quan" OR DE 
"MUSCLE strength" OR DE "PILATES method" OR DE "PLYOMETRICS" OR 
DE "QI gong" OR DE "REDUCING exercises" OR DE "RUNNING" OR DE 
"RUNNING -- Social aspects" OR DE "SCHOOLS -- Exercises & recreations" OR 
DE "SEXUAL exercises" OR DE "SHOULDER exercises" OR DE "STRENGTH 
training" OR DE "STRESS management exercises" OR DE "STRETCHING 
exercises" OR DE "TAI chi" OR DE "TREADMILL exercise" OR DE 
"WHEELCHAIR workouts" OR DE "YOGA"  
S7 DE "PHYSICAL activity 
S6 S1 OR S2 OR S3 OR S4 OR S5  
S5 AB young N1 (people or person)  
S4 AB child* or adolesc* or teen* or youth or girl* or boy*  
S3 DE "YOUTH"  
S2 DE "TEENAGERS"  
S1 DE "CHILDREN" 
 
D. CINAHL Plus:  
S47 S4 AND S12 AND S16 AND S44 Limiters - Publication Year: 2000-2015; Peer 
Reviewed; Language: English  
S46 S4 AND S12 AND S16 AND S44 Limiters - Publication Year: 2000-2015  
S45 S4 AND S12 AND S16 AND S44  
S44 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR 
S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR 
S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43  
S43 (MH "Central Nervous System Neoplasms 
S42 (MH "Wilms' Tumor+")  
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S41(MH "Neuroblastoma+")  
S40 (MH "Lymphoma+")  
S39 (MH "Leukemia+")  
S38 AB Leukemia orLymphoma or Neuroblastoma or "Wilms’ tumor"  
S37 AB diabetes  
S36 (MM "Diabetes Mellitus, Type 1") OR (MM "Diabetes Mellitus, Type 2")  
S35 AB cystic fibrosis  
S34 (MM "Cystic Fibrosis")  
S33 AB respiratory N1 (allerg* or hypersensitivity)  
S32 AB "Bronchopulmonary Dysplasia" or "Broncho pulmonary Dysplasia" or 
"Broncho-pulmonary Dysplasia"  
S31 AB sleep apnea  
S30 AB asthma* or wheez*  
S29 AB "Chronic Respiratory disease" or "Chronic lung disease"  
S28 (MM "Bronchopulmonary Dysplasia")  
S27 (MH "Sleep Apnea Syndromes+")  
S26 (MH "Pulmonary Disease, Chronic Obstructive+") OR (MM "Asthma") OR 
(MH "Respiratory Hypersensitivity+")  
S25 AB high N1 (blood pressure)  
S24 AB Hypertension  
S23 (MH "Hypertension+")  
S22 AB "Cardiomyopathy"  
S21 (MH "Myocardial Diseases+")  
S20 AB "Congenital Heart Disease" or "Atrial Septal Defect" or "Coarctation of the 
Aorta" or "Complete Atrioventricular Canal defect" or "Ventricular Septal Defect" or 
"Tetralogy of Fallot"  
S19 (MH "Heart Defects, Congenital 
S18 AB overweight or obes*  
S17 (MM "Pediatric Obesity")  
S16 S13 OR S14 OR S15  
S15 AB activity N1 monitor*  
S14 AB acceleromet* or actigraph*  
S13 (MM "Accelerometers")  
S12 S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11  
S11 AB (screen or TV or television or PC or computer) N1 time  
S10 AB (sedentary or sitting) N1 time  
S9 AB sedentary behavio?r*  
S8 AB active N1 (living or lifestyle)  
S7 AB (physical* activ*) or exercis* or sport*  
S6 (MM "Life Style, Sedentary")  
S5 (MM "Exercise") OR (MM "Physical Activity") OR (MM "Sports")  
S4 S1 OR S2 OR S3  
S3 AB young N1 (people or person)  
S2 AB child* or adolesc* or youth or teen* or boy* or girl*  
S1 (MM "Adolescence") OR (MM "Child"). 
 
Than we update the search till March 2017 for those systematic reviews for 
children with chronic disease.   
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Inclusion, Exclusion Criteria of Systematic Literature Reviews  
Table 1: Inclusion and exclusion criteria for selection of studies  
 
Inclusion criteria Exclusions criteria 
Participants aged ≤ 19 years  Participants aged >19. 
Children and adolescent with common chronic 
diseases: cardiovascular diseases, chronic 
respiratory diseases diabetes and malignancy. 
Chronic diseases defined as medical conditions 
lasting at least 6 months, diagnosed by a doctor or 
by using generally accepted objective criteria.  
Children and adolescents with acute diseases or 
conditions (e.g. post-surgery) that may have 
impacted their PA levels. 
Participants who had any limitation to their PA e.g. 
orthopaedic injury.  
MVPA and/ SB measured by accelerometer 
methods for at least 6 h/day for three consecutive 
days or more. 
- Studies that used subjective methods of MVPA 
and SB measurement (child report, parent, or carer 
proxy report). 
- Studies that used objective and direct observation 
methods apart from accelerometers (e.g. heart rate 
monitors, pedometers).  
- Studies which measured MVPA or SB for less 
than 6 hours per day.  
- Studies that collected PA data over two days or 
less. 
- Studies that focused only on specific periods of 
the day (e.g. school activity only or outdoor 
activity only). 
Articles published in English from 2000. 
Published in peer-reviewed journals. 
Articles published before 2000. 
Review papers without original data, studies using 
previously reported data. 
Human studies Animal studies.  
MVPA: Moderate-to-Vigorous Intensity Physical Activity; PA: physical activity; SB: sedentary 
behaviour. 
 
Quality Assessment Criteria of Systematic Literature Reviews  
Table 2: Study Quality Assessment Criteria 
Criterion Definition Mark Allocation 
Sample recruitment Sample: How were they recruited e.g. poster. 
Time: When was the study conducted 
Place: Where did the recruitment take place 
1 point for listing 3 
criteria 
Sample description of 
the sample (number, age, 
gender) 
Number of participants recruited 
Mean age of participants. 
% Gender male and female 
1 point for listing all 3 
criteria 
Attrition Number of participants recruited and the number 
actually measured 
1 point for listing both 
criteria 
Data collection and 
reduction 
Type of device; epoch; no of days of active 
commuting specified as minimum; duration of 
monitoring time; monitor placement; data 
reduction decisions 
1 point for listing 3 
criteria. 
MVPA definition given. MVPA defined and accelerometer cut-off or other 
method given 
1 point for listing both 
criteria 
Results Adequate description of numbers actually 
analysed, with summary MVPA data 
1 point for listing both 
criteria 
MVPA: Moderate-to-Vigorous Intensity Physical Activity.  
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APPENDIX II 
Invitation letter 
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Child Information Sheets 
 
Consent Forms 
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ActivPAL-activity Diary 
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Ethical Approval 
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APPENDIX III 
Comparison of activity levels between Libyan and other healthy children -who 
age and sex matched 
Table 1, presented the comparison of activity levels between Libyan and other healthy 
children  
There is a problem comparing Libyan with healthy Scottish children because of 
difficulties matching age and sex between Libyan healthy and other healthy control 
children. This because I usually we matched the children with chronic disease and 
healthy children. Therefore Table 1 in Appendix III, shows a sub group (six of Libyan 
healthy vs six of other healthy children) where age and sex could be matched. There 
were there was no significant difference in their activity levels (paired t-test p= 0.53). 
 
Measuring of MVPA in children with chronic disease and healthy peers 
Appendix III in the table 2 shown the preliminary analyses of time spent in MVPA 
measured by using cut-point ≥1418 counts per 15s as suggested by the Janssen et al 
for all 4 patient groups and all four control groups. Also presented the total number 
and % of children with chronic disease and healthy peers who were meeting the MVPA 
recommendation. Our result shown that, time spent in MVPA was lower in children 
with chronic disease compared to healthy peers, 78% (n=62) in children with chronic 
disease and 95% (n=76) in healthy children meeting the MVPA recommendation 
despite the fact the step count was lower than current guideline recommendations. 
Unfortunately, this discrepancy between their MVPA level and number of steps/day 
suggests that this cut point is not a secure basis on which to proceed.  
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Table 1: Comparison of activity levels between 6 of Libyan and 6 of other healthy children -who age, and sex matched 
Participants 
 
Gender age  No. of 
Monitoring days 
Monitoring Tim 
minutes 
Non-Wear 
Time minutes 
Time spent 
sitting 
minutes 
Time spent 
standing 
minutes  
Time spent in 
PA minutes 
No steps per 
24h 
Time spent in 
sleep minutes 
Healthy 15* F 9.3 7 869.1 11.1 582.6 165.7 120.8 9020.0 564.2 
Healthy 23 F 9.5 7 862.1 14.9 577.3 172.1 112.7 9625.7 565.8 
Healthy 20* M 7.2 7 792.7 0.0 470.0 184.3 138.4 10858.9 603.5 
Healthy 27 M 7.8 6 781.7 7.7 471.9 176.3 137.2 10160.7 612.1 
Healthy 24* F 4.4 5 836.8 0.0 489.3 209.9 137.3 11095.0 603.2 
Healthy 31 F 4.2 6 848.2 0.0 470.8 246.2 131.2 9818.3 591.8 
Healthy 43* M 9.7 7 893.8 0.0 519.2 262.6 114.4 9174.5 535.0 
Healthy 48 M 9.9 8 913.6 0.0 534.4 254.5 134.7 10168.5 526.1 
Healthy 43* M 6.5 8 868.6 0.0 490.6 265.8 137.9 9436.3 571.4 
Healthy 48 M 6.5 8 842.1 10.3 476.2 250.7 147.3 14074.0 587.5 
Healthy 51* F 7.9 6 808.3 14.1 422.7 224. 8 161.2 11662.67 617.6 
Healthy 10 F 7.6 7 812.1 0 400.7 237.8 173.6 12711.6 611.2 
 
Table 2: Time spent in MVPA by using cut-point ≥1418 counts per 15s as suggested by the Janssen et al for all 4 patient groups and all four control 
groups 
Variables CD 
(n= 80) 
HC 
(n= 80) 
T1DM 
(n= 20) 
HC 
(n= 20) 
JIA 
(n= 20) 
HC 
(n= 20) 
CHD 
(n= 20) 
HC 
(n= 20) 
CF 
(n= 20) 
HC 
(n= 20) 
Time spent in MVPA 
based on steeping time h 
1.6(0.6) 2.1(0.5) 1.5 (0.7) 1.8 (0.4) 1.9 (0.4) 2.2 (0.4) 1.6 (0.8) 2.1 (0.5) 1.5 (0.5) 2.1 (0.5) 
No. of participants NOT 
meeting MVPA 
recommendation 
62 (78%) 76 (95%) 15 (75%) 19 (95%) 18 (90%) 20 (100%) 14 (70%) 18 (90%) 15 (75%) 19 (95%) 
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